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Abstract 
Wound healing is a complex process that involves several overlapping and 
interacting biological pathways. The consequences of delayed or abnormal 
wound healing may result in tissue formation that has impaired function or 
structural abnormalities. As a result, clinicians have sought ways to enhance 
this process. Recently, the use of autologous platelet concentrates have 
become popular in the management of wound healing sites. However, 
controversy exists as to how these biomaterials should be prepared and 
applied. We therefore sought to investigate whether a biologically viable and 
clinically effective platelet concentrate could be prepared using standard 
laboratory equipment. The findings are presented in a series of articles that 
have been published in peer-reviewed journals. The results suggest that the 
experimental platelet concentrate produced, has a morphological structure that 
consists of a dense fibrin network intermingled with platelets, has the ability to 
accelerate cellular growth in-vitro, has no adverse effects on cells in-vitro, can 
concentrate and release a systemically ingested antibiotic over a period of 24 
hours in-vitro, can be stored for at least 60 minutes without showing signs of 
deterioration, and has shown clinical evidence of accelerating wound healing in 
sinus augmentation and alveolar ridge preservation procedures. The reduced 
cost of producing such a biomaterial allows it to be available to resource poor 
settings and to wider range of healthcare providers as compared to standard 
platelet concentration techniques. Further studies are required to investigate the 
clinical potential of this promising biomaterial.    
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Chapter 1  
1.1 Introduction 
Wound healing is a complex process that involves several overlapping and 
interacting biological pathways which aim to reconstitute lost or injured tissue 
(Etulian, 2018). It is characterized by either “regeneration” (where the damaged 
tissue is completely restored to its original state) or “replacement” (where the 
damaged tissue is replaced by scar tissue that does not have the same 
properties of the lost tissue) (Krafts, 2010). Wound healing is often a 
combination of both these processes. Clinically, the consequences of delayed 
or abnormal wound healing may have a direct effect on the treatment, resulting 
in tissue that has impaired function or structural abnormalities. As a result, 
clinicians have sought ways to enhance wound healing to affect a better clinical 
outcome (Knighton et al, 1986).  
Based on the biological principles of wound healing, the application of 
concentrated growth factors (GFs) to damaged tissue has been explored as a 
promising pathway to improve clinical results (Knighton et al, 1986). These GFs 
have traditionally been derived from exogenous sources, but recently, newer 
techniques have been developed so that the use of autogenous GFs has 
become the preferred choice. These autogenous GFs are harvested directly 
from the host, thereby reducing the risk of cross infection or adverse immune 
responses.  
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In recent times, autogenous platelet concentrates have become the main 
source of autogenous GFs associated with the clinical management of wounds 
(Whitman, 1997).  This is due to the fact that platelets are easy to harvest, are 
readily available, and have a high concentration of GFs (many of which have 
been associated with wound healing).  
Several methods have been proposed as a means of concentrating autologous 
platelets. One of the most common methods used, results in the formation of 
platelet-rich plasma (PRP) (Whitman, 1997). This is an autologous platelet 
concentrate that is used in the management of surgically induced wounds or in 
wounds where the healing is impaired. The preparation of PRP involves 
centrifuging blood to divide it into its constituent components, and then 
chemically activating the platelets to form a gel like biomaterial that could be 
applied to the wound site. This platelet concentrate had initially been introduced 
as an adjunct treatment option for maxillofacial procedures but has since been 
widely used for a variety of clinical treatments. However due to several factors, 
including the processing time, cost, materials, equipment, and the need for 
additive chemicals, simpler techniques were investigated to produce autologous 
platelet concentrates. 
In 2001, Choukroun et al introduced Leukocyte- and platelet- rich fibrin (L-PRF). 
This was an autologous platelet concentrate that differed in its preparation 
method to PRP, in that was it less complex and required fewer steps, and less 
time. In addition, no chemicals are used during its preparation. This method has 
shown that L-PRF not only concentrates platelets, but also leukocytes, and 
embeds these in a dense fibrin meshwork, resulting in a biomaterial which is 
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easily manipulated for clinical use. The introduction of L-PRF saw platelet 
concentrates being widely used, initially in dental procedures and later 
expanding to several other medical disciplines. However, based on the original 
protocol, the preparation of L-PRF requires the use of specific equipment, which 
may not be easily available in resource poor settings.  
Based on the positive clinical reports of L-PRF presented in the literature, we 
proposed modifying the original preparation protocol so that standard 
equipment and materials could be used to prepare an autologous biologically 
active leukocyte- and platelet rich concentrate. This would potentially allow 
platelet concentrates to be made available to a much larger patient base than 
was previously possible. In this context, in 2009, the author modified the 
classical L-PRF preparation method and introduced the following method of 
concentrating autologous leukocytes and platelets; 
• A standard table-top laboratory centrifuge was used (PLC-03, Hicare 
International, Taiwan). 
• Standard blood silica-coated collecting tubes were used (Greiner BioOne 
International AG, Germany). 
• Autologous blood collected in the tubes were then centrifuged for 10 to 
12 minutes at ± 400g (based on the radial diameter of the centrifuge). 
• The fibrin clot was then separated from the red blood cells using surgical 
scissors and tissue forceps.   
• This fibrin clot could then be physically manipulated for clinical use 
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The current thesis as presented by the candidate is presented in the form of 
Doctoral thesis (PhD) by publications as set out by the guidelines of The 
University of the Western Cape (C2012/01). This has a number of advantages 
in that; 
• It allows students and future academics opportunities to develop a 
research identity early on in their studies/careers, 
• contributes to the early dissemination of new knowledge produced and 
the impact of the research is more immediate, 
• the publications become a barometer of progress towards the completion 
of the doctoral degree, 
• external feedback as a result of the publication, will be received at a 
much earlier stage from independent and objective reviewers, thereby 
strengthening the academic quality of the research in the thesis. 
The culmination of clinical reports and laboratory research has been presented 
in the form of seven scientific articles, presented and published in peer 
reviewed healthcare journals extending from 2011 to 2018.  The papers are 
presented in the form of independent chapters, but do not appear in 
chronological order. They are rather presented in a sequence that introduces 
the reader to the basic concepts of L-PRF and sequentially elaborates on the 
scientific rationale and laboratory evidence for its justification as a viable 
biomaterial. The last article presented culminates in clinical case reports that 
support the advantages of using the material in clinical treatment.  
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All of the publications have been submitted to peer reviewed journals that are 
indexed on PubMed®, with six of the publications having been submitted to a 
journal accredited by The Department of Higher Education and Training of The 
Republic of South Africa. The South African Dental Journal was selected as the 
main target for publication, since this journal is disseminated to the majority of 
dentists in private and public sectors in South Africa. Two of the articles (VI and 
VII) were published before registration of the PhD but were included due to their 
recognised significance within the scientific literature. This is evident from the 
fact that they have collectively been cited at least sixty times by various authors 
in various international publications since 2013 (Google Scholar). One of the 
presented articles (III) was based on research conducted as part of a previous 
master’s program at The University of Western Cape but was included based 
on its relevance to the biological properties of the current tested material, as 
well as the fact that results from the research had never been submitted for 
publication in an academic journal. 
Of the disadvantages of presenting this thesis by publication, is the fact that 
although the articles represent different aspects of a universal theme, that this 
often resulted in repetition of concepts. This was necessary, based on the fact 
that the papers themselves were published independently of each other, and 
not as a series.  Nevertheless, the cumulative repetition was mostly limited to 
background information and sought to reinforce the foundation for the current 
hypothesis with regards the development of the biomaterial. Another 
disadvantage was that the reference formats for each paper was carried out 
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according to the publication guidelines, therefore presenting some 
inconstancies across the various articles.   
A brief overview of how the publications section of this thesis is constructed and 
linked is presented below;  
• Chapter 3  
This chapter introduces the reader to the factors affecting the preparation 
of L-PRF which is presented as a narrative review of the recent scientific 
literature (I). This forms the basis for understanding of how manipulating 
certain parameters can result in the formation of a viable leukocyte- and 
platelet- rich concentrate. It also introduces a proposed classification 
system for leukocyte- and platelet- rich concentrates, based on the 
method of production. 
• Chapter 4 
In this chapter we analysed the morphological ultrastructure by 
describing its basic architecture and its fibrin fibre characteristics (II). 
When compared to the literature, the biomaterial displays features that 
are consistent with classical L-PRF, but has enough distinct properties so 
as to distinguish itself from the newer L-PRF variants. 
• Chapter 5 
A further analysis of the ability to store the new biomaterial is presented 
(III). We show that the material could be stored for at least 60 minutes in 
its original blood collecting tube without disintegrating as was previously 
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put forth by other authors. This has clinical implications, since it allows 
for more clinical treatment time to elapse between L-PRF preparation 
and its transfer to the recipient site. 
• Chapter 6 
No previous studies indicated whether preparing L-PRF using the 
modified method, had any biological effect on living cells. We therefore 
sought to determine this by using an in-vitro model (IV). We showed that 
the biomaterial had the ability to stimulate cellular proliferation 
significantly for at least 24 hours and that no cytotoxic or adverse effects 
were evident. This was independent of other bio-stimulants such as the 
addition of hyaluronic acid.     
• Chapter 7 
Fibrin has been tested as a potential drug carrier for a number of years. 
Because of the dense fibrin network of the tested biomaterial, we sought 
to determine whether it had the ability to store and release a systemically 
administered antibiotic (V). We showed that based on an in-vitro study, 
that the material was capable of storing and releasing the tested 
antibiotic for at least 24 hours. This may have therapeutic implications for 
localised drug delivery. 
• Chapter 8 
In this chapter, we report the clinical results of using the biomaterial for 
various oral surgical procedures. Positive outcomes are presented for 
cases in which the material is used to accelerate wound healing in bone 
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and stimulate bone regeneration in a sinus augmentation procedure (VI 
and VII). It provides evidence for the fact that the material can be used 
safely in humans and that it has a beneficial therapeutic effect. 
The materials, methods and ethical considerations are presented in detail in 
each of the above articles. An appendix is attached at the end of this thesis and 
contains all of the original articles. 
  
9 
Chapter 2  
2.1 Literature Review 
In order to better understand the rationale for the use of platelet-based 
concentrates in wound healing therapy, we provide an overview of the latest 
concepts of the phenomenon and presents its biological relationship to platelet 
concentrates. The history of the development of autologous platelet 
concentrates and the evidence for its current use in clinical practice is also 
documented.  
2.2 Current concepts of wound healing 
Wound healing is a highly complex process mediated by both local factors and 
systemic mediators (Etulain, 2018). An excellent review of wound healing is 
presented by Broughton et al (2006), as well as by Krafts (2010), both of whom 
describe the phenomenon as a coinciding process of inflammation, proliferation, 
and remodeling. Although there may be variations in the terminology used, in 
the context of wound healing, most authors use the term “repair” to define tissue 
that is restored after trauma (Krafts, 2010). This encompasses two separate, 
but often overlapping components i.e. regeneration, and replacement. 
Regeneration is characterized by complete reconstitution of lost tissue, both in 
terms of structure and function, whereas replacement is essentially repair in 
which the wound area is replaced with tissue that does not have the same 
structure or function as the original. This tissue is sometimes referred to as 
“scar” tissue. Differences in wound healing are also evident with regards to the 
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type of tissue involved, the age of the patient, the systemic status of the 
individual, and the degree of wound damage (Broughton et al, 2006; Krafts, 
2010).  Because of the variation of tissue types, we limit this review to the 
wound healing associated with epithelial covered tissue (such as cutaneous 
tissue and the oral mucosa), and bone. Both of which are significant 
components of the oral and maxillofacial anatomy. 
Immediately after a wound is created (traumatically or surgically), exposed 
collagen activates the coagulation cascade via both the intrinsic and extrinsic 
pathways (Etulain, 2018). This induces hemostasis which not only reduces the 
blood flow from the area, but also provides a fibrin-based scaffold that allows 
incoming cells to migrate to the area. In addition, this scaffold acts as a 
reservoir for cytokines and growth factors that are associated with wound 
healing (Krafts, 2010). Concurrently, an inflammatory response is initiated by 
cell signaling molecules that are released from the damaged tissue and the 
incoming platelets. These molecules include IL-1, TNF-α, TGF-β and PDGF, the 
result of which, is an influx of neutrophils that are concentrated at the edges of 
the wound margin after 24 hours (Broughton et al, 2006). These neutrophils 
then use the fibrin scaffolding of the blood clot to invade the area and break 
down local debris and bacteria. Monocytes are also attracted to the area and 
are transformed to macrophages within 48-96 hours after the wound was 
created. These macrophages serve various functions, including the release of 
cytokines and proteolytic enzymes designed to clear the wound from debris and 
foreign material. However, macrophages do not only play a role in inflammation, 
but also contribute to the tissue proliferation phase of wound healing by 
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releasing mediators that promote angiogenesis and increased collagen 
production (Behm et al, 2012). 
With regards to cutaneous tissue and the oral mucosa, epithelialization occurs 
early in wound repair (Krafts, 2010). If the basement membrane remains intact, 
the epithelial cells migrate in its normal pattern i.e. from the basement 
membrane upwards. In this scenario, epithelial progenitor cells remain intact 
below the wound which allows for the normal layers of epidermis/mucosa to be 
restored within 2 to 3 days. If the basement membrane has been damaged, 
then epithelial cells located on the wound edge proliferate and send out 
projections to re-establish a protective barrier (Broughton et al, 2006). The 
underlying tissue in the meantime, undergoes increased angiogenesis, resulting 
from endothelial cell migration and capillary formation. This allows nutrients to 
be directly delivered to the sight, thereby stimulation tissue proliferation and the 
formation of “granulation tissue” (Krafts, 2010; Broughton et al, 2006). 
Granulation tissue is essentially formed due to an increase in collagen 
production by activated fibroblasts at the wound site and is characterised by a 
highly vascular immature tissue composed of mostly type III collagen (Gonzalez 
et al, 2016). This is followed by the maturation and remodeling phase where the 
collagen is laid down in an organized network which over the following months, 
remodels to a point where the healed site has 80% of the strength as compared 
to the lost tissue (Broughton et al, 2006). 
Bone on the other hand, follows a different pathway to healing. Bone healing 
can be divided into two large categories, i.e. direct and indirect fracture healing 
(Marsell and Einhorn, 2011). This refers to whether the bone portions are 
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surgically approximated (direct healing) or not (indirect healing). Common to 
both, is that after the initial inflammatory phase (which is stereotypical and 
resembles that seen in soft tissue), that specific mesenchymal stem cells 
(MSCs) are recruited to the area in order to differentiate into osteogenic cells 
and initiate the process of new bone formation (Marsell and Einhorn, 2011). 
These stem cells are derived from the surrounding injured bone as well as from 
the peripheral blood. In indirect bone healing, and different to the healing 
process of soft tissue, the fibrin clot formed in the initial healing phase 
undergoes endochondral transformation, which brings about more rigidity to the 
traumatized tissue. At the same time, intramembranous ossification develops 
subperiostally at the distal and proximal portions of the fracture. A bridging 
process then occurs between the area of endochondral and intramembranous 
ossification, thereby improving mechanical stability and weight bearing ability of 
the entire wound site (Marsell and Einhorn, 2011).     
For direct healing, the process is somewhat different, in that the fractured bone 
portions are directly in contact with each other, with a gap of less than 0.01mm. 
In this situation, cutting cones are formed at the ends of the osteons closest to 
the fracture site. The tips of the cones are formed by osteoclasts which resorb 
the region ahead of them. At the same time osteoblasts are stimulated distally, 
resulting in new bone formation and reconstitution of the lost tissue. No callus is 
formed and the process in independent of endochondral and intramembranous 
ossification (Marsell and Einhorn, 2011). However, common to both 
mechanisms of bone healing, is remodeling and that the area is healed without 
scar formation.  
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2.3 The significance of cytokines and growth factors in wound healing 
Although wound healing is driven by the interaction and proliferation of various 
cell types, the underlying process is highly dependent on the participation of key 
cytokines and growth factors, all of which play a significant role in determining 
the final outcome. Growth factors (GFs) are specialized polypeptide molecules 
that bind to receptors on target cells, thereby stimulating cellular migration, 
proliferation, differentiation, survival, and secretion (Behm et al, 2012). These 
include; 
2.4 Transforming growth factor beta (TGF-β) 
TGF-β also sometimes referred to as TGFβ, belongs to a superfamily of GFs 
that has a wide range of functions such as BMPs, activins, inhibins, and 
Mullerian inhibiting substance (Gilbert et al, 2016). Members of the TGF-β 
family are widely recognized as key signal transducers and normally occur is 
three isoforms i.e. TGF-β1, TGF-β2 and TGF-β3. They are produced by 
platelets, endothelial cells, lymphocytes and macrophages, and effect their 
function by binding to cell-surface receptors that have serine/threonine kinase 
activity. This triggers phosphorylation of cytoplasmic transcription factors, 
referred to as Smads (small mother against decapentaplegic). These then enter 
the nucleus and affect gene transcription (Gilbert et al, 2016).  
TGF-β has a wide range of functions affecting most of the processes governing 
tissue repair. It participates as a potent chemo-attractant and inflammatory 
mediator for various types of immune cells, including neutrophils, basophils, 
eosinophils, mast cells, and circulating monocytes. It also plays an important 
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role in angiogenesis and granulation tissue formation (Broughton et al, 2006; 
Krafts, 2010; Gilbert et al, 2016).  
The proliferative phase of cutaneous wound healing involves three major TGF-
β-mediated events such as re-epithelialization, angiogenesis, and extracellular 
matrix synthesis. In response to injury, epithelial cells located at the wound 
margins become activated and undergo alteration of their cytoskeleton. This 
allows them to lose cell to cell adhesion and increasing cellular motility. This is 
directly related to TGF-b and its ability to affect epithelial to mesenchymal 
transition of the epithelial cells (Gilbert et al, 2016).  
All of the isoforms of TGF-b are also involved in the angiogenic phase of wound 
healing. This phase is dominated by the development of de novo blood vessels 
in the area which allows nutrients to be delivered to the rapidly growing tissue. It 
is thought that TGF-β stimulates the release of VEGF which directly encourages 
hematopoietic stem cells to promote angiogenesis. Another effect of TGF-β on 
angiogenesis has also been suggested, with the proposed mechanism being 
the same as that seen in its role of re-epithelialization i.e. its ability to stimulate 
epithelial to mesenchyme transition thereby allowing cells from existing vessels 
to branch and form new capillaries into the newly growing tissue.  During this 
phase, TGF-β also stimulates the synthesis of the extracellular matrix (ECM) 
and plays a role in recruiting fibroblasts from the surrounding tissue and 
vasculature. Once the fibroblasts have entered the wound area, they undergo 
proliferation and the formation of a provisional ECM, most of the process being 
regulated by TGF-β. It does this by promoting collagen production and inhibiting 
matrix metalloproteinases (MMPs) (Gilbert et al, 2016; Behm et al, 2012). 
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The final phase of wound healing is characterized by apoptosis of the residual 
cells, wound contracture, the replacement of fibronectin, and the substitution of 
type III collagen by type I collagen. Wound contracture is mediated by 
myofibroblasts, i.e. a special cell type of fibroblast that has contractile 
properties. This is evidenced by the presence of Alpha-smooth muscle actin (α-
SMA). The expression of α-SMA is directly controlled by TFG-β1 through Smad 
dependent and Smad independent activity (Gilbert et al, 2016; Behm et al, 
2012).  This control is limited to areas of stiff ECM often found in the late stages 
of granulation tissue formation.  
From the above, it is therefore clear that TGF-β is a crucial component of all of 
the phases of wound healing and is required for optimal tissue regeneration. 
The therapeutic indication for the exogenous introduction of TGF-β to the area, 
therefore has a valid biological basis. 
2.5 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) also known as Vascular endothelium 
growth factor is another GF that is critical for normal wound healing. An 
excellent review of its role in wound healing has been described by Bao et al 
(2009). 
VEGF is a homodimetric glycoprotein that shares 20% of its amino acid 
homology with that of platelet-derived growth factor (PDGF). Due to alternative 
splicing of its mRNA during its production, five isoforms of VEGF exist. These 
include VEGF-A, VEGF-B, VEGF- C, VEGF-D, and placental growth factor. The 
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most studied variant is VEGF-A, hereforth referred to as VEGF (Bao et al, 2009; 
Behm et al, 2012).  
VEGF is produced by a number of different cell types that participate in wound 
healing. These include endothelial cells, fibroblasts, smooth muscle cells, 
platelets, neutrophils, and macrophages. One of the major roles of VEGF, is 
stimulation of angiogenesis. Wound-healing angiogenesis involves multiple 
steps including vasodilation, basement membrane degradation, endothelial cell 
migration, and endothelial cell proliferation. This is followed by capillary tube 
formation and the anastomosis of parallel capillary sprouts, and finally, new 
basement membrane formation. VEGF plays a role in most of these processes 
(Broughton et al, 2006; Krafts, 2010; Bao et al, 2009; Behm et al, 2012). It has 
the ability to stimulate vasodilation by increasing vascular permeability. With an 
increase in permeability, an increased stretch of the vessel occurs, resulting in 
further activation of VEGF, thereby setting up a positive feedback loop.  
It further facilitates ingress of new vessels into the wound site by setting up a 
proteolytic environment that ultimately destroys the basement membrane of 
endothelial cells, thereby allowing these cells to migrate freely into the wound 
site via chemotaxis. Once these cells have entered into the affected area, 
VEGF promotes endothelial cell proliferation by selective mitogenic activity (Bao 
et al, 2009).  Furthermore, it delays senescence and restores the proliferative 
capacity of endothelial cells.  The increased replication and increased absolute 
lifespan of endothelial cells augments VEGF-induced proliferation thereby 
promoting vascular formation.  In wound healing, this vasculature provides a 
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conduit for nutrients and other mediators of the healing response as well as 
removal of metabolites.  
The evidence therefore implicates VEGF as a significant factor in wound 
healing. Produced by inflammatory cells and local wound conditions, VEGF 
alleviates tissue hypoxia and metabolic deficiencies by promoting early events 
in angiogenesis, as well as endothelial cell function (Broughton et al, 2006; Bao 
et al 2009; Krafts, 2010; Behm et al, 2012). Maximal activity occurs during a 
“window” period approximately 3 to 7 days after injury and once the wound is 
granulated, angiogenesis ceases and blood vessels decline as endothelial cells 
undergo apoptosis. 
Because of the biological effect of VEGF, several clinical trials have been 
started to investigate its therapeutic potential in the management of nonspecific 
limb ischemia, Buerger’s disease, and myocardial ischemia (Bao et al, 2009). 
Other conditions that may benefit from the therapeutic use of VEGF is chronic 
wound management, the treatment of pressure sores, and diabetic ulcers.  The 
use of VEGF in the management of surgical wound sites therefore has a sound 
biological basis.  
2.6 Insulin-like Growth Factor (IGF) 
Insulin-like Growth Factor (IGF) is one of the key players in skeletal 
development and the maintenance of the skeletal structures during life (Behm et 
al, 2012). It therefore has an essential role in the wound healing of skeletal 
tissue. However, its physiological significance is not limited to skeletal tissue, 
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with it playing a significant role in the regeneration of both muscle and neural 
tissue (Laron, 2001; Reible et al, 2018).  
Having first been identified by Salmon and Daughaday (1957), IGF is now 
recognized as part of the family of insulin related peptides and chemically 
characterized as small peptide consisting of 70 amino acids with a molecular 
weight of 7649 Da. Two distinct forms exist: IGF-1 with a molecular mass of 7.5 
kDa and isoelectric point of 8.5, and IGF-2 with a molecular mass of 7.4 kDa 
and isoelectric point of 7.02 (Laron, 2001; Reible et al, 2018).  
IGF-1 is the most widely studied form with respect to cartilage injury and repair. 
Similar to insulin, IGF-1 has an A and B chain connected by disulphide bonds. 
The C peptide region has 12 amino acids. The structural similarity to insulin 
explains the ability of IGF-1 to bind to the insulin receptor. IGF-1 is secreted by 
many tissues, most commonly the liver and is transported to other tissues, 
acting as an endocrine hormone.  IGF-1 is also secreted by other tissues, 
including platelets and cartilaginous cells, and acts locally as a paracrine 
hormone (Laron, 2001; Behm et al, 2012; Reible et al, 2018). Evidence 
indicates that the molecule acts as an anabolic hormone, as is seen in cases 
where there is underdevelopment of skeletal structures due to IGF-1 deficiency 
(Laron, 2001). This is most often seen in cartilaginous tissue where the addition 
of exogenous IGF-1 is found to stimulate chondrocytes and accelerate tissue 
repair. In addition, exogenous administration of IGF1 induces an increase in 
muscle oxidative enzymes and fatigue resistance.  IGF-1 is therefore plays a 
significant role in the anabolic component of wound healing and is required for 
normal growth.  
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2.7 Fibroblast growth factor (FGF) 
Fibroblast growth factor or FGF is a key player in tissue regeneration and repair 
(Belov and Mohammadi, 2013; Maddaluno et al, 2017). The FGF family 
includes 22 polypeptides that regulate migration, proliferation, differentiation, 
survival, metabolic activity and/or neural function in a variety of cells. FGFs 
range in size from 150 –300 amino acids and can historically be divided into 
seven subfamilies, however, other studies have proposed the existence of eight 
(Werner et al, 2011; El Agha et al, 2016; Maddaluno et al, 2017). According to 
their mode of action, FGFs can be divided into the following groups, i.e. 
paracrine, endocrine and intracrine. Paracrine FGFs are involved in the 
development of multiple organs such as the heart, lung, brain, muscle, kidney, 
hair, ear and limbs. Endocrine FGFs (FGF15/19, 21 and 23) are involved in 
multiple metabolic pathways such as glucose, lipid and phosphate metabolism 
(Belov and Mohammadi, 2013). They have low affinities which enables them to 
function in a hormone-like fashion. Intracrine FGFs (FGF11–14) are retained 
inside the cells where they control neuronal excitability. Most of these, act by 
binding to and activating transmembrane tyrosine kinase receptors, designated 
FGFR1-4 (Belov and Mohammadi, 2013; Maddaluno et al, 2017). Through 
highly complex molecular pathways, FGF is known to play a role in 
embryogenesis, gastrulation, somatogenesis, organogenesis, Vitamin D 
homeostasis and glucose metabolism (Belov and Mohammadi, 2013). During 
cutaneous wound healing, several types of FGFs are expressed at the wound 
site, including FGF1, FGF2, FGF7, FGF10, and FGF22. The expression of 
these are greatly increased at different phases of the repair process. FGF2 
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seems to be particularly important for wound angiogenesis, whereas FGF7, 
FGF10, and FGF22, are important regulators of wound re-epithelialization 
(Werner et al, 2011; El Agha et al, 2016; Maddaluno et al, 2017).  
2.8 Platelet-derived growth factor (PDGF) 
Patelet-derived growth factor (PDGF) is a two-chain polypeptide, which belongs 
to the growth factor family (Shah et al, 2014). The original source of PDGF was 
platelets, but PDGF has been isolated from a variety of normal and neoplastic 
tissues, including bone matrix and osteosarcoma cells (Shah et al, 2014). 
PDGF is contained in alpha granules of platelets and is released only during 
blood clotting or when platelets adhere at sites of blood vessel injury. PDGF 
may serve to promote wound healing since it is the most potent mitogen in 
serum for cells of mesenchymal origin including fibroblasts, glial cells, and 
smooth muscle cells. PDGF stimulates bone DNA and protein synthesis and 
may be a systemic or local regulator of skeletal growth. As a systemic growth 
factor, it could be released during platelet aggregation and have important 
effects in the early stages of fracture healing. PDGF also has a significant 
influence on wound healing since it is the most potent mitogen in serum for cells 
of mesenchymal origin including fibroblasts, glial cells, and smooth muscle cells 
(Shah et al, 2014).  
Four different chains (A, B, C, and D) are identified in the structure of PDGF. 
PDGF is now considered as a family of five heterodimeric and homodimeric 
proteins (PDGF-AB, PDGF-AA, PDGFBB, PDGF-CC, and PDGF-DD) (Shah et 
al, 2014). The mature parts of the A- and B-chains of PDGF are 100 amino acid 
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residues long and show 60% amino acid sequence identity. Each chain has 8 
cysteine residues, which are conserved between the 2 chains. PDGF is a highly 
basic glycoprotein with a pH 10.2 with both PDGF A and B having essentially 
equal amino acid composition and immunological reactivity (Shah et al, 2014). 
PDGF has a direct role in wound healing by increasing the numbers of 
mesenchymal cells in the wound (Bhem et al, 2012; Shah et al, 2014). This is 
accomplished in two ways i.e. as platelets aggregate in the wound, they release 
PDGF which diffuses into the surrounding tissue and acts as a chemo 
attractant, recruiting cells into the wound, and secondly, at the higher 
concentrations found in the wound, PDGF increases the proliferation of the 
cells. In this way, it regulates the number of cells in the wound and the 
deposition of matrix. PDGF also activates cell membrane receptors on target 
cells, which in turn are thought to develop high-energy phosphate bonds on 
internal cytoplasmic signal proteins; the bonds then activate the signal proteins 
to initiate specific activities within the target cell (Shah et al, 2014). The most 
important specific activities of PDGF include mitogenesis, angiogenesis, and 
macrophage activation. It also stimulates mitogenicity and chemotaxis of 
fibroblasts, smooth muscle cells and neutrophils.  Moreover, PDGF has been 
shown to stimulate the production of several matrix molecules like fibronectin, 
collagen, proteoglycan, and hyaluronic acid. PDGF may also be of importance 
at later stages of wound healing as it stimulates contraction of collagen matrices 
in vitro implicating a role in wound contraction in vivo (Shah et al, 2014). 
Furthermore, PDGF stimulates the production and secretion of collagenase by 
fibroblasts, suggesting a role in the remodeling phase of wound healing. From 
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the above, it can therefore be seen that PDGF is an essential component of 
wound healing. 
2.9 The role of platelets and platelet concentrates used in wound healing 
A portion of this review has previously been published as part of another 
original thesis by the same author (Peck, 2011). Due to the fact that most of 
physiology and literature with regards to history of platelet concentrates have 
not changed since then, we have used excerpts from that thesis and updated 
the information based on current information.   
2.10 Platelets 
Platelets are anucleate, discoid shaped blood cells that are derived from 
megakaryocytes in the bone marrow. They enter the peripheral blood, where 
they circulate for 7-10 days before being destroyed by the spleen and 
pulmonary vascular bed. The normal concentration of platelets varies amongst 
population groups, but on average is about 100-400 × 109/L of circulating blood 
(Ezeilo et al, 2002). 
Structurally, platelets consist of the following three identifiable zones i.e.: 
• A peripheral zone containing the plasma membrane, receptors and the 
open canalicular system (OCS). The OCS is a final common pathway for 
uptake of particulates and discharge of secretory products in thrombin-
activated human platelets (Escolar and White, 1991). 
• A sol-gel zone that is centrally located and contains the cytoplasm and 
contractile proteins. 
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• An organelle zone made up of granules, lysosomes, mitochondria and 
cytoplasmic organelles. 
The organelle zone has a high concentration of secretory granules which 
include α–granules, dense granules and lysosomes, with the α–granule being 
the most abundant. There are approximately 50–80 α–granules per platelet, 
ranging in size from 200 - 500 nm (Blair and Flaumenhaft, 2009; Carlson and 
Roach Jr, 2002; Lacci and Dardik, 2010). The total α–granule membrane 
surface area per platelet is 14 μm2 which is eight times more than the dense 
granules and approximately equal to that of the OCS. The α–granules contain a 
large number of mediators that include, amongst others, platelet factor 4, IL-8, 
PDGF, TGF-b and VEGF (Heijnen and van der Sluijs, 2015). Platelet dense 
granules (three to eight per platelet) form the second major secretory 
compartment. They contain mainly small molecules such as ADP, ATP, 
serotonin, calcium, pyrophosphate and polyphosphate. The remaining granules, 
the lysosomal granules, contain hydrolytic enzymes that dissolve phagocytosed 
debris. The functions of platelets are therefore directly related to the properties 
of their secretory granules (Blair and Flaumenhaft, 2009). This allows platelets 
to be participate in coagulation, wound repair, inflammation and angiogenesis 
(Heijnen and van der Sluijs, 2015). 
2.11 The role of platelets in haemostasis and wound healing 
When a blood vessel is injured, it immediately contracts at the site of injury. At 
the same time, platelets adhere to the underlying exposed collagen and form a 
temporary plug. This plug formation is divided into 3 interrelated stages that 
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includes platelet adhesion, a release reaction, and platelet aggregation. Platelet 
adhesion is trigged by the exposure of injured collagen, secondary to tissue 
injury. This results in changes in platelet shape from normal discoid to spherical, 
with a number of protruding long projections known as filipodia, which results in 
better adhesion (Ezelio, 2002). The release reaction is characterised by the 
secretion of substances outside the platelet membrane. Although both α-
granules and dense granules release proteins that are involved in coagulation, 
α-granules secrete polypepides that play a role in both primary and secondary 
haemostasis. Another important function of the α-granules is the secretion of 
adhesive proteins (fibrinogen and von Willebrand factor). These are essential 
for platelet-platelet and platelet-endothelial interactions and are responsible for 
platelet aggregation i.e. the third stage of platelet plug formation. Coagulation 
factors V, XI and XIII are also found in platelet granules, and are released upon 
platelet activation.  Platelet α-granules contain the inactive precursor of 
thrombin, i.e. prothrombin, and significant stores of high molecular weight 
kininogens, which augment the intrinsic clotting cascade. In addition, platelets 
release inhibitory proteases, such plasminogen activator inhibitor-1 (PAI-1) and 
α2-antiplasmin, which limit plasmin-mediated fibrinolysis, thereby promoting clot 
formation (Ezelio, 2002). 
Evidence also suggests that platelets may form an integral part of the 
inflammatory response (Blair and Flaumenhaft, 2009). Platelet α–granules 
influence inflammation by secreting high concentrations of pro-inflammatory and 
immune-modulating factors. In some cases, these chemokines provide 
feedback to stimulate chemokine receptors on the platelet surface, thereby 
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causing platelet activation, secretion, and perpetuation of the inflammatory 
cycle. Activated platelets bind to circulating immune cells in the blood, and 
surface-adherent platelets facilitate the recruitment, rolling, and arrest of 
monocytes, neutrophils, and lymphocytes to the activated endothelium. 
Platelets have also been known to recruit neutrophils in certain circumstances 
(Blair and Flaumenhaft, 2009; Tözüm and Demiralp, 2003).  
The chemical mediators released by platelets also play an essential role in 
wound healing. The joint action of these mediators’ results in revascularization 
of damaged tissue through; 
• the induction of migration, proliferation, differentiation, and stabilization 
of endothelial cells for new blood vessels; 
• restoration of damaged connective tissue through migration, 
proliferation, and activation of fibroblasts; 
• and proliferation and differentiation of mesenchymal stem cells into 
tissue-specific cell types. 
Based on the above physiological characteristics, the use of platelets in the 
form of autologous concentrates has been advocated for tissue regeneration. 
2.12 Platelet concentrates and tissue regeneration  
The exact history for the use of autologous platelet concentrates in wound 
healing is unclear and inconsistent in the literature. Nevertheless, in 1986 
Knighton et al described the use of autogenous platelets to accelerate wound 
healing in chronic nonhealing wounds. According to our knowledge, this was 
one of the earliest accounts of autologous platelet concentrates being used as 
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an adjunct to wound healing in humans. In 1993 Hood et al and later Hill et al 
(1993), described a “newly developed autologous platelet-concentrated fibrin 
glue” that had wound healing properties. Four years later, Whitman et al (1997) 
introduced the use of autologous platelet concentrates to enhance wound 
healing for various maxillofacial procedures. These included mandibular 
reconstruction, sinus augmentation, reparation of Schneiderian membrane 
tears, the reconstruction of oral-antral fistulas and the control of haemorrhage. 
The platelet concentrate used in this case was similar to that previously 
described by Matras (1982) and Oz et al (1992), with minor modifications made 
to the preparation protocol. In 1998, Marx and colleagues introduced the term 
“platelet-rich-plasma” or “PRP” to describe this platelet concentrate. However, it 
must be borne in mind that the use of the term “platelet-rich-plasma”, was 
already in use and referred to platelet extracts used to control haemorrhage 
during surgery. Ultimately, this has led to confusion in the literature, with Dohan 
Ehrenfest et al (2012b) proposing a standardised nomenclature to denote 
various platelet concentrates.  
By the year 2000, PRP had gained widespread acceptance as a viable 
treatment option for various clinical procedures. Although research has focused 
on the ability of PRP to accelerate bone healing, it has been used successfully 
for the reparation of dural tears, during and after facial plastic surgery, as a 
haemostatic and lymphostatic agent in radical neck dissection, enhancement of 
knee and lumbar fusions, the management of chronic wounds such as diabetic 
ulcers, the treatment of burns, snake and spider bites, in the treatment of 
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various cardiothoracic procedures, in major and minor vascular surgery, and in 
other areas such as ophthalmology and urology (Jameson, 2007). 
By 2007, several theories of how PRP contributed to enhanced wound healing 
were proposed. Central to all of them, was the ability of a high concentration of 
platelets to release growth factors and other mediators to stimulate the 
preferential migration of undifferentiated stem cells to the wound site.  
2.13 PRP preparation methods 
Since the original preparation method of PRP had been described, several 
modifications of the technique have been explored, and, even though minor 
differences in preparation techniques exist, common to all of them are the 
following: 
1. Blood is collected with anticoagulant just before or during surgery and is 
immediately processed by centrifugation. The time for platelet 
concentrate preparation is variable, but is always completed within an 
hour. A first centrifugation step is designed to separate the blood into 
three layers, red blood cells (RBCs) are found at the bottom, acellular 
plasma (PPP, platelet-poor plasma) is in the supernatant and a ‘buffy 
coat’ layer appears in between, in which platelets are concentrated. 
2. The next steps vary among the numerous protocols, but are an attempt 
to discard both the RBC layer and the PPP to collect only the ‘buffy coat’ 
layer. 
3. Finally, the residual platelet concentrate is applied to the surgical site 
with a syringe, together with thrombin and/or calcium chloride (or similar 
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factors) to trigger platelet activation and fibrin polymerization (Dohan 
Ehrenfest et al, 2012b). 
This variation in preparation protocol has led to the non-standardisation of PRP 
with the result that potential biological differences may exist between them 
(Dohan Ehrenfest et al, 2010c; Dohan Ehrenfest et al, 2018). However, whether 
this translates into any clinical significance, remains a point of contention. 
2.14 Safety and efficacy 
The preparation of PRP is not purely autologous and the inclusion of various 
additives, some of which are animal-derived, are common to most of the 
preparation techniques. These are added to stimulate platelet activation include 
bovine thrombin and calcium chloride. Other agents include acid citrate 
dextrose-A (ACD-A) and citrate phosphate dextrose (CPD), both of which are 
used to support the metabolic needs of platelets in anti-coagulated blood 
(Dohan Ehrenfest et al, 2009). 
Critics of PRP preparation techniques highlight the fact that several studies 
show that exposure of surgical patients to bovine thrombin may result in the 
generation of anti–bovine antibodies that cross-react with certain human 
coagulation factors (Ofosu et al, 2009). The generation of these antibodies is 
well documented and may also be seen in patients treated with human plasma–
derived, or recombinant therapeutic proteins. Furthermore, the purity of bovine 
thrombin preparations have recently been questioned since they differ markedly 
in concentration (with the bovine thrombin content varying from >90% to <30% 
for various different preparations) (Ofosu et al, 2009). Clinically, the adverse 
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effects of using bovine-derived products range from acute and delayed allergic 
reactions to coagulative and bleeding reactions, and both these have been 
documented with the use of PRP (Wai et al, 2003). Although a decline in the 
adverse events associated with the use of these agents have been noted during 
the past decade, researchers attribute this decline to underreporting and a lack 
of adequate research data (Clark et al, 2010). The potential adverse effects of 
using bovine or donor-derived thombin is, therefore, a significant consideration 
in the preparation of platelet concentrates and has led to researchers seeking 
alternative means of creating viable preparation methods for these products. 
2.15 Joseph Choukroun and platelet-rich-fibrin (PRF) 
Joseph Choukroun (cited by Dohan et al, 2006a) successfully introduced a new 
technique of concentrating autologous platelets for surgical use. Choukroun 
referred to the platelet concentrate as “platelet-rich-fibrin (PRF)” and the new 
method of preparation, as “Choukroun’s PRF”. The nomenclature was chosen 
to distinguish this platelet concentrate from other current forms of PRP. 
Different from traditional methods of producing PRP, Dohan et al (2006a) 
described the PRF preparation method as follows; 
1. Venous blood is collected from the patient in standard 10-ml 
anticoagulant-free blood collecting tubes (either glass tubes or silica 
coated plastic tubes).  
2. The collected blood is immediately centrifuged in a tabletop centrifuge at 
a relative centrifugal force of 400 x g for 10-12 minutes (Dohan et al, 
2006a; Dohan et al, 2006b). The absence of anticoagulant implies the 
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activation of most platelets of the blood sample in contact with the tube 
walls and the release of the coagulation cascades within a few minutes. 
Fibrinogen is initially concentrated in the upper part of the tube, before 
the circulating thrombin transforms it into fibrin. A fibrin clot is then 
obtained in the middle of the tube, just between the red corpuscles at the 
bottom and acellular plasma (PPP) at the top. Platelets and leukocytes 
are trapped in large numbers within the fibrin mesh, and this portion of 
the when isolated, is termed PRF (Gassling et al, 2010). 
3. PRF is then separated from the red blood cells by using various 
instruments such as surgical tissue forceps or scissors (Dohan et al, 
2006a; Dohan et al, 2006b). 
4. The resultant biomaterial can then be used as is, or it be compressed to 
form an “autogenous membrane” or a dense “plug” used that is used for 
post dental-extraction treatment (Dohan et al, 2006a; Dohan et al, 
2006b) 
The above procedure is often denoted as the “classical” method of PRF 
production. This has however changed recently, with modifications made to the 
tubes and the centrifuge used to produce PRF (Miron et al, 2018). Changes 
have also been made to the time and centrifugal force used, with the resultant 
preparations termed A-PRF, APRF+ and IPRF respectively. Interestingly, PRF 
prepared using the classical protocol uses different preparation guidelines to 
that currently advocated by the original proponents of the technique (Miron et al, 
2018). Nevertheless, and irrespective of the protocol used to prepare PRF, it 
distinguishes itself from PRP in that it is easier to prepare, requires little 
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specialized equipment, uses no additives, is less expensive, and requires less 
time (Dohan et al, 2006b; Dohan Ehrenfest et al, 2010a). The term PRF and L-
PRF is often used interchangeably in the literature and this trend has been 
continued in this review.  
2.16 PRF: Structure, biological properties and clinical applications  
Morphologically, PRF appears as a gel like clot that has two main areas: a 
yellow portion constituting the main body, and a red portion constituting the 
upper most part of the red blood cell layer (Paper III). Biological analysis shows 
that the yellow portion is made up of three major components, i.e. platelets, 
leukocytes, and fibrin. It is thought that the fibrin acts as a vehicle for these cells 
and other cytokines during the process of wound healing (Choukroun et al, 
2006b; Dohan Ehrenfest et al, 2010b, 2010b; Gassling et al, 2010; Kang et al, 
2010). 
An analysis of the concentration of platelets found in PRF showed that it 
trapped ± 97% of the total platelets available (Dohan Ehrenfest al., 2010a). 
Different to other platelet concentrates, PRF also contains a high concentration 
of leukocytes. Up to 50% of available leukocytes can be trapped in a platelet 
concentrate using the Choukroun PRF preparation method (Dohan Ehrenfest et 
al, 2010a).These leukocytes are thought to undergo degranulation during clot 
formation, thereby activating a number of cytokines that protect the wound from 
infection (Dohan et al, 2006a; Dohan et al, 2006b). One study compared PDGF-
AB, PDGF-BB, and TGF-b levels in PRP samples that were either leukocyte-
rich or leukocyte-poor. The presence of leukocytes resulted in significantly 
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higher mean absolute levels of PDGF-AB and PDGF-BB compared to 
leukocyte-poor PRP (Zimmerman et al, 2003). For TGF-b, higher 
concentrations were detected for the leukocyte containing PRP when its levels 
were related to platelet concentration. 
Dohan Ehrenfest et al (2010a) noted that PRF had a distinct architecture with a 
specific cellular distribution. Rather than the cells being evenly distributed 
throughout the PRF clot, it was shown that the highest concentration of platelets 
and leukocytes were found in the yellow area just above the red blood cell layer, 
with the concentration and homogeneity of cells becoming progressively less as 
the distance from the red blood cell layer increased (Dohan Ehrenfest et al, 
2010a). This architecture has been confirmed by recent independent animal 
studies (Bai et al, 2017). Newer generation platelet and leukocyte concentrates 
such A-PRF, A-PRF+ and IPRF have a different ultrastructure and biological 
profile compared to PRF and as such are not considered equivalent to the 
original biomaterial (Miron et al, 2017a; Miron et al, 2018, Fujioka-Kobayashi et 
al, 2017).  
When compared to traditional PRP, PRF shows a higher concentration of 
growth factors, including PDGF and TGF-b (Gassling et al, 2010; He et al, 
2009; Kang et al, 2011). Because no additional activators are used during its 
preparation, the material undergoes slow polymerization, thereby allowing it to 
trap a number of key cytokines. These cytokines are released over a longer 
period when compared to PRP. This characteristic has been proposed as one 
of the major reasons that the biomaterial displays positive clinical outcomes.   
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Several researchers have studied the clinical and biological effects of PRF on 
wound healing. Shen et al (2008) showed that PRF had the ability to inhibit 
epithelial cell growth, enhance osteoblast proliferation, and increase gingival 
fibroblast proliferation. He et al (2009) analyzed the effect of PRF and PRP on 
rat osteoblasts over a period of 28 days. It was found that PRF released 
autologous growth factors gradually over this period and had a significantly 
greater ability to induce mineralization when compared to PRP. Jang et al 
(2010) showed that when PRF was combined with silk powder, it could 
successfully be used to treat peri-implant bone defects. Choukroun et al (2006) 
evaluated the potential of PRF in combination with freeze-dried bone allograft to 
enhance bone regeneration when used in lateral sinus floor augmentation. At 4 
months, the histologic maturation of the test group appeared identical to that of 
the control group at 8 months i.e. the quantities of newly formed bone were 
equivalent. The authors therefore concluded that PRF accelerated bone 
regeneration when was used in combination with freeze-dried bone to perform 
sinus floor augmentation.  
2.17 PRF: Clinical applications 
In a case report by Anilkumar et al (2009), a PRF membrane was used in 
conjunction with a lateral sliding flap to successfully restore buccal soft tissue 
recession on a single tooth. The patient initially presented with gingival 
recession of 5 mm. After the surgical site was prepared, an autologous PRF 
membrane was used to cover the exposed root area. This was then closed with 
a pedicle flap gained from the adjacent tooth. A 6-month clinical follow up 
showed complete root coverage with excellent colour and gingival contour. Del 
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Corso et al (2009) confirmed this clinical application when he published several 
case reports showing the successful use of PRF membranes in the 
management of both single and multiple gingival recession defects. Using 
multiple PRF membranes, instead of connective tissue grafts, the author was 
able to restore the lost soft tissue successfully by layering the PRF membranes 
over each other thereby increasing gingival height and thickness. The clinical 
results were maintained successfully for at least one year (Del Corso et al, 
2009). 
In a clinical study over six months, Mazor et al (2009) showed that PRF could 
be used as the sole grafting material for sinus augmentation. In a similar study, 
Diss et al (2008) evaluated the radiographic changes in the apical bone levels 
of 20 patients treated with 35 microthreaded implants placed using the 
osteotome mediated sinus floor elevation technique. PRF was the sole grafting 
material used. Despite a limited residual bone height of 4.5 to 8 mm, a healing 
period of 2-3 months was found to be sufficient to resist a torque of 25 Ncm 
applied during abutment tightening. One implant failed during the initial healing, 
but at one year, 34/35 implants were clinically stable, and the definitive 
prostheses were in function, resulting in a survival rate of 97.1%. The mean 
sinus bone gain was 3.2 mm with radiographic documentation of apical 
displacement of the sinus floor (Diss et al, 2008). Other authors have had 
similar results (Simonpieri et al, 2011, Simonpieri et al, 2009, Toffler, et al, 
2010). 
Using radiographic analysis, Mazor et al (2009) tested the efficacy of using PRF 
as barrier membranes to close windows created in the lateral maxillary sinus 
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wall after sinus augmentation procedures. In the 9 cases where bone biopsies 
were harvested in the area of the window, no connective tissue invagination 
was observed, and bone samples were all very dense. This indicated that PRF 
was able to successfully protect the sinus graft area from the ingress of soft 
tissue. From the results of this study, Mazor et al (2009) concluded that PRF 
may be used to replace xenogenic and collagen membranes that are commonly 
used for this procedure. 
Because of the biological properties of PRF, several authors have attempted to 
use it in combination with bone substitutes to enhance healing during guided 
bone regeneration (GBR) procedures. Simonpieri et al (2009), reported on a 
new technique for maxillary reconstruction using a combination of freeze-dried 
bone allograft, PRF membranes and 0.5% metronidazole solution. PRF 
fragments were mixed with the graft particles, thereby functioning as a 
“biological connector” between the different elements of the graft. Using the 
reported protocol, they observed a high degree of gingival maturation after 
healing with a thickening of keratinized gingival tissues. In addition, they 
emphasized that the use of PRF seemed to reduce postoperative pain and 
oedema, and limited minor infections (Simonpieri et al, 2009). 
Toffler et al (2014) using a similar PRF-bone graft mixture to successfully 
augmented a narrow alveolar ridge for future implant placement. In this GBR 
procedure, the PRF membrane was fragmented and mixed with the bone graft 
material. Further PRF membranes were then placed over the graft material to 
isolate the wound from the overlying tissue. 
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Alveolar ridge preservation or socket preservation is the term given to 
procedures that attempt to preserve bone at sites of tooth extraction. Several 
techniques exist, the most common being the placement of a bone grafting 
material in a freshly extracted tooth socket, followed by covering the socket with 
a collagen membrane or connective tissue graft. In a technique described by 
Toffler et al (2010), a PRF membrane can be compressed into a “plug” using 
and used as a grafting material to fill recently extracted tooth sockets. The 
authors claim that this can be used to expedite soft tissue healing and allow for 
ideal implant placement.  
PRF has been used to repair perforations of sinus membranes after injury 
during sinus augmentation procedures. Choukroun et al (2006) showed that 
sinus membrane perforations were successfully treated with PRF membranes 
thereby allowing sinus augmentation procedures to be completed successfully. 
In a similar study, Mazor et al (2009) showed that these perforations were 
completely sealed after sixth months and no adverse effects were noted during 
the healing process. Mazor et al (2009), therefore, concluded that the use PRF 
is a viable treatment option in the management of iatrogenic sinus perforations 
(Mazor et al, 2009). 
2.18 Current controversies regarding PRP and PRF 
Although widely used in a variety of clinical fields, the ability of PRP to enhance 
wound healing has been questioned (Wang et al, 2007; Trombelli et al, 2008; 
Plachokova et al, 2008). A systematic review of more than 100 papers 
concluded that significant evidence existed for the use of PRP in periodontal 
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defects. However, the same study concluded that the effect of PRP on sinus 
augmentation was less than 10% when compared to controls and suggested 
that no substantial evidence existed for its use in other dental procedures 
(Plachokova et al, 2008). The heterogeneity in studies that examine PRP is 
regarded as a major cause for the lack of conclusive evidence available for its 
use (Wang et al, 2007). 
PRF is a platelet concentrate which has features that are distinctly unique when 
compared to PRP and therefore cannot be regarded as the same biomaterial. 
Although as mentioned previously the material has shown beneficial results in a 
number of clinical case reports, it however suffers from the same scientific 
weaknesses as PRP in that the biomaterial currently lacks long-term controlled 
trials that would endorse its routine use in surgical procedures. Recently, a 5-
year follow up report has been published which demonstrates the clinical safety 
and efficacy of using this biomaterial (Simonpieri et al, 2011).  
Because of the growth in popularity of the biomaterial, a number of systematic 
reviews with regards to its clinical efficacy has recently been published (Najeeb 
et al, 2017; Miron et al, 2017b; Miron et al, 2017c; Ali et al, 2015). In most cases 
these reviews are not conclusive nor show any major clinical advantage for the 
use of PRF in routine dental surgery. Most studies conclude that heterogeneity 
in the literature limits the evidence that is available for further analysis. 
Moreover, the term PRF is used in the literature to denote a range of 
biomaterials that may all not have been prepared using the same protocol 
(Miron et al, 2018). As such, most authors suggest that larger and better 
controlled clinical trials are needed to study the potential of this biomaterial.     
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2.19 Summary 
The use of autologous platelet concentrates has become common for the 
management of a wide range of clinical scenarios (Creslik-Bielecka et al 2012; 
Harrison, 2018). However controversy exists as to how these biomaterials 
should be prepared and applied (Zimmerman et al, 2003; Bielecki et al, 2012; 
Kobayashi et al, 2016; Dohan Ehrenfest et al, 2012a; Ghanaati et al, 2018; 
Kubesch et al, 2018) . We therefore sought to investigate whether a biologically 
viable and clinically effective platelet concentrate could be produced using 
standard locally available laboratory equipment. The findings are presented in a 
series of articles that have been published in peer-reviewed journals.  
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Chapter 3  
3.1 Factors affecting the preparation, constituents, and clinical efficacy 
of leukocyte- and platelet- rich fibrin (L-PRF)  
The use of leukocyte and platelet- rich fibrin (L-PRF) in various medical 
procedures has enjoyed exponential growth recently (Miron et al, 2017a; Miron 
et al, 2017c). An electronic search of the PubMed ® database, showed that 756 
publications having being reported during the past 5 years. Of these, 56 or 7.5% 
have been classified as clinical trials whereas case reports constitute a much 
higher percentage (13.5%). In almost all of the reports, the method of L-PRF 
preparation has not been standardised (Miron et al, 2017c; Miron et al 2018). 
The heterogeneity of the methods used, makes direct comparisons between the 
studies challenging, since one cannot assume that the platelet concentrate 
produced by these varying methods are the same. Based on the above, and the 
fact that the author has been approached by several clinicians, with regards to 
standardised settings for the production of L-PRF, it was decided to elaborate 
on the factors affecting the preparation of L-PRF by publishing a narrative 
review, using relevant data derived from the literature. In our report, we propose 
a new classification of L-PRF type platelet concentrates, so as to distinguish L-
PRF (produced by the original protocol), from other types of platelet 
concentrates. We also highlight the most common factors that influence its 
preparation. The report draws attention to the diversity of methods used to 
produce L-PRF and the fact that these different preparation methods may result 
in differences in the biomaterial formed. Evidence is presented to substantiate 
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these claims. Emphasis is placed on the centrifuge force and its role in 
optimising the production of L-PRF. Biological factors such as pH, growth factor 
release, the influence of bone morphogenic proteins and the presence of stem 
cells are addressed. Mention is also made of the clinical success of L-PRF 
produced by non-standardised methods.   The resultant article was published in 
The South African Dental Journal of August of 2016.          
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Abstract 
Platelet- rich fibrin (PRF) was first introduced by Choukroun et al in 2001 as a 
method of concentrating autologous human leukocytes, platelets and fibrin for 
autotransplantation into surgical wound sites to accelerate healing. Even though 
several clinical reports have documented the use of L-PRF, controversy still 
exists with regards to several aspects of this biomaterial. Several publications 
report the use non-standardised methods to prepare L-PRF, resulting in 
variable clinical results. The impact of the type of centrifuge, as well as the 
growth factor release kinetics have recently been studied and have yielded new 
insights into the structure and function of L-PRF.  The presence of bone 
morphogenic proteins as well as stem cells has also been documented.  In this 
report we analyse various factors affecting L-PRF preparation and its 
constituents and highlight some of the controversies surrounding the 
biomaterial. 
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Introduction 
Platelet- rich fibrin (PRF) was first introduced by Choukroun et al in 2001 as a 
method of concentrating autologous human leukocytes, platelets and fibrin for 
autotransplantation into surgical wound sites to accelerate healing 1. This 
method of concentrating blood platelets was different to previous techniques in 
that it only centrifuged the collected blood once, no anticoagulant agents were 
added, and leukocytes and fibrin were deliberately included in the final product. 
Previous similar techniques had only sought to concentrate platelets, with little 
consideration for the other constituents 2,3. Choukroun’s protocol (Process 
protocol, Nice, France) was simple and essentially consisted of collecting 
venous blood into dry glass tubes, afterwhich the tubes would be spun at a low 
centrifuge speed to allow the blood to separate into the constituents 4.  This 
resulted in 3 distinct layers forming in the blood collecting tube, i.e. a red blood 
cell layer at the bottom of the tube, an accellular layer at the uppermost part of 
the tube, and a leukocyte- and platelet- rich fibrin (L-PRF) layer formed in the 
middle of the tube 4. The L-PRF layer was considered as the active biomaterial 
and has since its development, been promoted as an agent that accelerates 
wound healing and tissue regeneration 5. Even though several clinical reports 
have documented the use of L-PRF in oral and extra-oral surgical procedures, 
controversy still exists with regards to several aspects of this biomaterial. In this 
report we attempt to highlight some of these. 
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The terminology and classification of L-PRF 
In an attempt to distinguish various platelet concentrates from each other, 
Dohan Ehrenfest et al used three key parameters i.e; the preparation process, 
the pharmacological properties, and the characteristics of the final material to 
establish a functional classification of platelet concentrates 5. Using these 
parameters with specific criterion, the authors were able to classify platelet 
concentrates into four distinct categories (Table 1) 5.  
    
Table 1: Categories of platelet concentrates as proposed by Dohan Ehrenfest 
et al 5 
1. Pure platelet-rich plasma (P-PRP) 
2. Leucocyte- and platelet-rich plasma (L-PRP) 
3. Pure platelet-rich fibrin (P-PRF) 
4. Leukocyte- and platelet-rich fibrin (L-PRF) 
 
Although this classification elucidates the distinction of various platelet 
concentrates simpler, it is not the only system to classify platelet concentrates 
that exists, and other systems have since been described 7. Further, Dohan 
Ehrenfest’s proposed classification is widely quoted in the literature and at the 
time of its publication, Choukroun’s PRF was the only platelet concentrate 
included in the category of L-PRF. 
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As the popularity of Choukroun’s protocol for the production of L-PRF grew, 
publications emerged that purported to produce L-PRF, but had not used the 
exact criterion as described by Choukroun (Process protocol, Nice, France) 8-11. 
It is unclear whether L-PRF not produced by this method can be classified as a 
true L-PRF 4. Publications incorrectly use the term L-PRF and Choukroun’s 
PRF interchangeably, even though the exact method as described by 
Choukroun is not used to produce the resultant platelet concentrate 12. This has 
lead to incorrect assumptions and a clear classification of platelet concentrates 
that is universally accepted is therefore sought. For the purposes of clarity, the 
following proposed terminology will be used throughout this article; 
• L-PRF – Leukocyte and platelet-rich fibrin. Defined as a broad and all-
inclusive category that is used to describe a mixed platelet, leukocyte 
and fibrin concentrate prepared using no-anticoagulants and a single 
spin centrifuge technique.  
• L-PRF (C) – Leukocyte and platelet-rich fibrin (Choukroun type). Defined 
as a specific leukocyte and platelet-rich fibrin prepared using 
Choukroun’s protocol i.e. (the equipment and the preparation method 
follows the exact recommended protocol as outlined by Choukroun).  
• L- PRF (I/E) – Leukocyte and platelet-rich fibrin (Intraspin/ EBA 20 type). 
Defined as a specific leukocyte and platelet-rich fibrin prepared using 
either an Intra-spin (Intra-Lock International, Boca-Raton, FL, USA), or 
EBA 20 (Andreas Hettich GmbH & Co KG, Tuttlingen, Germany) 
centrifuge and following the recommended protocol as outlined by the 
Dohan Ehrenfest et al  4.  
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• L-PRF (O) – Leukocyte and platelet-rich fibrin (Other). Defined as a 
leukocyte and platelet-rich fibrin prepared similar to L-PRF (I/E) and L-
PRF(C), but using a non-purpose built centrifuge. 
Techniques and methods of producing L-PRF 
Choukroun’s initial method of producing L-PRF was intended to be a simple 
technique that would allow for the production of high quality platelet and 
leukocyte concentrates, that could easily be prepared and used in everyday 
healthcare facilities 4. This method specifically used a PC-02 table centrifuge 
and a collection kit from Process (Nice, France) 4.Further a blood sample is to 
be taken without anticoagulant in 10-mL blood collecting tubes which were then 
immediately centrifuged at 3000 rpm (approximately 400g of relative centrifugal 
force) for 10 minutes. The formed L-PRF clot was then removed from the blood 
collecting tube and used as required.  
The influence of centrifuge type and relative centrifugal force on L-PRF 
Even though Choukroun’s protocol was clearly outlined, several publications 
were subsequently produced that did not follow the intended protocol 13. Key to 
the difference between these publications and the proposed protocol, was the 
lack of use of a specific centrifuge (PC-O2, Process, Nice, France) and a 
specific relative centrifugal force (400g). In many publications, the relative 
centrifugal force was not reported, however the centrifuge speed and time was 
rather quoted 13-15. This is a significant deviation from the protocol since the 
influence of the relative centrifugal force is underestimated.     
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Relative centrifugal force (RCF) can be defined as the amount of accelerative 
force applied to a sample in a centrifuge 16. It is not equivalent to revolutions per 
minute (RPM) and the terms cannot be used interchangeably. Centrifuges work 
by putting samples in rotation around a fixed axis, thereby resulting in an 
accelerative force being applied perpendicular to the axis 16. This resultant force 
causes the separation of various elements in the sample based on the 
individual weight of the sample elements and is the basis for blood separation 
techniques carried out by laboratory centrifuges.  RCF is measured in multiples 
of the standard acceleration due to gravity at the Earth’s surface (x g) and is 
based on two specific variables i.e. how wide the rotor is and how fast it is 
moving 16. The radius of the centrifuge or rotor is as critical to the process as 
the RPM is. Processes where the RPM and the rotor radius are identical, are 
comparable and any deviation from reporting, may be inaccurate. 
Consequently, RCF will only be constant for centrifuges with the same rotor 
radii. If an RPM setting from a protocol where the operator used a centrifuge 
with a different radius from yours, you will get a different RCF 16. Therefore one 
cannot assume that all centrifuges used for producing L-PRF and spinning at 
3000RPM will produce a RCF of 400g. This is a significant parameter that is 
often misunderstood.    
The effect of varying RCF during platelet concentrate preparation was recently 
reported 17. In their analysis of various factors affecting the preparation of 
Platelet-rich plasma (PRP), showed that changes in RCF significantly 
influenced the platelet yield even though other parameters such as period of 
centrifuge time as well as temperature remained constant.  Dhurat and Sukesh 
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reviewed several PRP preparation methods 18. Based on their analysis, it was 
shown that authors using different RCF parameters resulted in variations in the 
platelet yields of the PRP produced. More significantly, scrutiny of the literature 
reveals that although PRP was clinically used for several years, that no 
standardised protocol has been documented. With regards to the preparation 
methods of L-PRF that are published in the literature, similar inconstancies 
exist. 
Other centrifuge parameters that may influence L-PRF preparation 
In a recent series of articles recently published, the effect of various parameters 
on the quality of L-PRF was investigated 19-21. Using the same centrifugal force 
(400g) as well as the same type of blood collecting tubes, the authors tested 4 
different commercially available L-PRF centrifuges. These results indicated that 
centrifuge vibration as well as centrifuge type, significantly affected the quality 
and quantity of the L-PRF clot produced. Under scanning electron microscope 
(SEM) analysis, the L-PRF clots produced from the different centrifuges showed 
variations in cell morphology and fibrin architecture, with some cells showing 
signs of significant damage. These differences were attributed to the type of 
centrifuge used. The Intra-Spin L-PRF centrifuge (Intra-Lock International, 
Boca-Raton, FL, USA), displaying cells with the most stable and normal shape 
20. It is therefore critical that all the factors are reproduced to be able to 
standardise the biomaterial. Researchers cannot simply recreate the biomaterial 
by using any centrifuge with a setting of 400g RCF at the appropriate spin time.  
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Growth factors and their release kinetics  
The preferred use of L-PRF in clinical practice is due largely to its reported 
release of autogenous growth factors. It is assumed that the high concentration 
of these growth factors result in reduced healing time as well as the stimulation 
of tissue regeneration 8.  These growth factors have been well documented in 
the literature 22. Recently however, the release kinetics of these growth factors 
has been questioned 23. Schär et al prepared L-PRF (I/E) with a single spin 
protocol at 400g for 12 minutes using an EBA 20 (Andreas Hettich GmbH & Co 
KG, Tuttlingen, Germany) centrifuge 23. This is the same centrifuge as the Intra-
Spin L-PRF centrifuge (Intra-Lock International, Boca-Raton, FL, USA) 24. Both 
these centrifuges have recently been upgraded 25,26. The authors compared the 
release of various growth factors from L-PRF, L-PRP and a coagulated blood 
clot. Based on these results, it was demonstrated that the total growth factor 
release of vascular endothelial growth factor (VEGF) as well as interleukin-1β 
(IL-1β) was higher for the blood clot than any of the platelet concentrates. 
Furthermore, no statistically significant difference in the amounts of insulin-like 
growth factor-1 (IGF-1) as well as platelet-derived growth factor AB (PDGF-AB) 
that were released, could be established between the blood clot and the various 
platelet concentrates. The highest concentration of transforming growth factor 
β1 (TGF-β1) released, was that from the L-PRF (I/E) clot. When investigating 
the release kinetics of L-PRF (I/E), L-PRP and the blood clot, the researchers 
reported that the various growth factors were released at different times as well 
as for different lengths of time. Upon examining this effect on the migration on 
human bone marrow-derived mesenchymal stem cells (MSC) and Human 
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umbilical vein endothelial cells (HUVEC), it was found that  no difference in the 
overall patterns of migration were seen for any of the groups tested. However it 
was reported that IGF-1 had a positive correlation on the migration of both cell 
types whereas PDGF-AB had a negative correlation to both cell types i.e. MSC 
and HUVEC. Interestingly, IGF-1 had the highest concentration in the blood clot 
and there was no difference in release kinetics of this growth factor when 
compared to L-PRF and L-PRP 23.  
In a similar study, where the release of growth factors as well as the effect of 
platelet concentrates on tendon cells was compared to that of a whole blood 
clot, it was shown that the platelet concentrates had the ability to significantly 
increase cell proliferation as compared to that of the blood clot 27. However, it 
must be pointed out that the technique of preparing these platelet concentrates 
was completely different between the two studies, thereby influencing the final 
architecture and possible biological properties of the various platelet 
concentrates used. 
Bone morphogenic proteins 
Bone morphogenic proteins (BMPs) are low molecular weight glycoproteins that 
are responsible for ectopic bone formation 28. First described in the 1960’s, 
these proteins play a critical role in various aspects of cell function, 
differentiation and tissue repair. More significantly, they are crucial in the 
maintenance of skeletal integrity and bone fracture healing.  BMPs are released 
and synthesised by a number of cells including osteoblasts, osteoprogenator 
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cells, chondrocytes, platelets and macrophages 28,29. It is therefore clear that 
the synthesis of these key proteins is not restricted to bone forming cells.     
It has recently been shown that L-PRF (I/E) releases BMP-2 over a period of 7 
days, but that the amount of BMPs that are released, is relatively small 21. 
Dohan Ehrenfest et al found it difficult to explain the exact origin of these BMPs, 
but attributed this to the presence of leukocytes in the platelet concentrate 21. 
However it has been shown previously that platelets themselves contain 
significant amounts of BMP-2 and that the release of these proteins is pH 
dependent 30. As a result, it has been suggested that platelet’s release of BMP-
2 may play a significant role in the initial stages of bone fracture healing, since 
the pH in this environment is optimal for platelet activation 30. Other researchers 
have found that other BMPs such as BMP-6, BMP-7 and BMP-4 are also 
released by platelets, and that the concentration of BMPs contained in platelets, 
is patient dependent 31,32. It has further been shown by genome-wide micro 
analysis that lysed platelets have the ability to upregulate proliferative pathways 
of osteoblast like cells in-vitro 33.  
The findings from various studies investigating the BMP potential of L-PRF as 
well as its variants is potentially groundbreaking, however in light of the above, 
future studies need to take into account patient variation as well as the pH of 
the test environment 21,28,30,32. This may have clinical implications and explain 
the reasons for inconsistent clinical outcomes of platelet-rich concentrates when 
used for bone grafting or regeneration. By implication then, it would currently be 
difficult to control the amount of BMP released from platelets when used in a 
clinical setting.   
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Stem cells 
Stem cells are undifferentiated cells that can differentiate into specialized cells, 
including more stem cells or other cells types during development 34. Recently, 
a variant of L-PRF(C) has been analysed, and thought to contain hematopoetic 
stem cells (HSC) 35.The presence of these HSC cells are mostly determined 
using immunohistochemical analysis for the detection of specific cell markers, in 
this case, CD34. This is a transmembrane phosphoglycoprotein that is 
predominantly used as a marker for HSC as well as hematopoetic progenitor 
cells 36. Although traditionally linked to cells of hematopoetic cell origin, CD34 
has recently been linked to other nonhematopoetic cells types such as 
mesenchymal stem cells (MSC), endothelial progenitor cells and interstitial 
dendritic cells 36. Therefore, the mere presence of CD34 positive cells, does not 
assume that a specific cell type such as HSC, exists. In order to verify the 
existence of HSC, the cells should in addition to the presence of CD34, display 
other traits such as a low expression of CD90, a lack of expression of CD38 and 
human leukocyte antigen-DR (HLA-DR), as well as a panel of mature lineage 
markers (lin-) 36.  
The potential of CD34 positive cell types in L-PRF(C) and its variants appears 
promising, but requires further investigation due to the variation in CD34 
detection methods. Almost all CD34 detection methods use antigen-antibody 
interactions. These interactions are noncovalent and are reversible, therefore 
potentially affecting the detection of the CD34 marker. Because of this, it is 
suggested that multiple methods be used to verify the presence of CD34 36.  
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Although peripheral blood has been used as a source for CD34 positive cells in 
many forms of therapy, the baseline concentration of these cells in peripheral 
blood is relatively low 37,38. As such, most therapies that require the use of 
CD34 positive cells enrich the presence of these cells in the vascular by using 
granulocyte colony-stimulating factor (G-CSF) 39. This allows for an adequate 
amount of cells to be harvested for local or systemic transplantation. Whether 
the levels of CD34 positive cells of L-PRF and its variants are at therapeutic 
concentrations, requires further analysis. 
Clinical results from studies using L-PRF        
Several randomised controlled trials have been published that involve the use of 
L-PRF in the clinical management of a variety of disorders 40-43. These trials 
have contradictory results, which may be related to the variation of techniques 
and equipment used to prepare L-PRF 41-45. Nevertheless, several articles 
present positive clinical outcomes even when not using standardised 
preparation techniques 46-49. Most of these publications are case reports, 
however, even randomised controlled trials where the RCF is not verified, have 
shown positive clinical outcomes 43. This is similar to reports about the use of 
PRP, which show a variety of clinical results based on the various methods of 
producing PRP 18. Further research is therefore required to verify clinical 
differences for the various methods of preparing L-PRF.   
Does generic L-PRF exist? 
L-PRF (O) is prepared using the RCF of 400g as well as the centrifuge time of 
12 minutes, using a non-purpose built table top centrifuge and standard blood 
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collecting tubes. This method allows for the preparation of a platelet and 
leukocyte concentrate without the need for specialised equipment. Several case 
reports have demonstrated positive clinical results using this preparation 
method 50,51. However one cannot assume that this generic type of L-PRF has 
similar properties to that of L-PRF(C) or to L-PRF(I/E) since it has previously 
been showed that the centrifuge type may a play a significant role in the final 
morphological features of the end product 19,20 . Further analysis of this 
biomaterial is therefore required to determine equivalence to the established 
protocols for L-PRF preparation.   
Conclusions 
The introduction of L-PRF as an bioactive material with possible regenerative 
properties has resulted in it being adopted for use in various clinical procedures. 
However, the widespread use of this material has resulted in several variants of 
it being produced. Whether the biological properties of all these variants are 
similar, is unknown. Contradictory clinical results are reported in the literature 
with several generic types of L-PRF showing diverse results. In order to 
minimise the controversies associated with L-PRF, further research is required 
to determine which factors affect the biological properties of the material and 
whether these factors are clinically beneficial and relevant.  
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3.3 Conclusion 
The current report highlights various factors that affect the preparation of L-PRF 
and concludes that these factors may play a role in the structure, biological 
behaviour, and clinical characteristics of the resultant biomaterial. To the 
author's knowledge, it is the first such publication that addresses these factors 
as a collective, in a single manuscript. It also critiques the claimed biological 
properties of the biomaterial, specifically the concentration of its BMP release, 
as well as the significance of the detected stem cells. Patient variation is 
mentioned as an important contributing factor that influences its biological 
properties.  This implies that it may be difficult to reproduce the exact 
biomaterial from different subjects. It is also shown that even though L-PRF is 
prepared using different protocols, that this variation does not necessarily imply 
negative clinical outcomes. Studies showing positive clinical outcomes, where a 
non-standard L-PRF preparation method was used, are highlighted. However, 
even though the clinical reports of the use of L-PRF are largely positive, 
inconsistencies are eluded to in the literature. The influencing factors 
highlighted in this paper may explain these inconsistencies. Furthermore, the 
authors question whether, based on the literature reports where positive clinical 
outcomes were observed when non-standard L-PRF preparation protocols were 
used, if a generic, biologically active, and clinically beneficial L-PRF, could be 
prepared using non-specialised equipment and materials.  Based on the 
author’s previous clinical reports (VI), as well as considering the factors 
affecting the preparation of the biomaterial, we further tested this hypothesis, 
the results of which are further expounded upon in subsequent chapters. 
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Chapter 4  
4.1 The effect of preparation method on the fibrin diameter of leukocyte- 
and platelet-rich fibrin (L-PRF). 
The structural properties of L-PRF are well known and have previously been 
reported upon in the literature (Dohan Ehrenfest et al, 2010a). It has also been 
shown that differences in preparation method could influence this structure, 
resulting in biomaterials that may not behave the same biologically (Dohan 
Ehrenfest et al, 2018). This may have clinical consequences. A significant 
feature of L-PRF is its fibrin fibre architecture which consists of an interwoven 
mesh of fibrin fibres interspersed with platelets and leukocytes.   It is this 
structure that is assumed to impart reliance to the biomaterial thereby allowing 
for the release of growth factors over an extended period (Dohan Ehrenfest et 
al, 2006a). This is a significant distinguishing factor that differentiates L-PRF 
from other platelet concentrates.  Since the structural properties of L-PRF were 
originally described, subsequent publications have further investigated these 
characteristics, with the most comprehensive of those being that of Bai et al 
(2017).   The study however had several limitations, including the use of animal 
blood, and a centrifuge that did not conform to that of the original protocol. A 
similar study was carried out by Sam et al (2015) in which they examined the 
mechanical and surface characteristics of L-PRF using a scanning electron 
microscope. Their study had similar limitations that plagued most L-PRF 
investigations i.e. the method used to prepare L-PRF did not follow the original 
protocol, making comparisons, difficult. In the present study we determined 
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whether modification of the original protocol used to prepare L-PRF (by using 
non-standardised equipment), influenced the fibrin fibre diameter and 
architecture of the resultant biomaterial. This is essential, since fibre diameter is 
known to be directly related to the stiffness of the clot and hence susceptibility 
to dissolution (Wei Li et al 2016). To the author’s knowledge, no similar 
investigation had previously been published with regards to this specific platelet 
concentrate. It allowed for the first time, a description of the morphological 
characteristics of this modified version of L-PRF, a biomaterial which had 
previously been proven to have positive clinical outcomes (VI).  For this 
investigation we chose to examine L-PRF that was prepared using two different 
methods, and examined their gross and ultrastructural morphology using SEM. 
The resultant manuscript was accepted for publication in the South African 
Dental Journal of May 2018. 
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Abstract 
Introduction: The use of leukocyte and platelet- rich fibrin (L-PRF) in 
regenerative surgery has increased exponentially in the last decade.  Because 
of it’s success, various centres have introduced the biomaterial as a routine 
inclusion in oral grafting procedures. Evidence suggests that the physical 
properties of fibrin fibers play an essential role in homeostasis of blood clots. 
Only a limited number of studies have investigated the features of fibrin fiber 
diameter of L-PRF concentrates. Aims and objectives: To investigate and 
compare the fibrin network and fiber diameter of L-PRF prepared by two 
different methods. Methods: Blood was collected from a single volunteer using 
established protocols. The resultant L-PRF clots were then prepared and 
examined using scanning electron microscopy. The results were subjected to 
statistical analysis. Results: L-PRF prepared using the modified method had 
larger diameter fibers than that prepared using the official protocol. The 
difference was statistically significant (P=0.001). There was also a larger 
amount of thicker fibers observed in the modified L-PRF group. Conclusions: 
Preparation methods affect the fiber diameter of L-PRF. This may have 
consequences that influence the biological properties of the biomaterial.  
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Introduction 
The use of leukocyte and platelet- rich fibrin (L-PRF) in regenerative medicine 
has increased exponentially in the last decade 1. First introduced by Choukroun 
et al in 2001, this autologous, blood derived platelet concentrate that has been 
extensively used in oral surgical procedures, with clinical success in the fields of 
surgical implantology and regenerative periodontology 1, 2. Because of its 
popularity, various centers have introduced the biomaterial as a routine 
inclusion in oral grafting procedures 1. Although Choukroun had specified the 
original method of L-PRF preparation, this protocol had been modified over 
time, with several variants of L-PRF now being made available 3, 4. The 
modification of the original protocol included updating the equipment and 
materials used, as well as varying the centrifuge time and force 4. This resulted 
in two further variants of L-PRF being introduced i.e. advanced PRF (A-PRF) 
and advanced PRF+ (A-PRF+) 4. Both of these variants use a lower centrifugal 
force when compared to the original protocol and this is thought to have distinct 
advantages over the original preparation method 3, 4.  
An important component of the biological advantages of L-PRF concentrates, is 
the specific structure which comprises a dense fibrin network, with high 
concentrations of platelets and leukocytes interspersed within the mesh of fibrin 
fibers 5,6.  It is thought that this allows growth factors to be trapped, and 
released over a prolonged period thereby enhancing healing and regeneration 6, 
7. Recently, the role of fibrin structure has been researched for its role in blood 
clots 8-11. Evidence suggests that the physical properties of fibrin fibers play an 
essential role in homeostasis of blood clots by affecting their mechanical and 
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biological contribution properties 8, 12. However, only a limited number of studies 
have investigated the features of fibrin fiber diameter of L-PRF concentrates 13, 
14. 
With the increase in popularity of L-PRF, several authors have reported positive 
clinical results using L-PRF that is prepared using non-standardised equipment 
or materials 15-17. An example of this type of “modified” L-PRF has been 
clinically documented in previous publications by Peck et al 18, 19. This deviation 
from the proposed protocol for L-PRF may result in structural or functional 
consequences to the biomaterial that is being produced 20-22. In this report, 
using scanning electron microscopy (SEM), we analyse and compare the fibrin 
network and fiber diameter of two different methods of L-PRF preparation i.e. 
our modified protocol for the preparation of L-PRF as previously described by 
Peck et al, and A-PRF+, prepared via the recommended protocol as previously 
outlined in the literature  4, 18, 19.       
Materials and methods 
The study was conducted at the Dental Faculty, University of the Western 
Cape, Cape Town, South Africa in 2017. Ethical clearance was obtained from 
the research ethics committee of the above said university with the following 
reference number: BM 16/3/31 
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Preparation of the L-PRF samples 
Thirty six milliliters of blood was obtained from a single 30 year old healthy male 
volunteer via venipuncture of the left antecubital vein. Two methods were used 
to prepare L-PRF, i.e.;  
1. Modified L-PRF:  
Blood samples were collected in 9ml blood collecting tubes that contain 
clot activator i.e., Vacuette® 9ml serum tubes with Z Serum Clot 
Activator (Greiner BioOne International AG, Germany). The blood 
samples were then immediately centrifuged at 400g for 12 minutes in a 
standard benchtop centrifuge (PLC-03, Hicare International, Taiwan).   
2. A-PRF+: 
Blood samples were collected in 10 ml A-PRF+™ tubes (Process for 
PRF, Nice, France), and centrifuged for 1300RPM for 8 minutes, using a 
dedicated tabletop centrifuge (PRF DUO™, Process For PRF, Nice, 
France).  
After being centrifuged, the blood from both groups separated into 3 distinct 
layers (Fig 1). From previous reports, the layers could be distinguished as a 
topmost layer consisting of acellular platelet poor plasma, Modified L-PRF/A-
PRF+ in the middle, and red blood cells at the bottom of the test tube 5, 6. In 
order to standardise L-PRF thickness, the resultant L-PRF clots from both 
groups were removed from the tubes, and subjected to controlled compression, 
using a specifically designed tool i.e., the PRF Box ® (Process for PRF, Nice, 
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France) (Fig 2) 23. All the samples were then transferred for preparation for 
scanning electron microscopy analysis.  
Preparation for scanning electron microscopy (SEM) 
All the samples were fixed using 2.5% gluteraldehyde in phosphate buffered 
saline (PBS) for 1 hour. Each specimen was removed and washed in PBS for 5 
minutes (twice) and thereafter distilled water for 5 minutes (twice). The 
specimens were then dehydrated serially with 50%, 70%, 90% and 100% 
ethanol, with each dehydration step taking 10 minutes. The samples were then 
transferred to the Electron Microscope Unit, Department of Physics, University 
of the Western Cape, for critical point drying, gold-palladium coating, and 
mounting for SEM analysis. 
Scanning electron microscope observation    
The surface microstructure of each specimen was analysed using the same 
scanning electron microscope (AURIGA Field Emission High resolution SEM, 
Carl Zeiss Microscopy GmbH, Jena, Germany). All measurements of the fibrin 
networks were carried out at 10 000 times magnification. At least 200 fibers 
were randomly selected from each group and measured for analysis using 
ImageJ version 1.51o software developed by Wayne Rasband (National 
Institutes of Health, USA). The data was captured using Microsoft Excel 2010 
(Microsoft Corporation, Washington, USA) and statistically analysed using the 
Mann-Whitney U and Wilcoxon W tests.  
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Results 
Descriptive analysis of Modified L-PRF and A-PRF+ fiber networks 
Under low magnification (1000 times) both samples show similar morphological 
characteristics. A dense mesh of fibrin fibers was evident with scattered cells 
seen on the surface for each sample (Fig 3). For the Modified L-PRF sample, 
more irregular bodies were present, possibly signifying the presence of platelets 
(Fig 3) 24. This may be characteristic of the region observed and may not be 
representative of the sample as a whole 6. No distinction in fiber architecture for 
the 2 groups was seen at this level of magnification. 
When observing the samples at higher magnification (10 000 times), the fiber 
mesh showed distinct characteristics (Fig 4 and 5). For both groups, the fibers 
were densely arranged in a netlike structure with clear spacing and crosslinking 
seen. Distinct differences could be noted with regards to fiber diameter, with 
both groups showing non-uniform fiber thickness. Thicker fibers were 
interweaved with thinner fibers and many of the fibers showed irregular surface 
characteristics indicative of platelet-fiber interaction 24. The presence of cellular 
bodies could be noted for both groups. Distinguishing between both groups 
solely on the basis of SEM analysis, was difficult.  
Analysis of Modified L-PRF and A-PRF+ fibrin fiber thickness 
A total of 437 fiber samples were analysed from both groups. The fibers were 
measured in nanometres (nm) with a range of 100-808nm and a mean of 
281nm being observed for the Modified L-PRF group. For the A-PRF+ group, 
fiber diameters ranged from 43-742nm with a mean diameter of 256nm. For 
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both the groups, statistical analysis revealed that the mean fiber diameter was 
not a clear reflection of the various fiber groups present. It also showed that that 
the fibrin fiber diameters were not equally distributed in each of the groups and 
that a wide range of fiber diameters were present (Fig 6). These fiber groups 
were present in both Modified L-PRF and A-PRF+, but were significantly 
different in their distribution for the two versions of L-PRF. Of the two groups 
tested, Modified L-PRF was characterized by larger diameter fibers and had a 
higher amount of thicker fibers when compared to A-PRF+ (Fig 6).   
Because of the wide range of fiber diameters noted in each of the sample 
groups tested, arbitrary size classes were selected to better illustrate the range 
of fiber diameters seen. This size selection was based on a previously 
published model which analysed human fibrin networks 25. Consequently the 
fiber diameters were categorised into 3 groups based on “thickness” i.e. thin 
(lowest thickness to 85nm), intermediate (86 - 202nm), and thick (203nm to 
highest). This is represented by the histogram A.  
Discussion 
L-PRF in its various forms has shown promising results in both in-vitro and in-
vivo studies 1, 15-19. This is attributed to the structural integrity of the biomaterial 
which results in a matrix that contributes to the prolonged release of various 
growth factors as well as provides a network for the migration of cellular 
components 2-6. The process of preparing L-PRF was initially documented by 
Choukroun in 2001 2. However since the original protocol was introduced, 
several authors have attempted to replicate the platelet concentrate using non-
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standardized methods 15-19. Although clinically successful, the ultrastructure of 
these L-PRF variants has not been reported upon extensively.  
The data from this study indicates that using both the A-PRF+ protocol as well 
as the modified protocol for the preparation of L-PRF that we used, may yield L-
PRF clots that appear similar macroscopically. Both preparation methods 
resulted in separation of the centrifuged blood into 3 distinct layers as 
previously described. When examining L-PRF clot size, the resultant L-PRF 
clots appeared smaller for the Modified L-PRF group, however this was not 
quantified statistically.  We speculate this may be due to using a 9ml blood 
collecting tube as opposed to 10ml in the A-PRF+ group. However the size of 
the collecting tube may not be the only factor affecting L-PRF size, since recent 
research indicates that using different centrifuges may affect L-PRF clot size 20-
22.   
Compressed L-PRF clots from both groups appeared similar under low 
magnification (x1000), with a dense fiber network and large range of fiber 
diameters being seen. The density of the fiber networks seen in this study has 
previously been reported upon and is thought to be related to the compression 
of the clots in the PRF-Box™ 23. When the fiber diameters were analysed as 
thin, intermediate, and thick, the majority of fibers in both groups were classified 
as thick. This differs from the findings of Vieira et al 2009, who reported that the 
predominant fiber patterns were thin.  
Previous studies that have examined the features of fibrin associated with L-
PRF, have often used the mean diameter of the fibers to describe the 
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characteristics of the L-PRF clot or are limited to a subjective description of the 
fiber diameter 13, 20. In the present study, statistical analysis revealed that using 
the mean diameter, did not reflect the range and frequency of the fiber types 
observed. Therefore when analyzing fiber diameters for Modified L-PRF and A-
PRF+, we identified clear groupings (Fig 6). These were statistically significantly 
different for the two L-PRF groups, with the Modified L-PRF showing a higher 
number of larger diameter fibers as compared to A-PRF+ (Table 1). The exact 
reasons for this difference in not known, but is probably due to differences in the 
centrifugal force used, centrifuge time, centrifuge make, agents present in the 
blood collecting tubes and shape of the blood collecting tubes 20, 26 .  Because 
all the samples were taken from the same individual in a 15 minute period, the 
above may serve as an adequate explanation for the differences in fiber 
diameters seen. However, one must consider that for different individuals or in 
instances where blood is collected from the same individual at different times, 
that other factors such as pH, the presence of zinc, ionic strength, 
concentrations of calcium, polyphosphate, fibrinogen, fibrinogen binding 
proteins and thrombin, may also influence fiber thickness and network density 
9,12.  
The tubes used to collect blood to prepare Modified L-PRF, are coated with 
silica. Silica is a known procoagulant. It binds to plasma proteins and has the 
ability to cause reversible structural changes to these molecules 27,28. This is 
dependent on the size of the silica particle, with smaller silica particles 
demonstrating the ability to shorten coagulation time and increase the activation 
of factor X, whilst at the same time activate platelets 28.  The fact that silica 
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coated tubes were used in the preparation of the Modified L-PRF, may further 
contribute to the morphological differences seen between the 2 groups. 
The individual fiber diameters seen in the samples tested may have implications 
for the mechanical stability of each L-PRF clot 29. Clots with thicker fibers tend 
to be less elastic than those with thinner fibers and may be more readily 
degraded by the fibrinolytic system 8, 29. This may have consequences for the 
biological behaviour of L-PRF since structural integrity and the controlled 
release of growth factors is thought to be a major contributing factor to its 
clinical success. Therefore, one might assume that because A-PRF+ has a 
lower amount of thick fibers than Modified L-PRF, that its rate of dissolution may 
be slower than that of the Modified L-PRF. As such, its ability to remain intact 
may be prolonged as compared to other platelet concentrates and may explain 
the extended release of growth factors as recently reported 3,4.   
Conclusions 
To the author’s knowledge, this is the first presentation of the morphological 
fiber characteristics of an L-PRF clot prepared using a specific modified protocol 
as previously described by the authors. When compared to an established 
protocol, the resultant L-PRF clot appears morphologically similar to it’s A-PRF+ 
counterpart with a dense fibrin network interspersed with platelets and other 
blood cells. However, clear differences are noted for the fibrin fiber diameter 
with Modified L-PRF showing a higher proportion of larger diameter fibers. The 
reason for these differences is speculated to be associated with the different 
protocols used to prepare the platelet concentrates.  One might therefore 
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assume that changes in the protocol of preparation of L-PRF may directly affect 
it morphological structure. Whether these differences affect the clinical efficacy 
of these biomaterials is unclear, and warrants further research.  
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Figures 
 
Figure 1. Modified L-PRF (left)  and A-PRF (right) 
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Figure 2. PRF Box with prepared L-PRF before compression 
Figure 3. Modified L-PRF and A-PRF+ (Low  magnification) 
A-PRF+ Modified -LPRF 
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Figure 4. Modified L-PRF (High magnification) 
 
 
Figure 5. A-PRF + (High magnification) 
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Figure 6. The distribution of fiber diameters for Modified L PRF (group 1) and 
A-PRF+ (group 2) measured as length in nm 
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Ranks 
 Grou
p 
N Mean 
Rank 
Sum of 
Ranks 
Length_nm M-
PRF 
231 238.06 54992.00 
A-
PRF+ 
206 197.63 40711.00 
Total 437   
 
Test Statisticsa 
 Length_nm 
Mann-Whitney U 19390.000 
Wilcoxon W 40711.000 
Z -3.343 
Asymp. Sig. (2-tailed) .001 
a. Grouping Variable: Group 
 
Table 1 a,b. Results of testing the difference in fiber diameter ( Length in nm) 
between both groups with the Mann Whitney test: 
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Histogram A. The distribution of “thin, intermediate and thick” fibers of 
Modified L-PRF (group1) and A-PRF+ (group 2)   
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4.3 Conclusion 
The current investigation, to the best of our knowledge, is the first to describe 
the gross and ultrastructural features of L-PRF prepared using a protocol that 
was previously introduced by the author. The findings showed that L-PRF 
produced in this way, had specific characteristics that include; a similar gross 
and microscopic surface morphology to that of L-PRF prepared using a lower 
centrifugal force. This included a dense mesh-like network of fibrin fibres 
interspersed with cellular components that may be indicative of platelets and 
leukocytes. The fibrin fibres had a non-uniform diameter with a mean of 281nm, 
and a distinct predominance of fibres that could be regarded as thick (> 
203nm). These "thick" fibres were found in higher amounts as compared to that 
of the L-PRF produced by a lower centrifugal force. Except for the differences in 
the amount of "thick" fibres, both groups showed very similar morphological 
characteristics. This may partly explain similarities seen in the clinical 
performance of these biomaterials, both which show the potential to accelerate 
wound healing. The effect of this biomaterial on cellular growth is further 
expounded upon in subsequent chapters.   
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Chapter 5  
5.1 Platelet- Rich Fibrin (PRF) - The effect of storage time on platelet 
concentration 
The development of autologous platelet concentrates has resulted in various 
forms of these biomaterials being used to stimulate faster wound healing over 
the past two decades (Dragonas et al, 2018; Najeeb et al, 2017; Ali et al, 2015). 
Most of these materials are prepared during or slightly prior to the clinical 
procedure. This is thought to result in an optimum biomaterial, which has 
maximum clinical efficacy. With the development of Choukroun’s method of 
producing L-PRF, this philosophy had been perpetuated, with the initial 
literature indicating that the biomaterial can only be stored for up to 15 minutes 
in the blood collecting tube after formation. It was assumed that this would 
preserve its mechanical properties (Dohan Ehrenfest, 2010c). This in turn, is 
thought to affect its biological behaviour (Dohan Ehrenfest et al, 2012a). This 
has clinical implications in that the biomaterial must be prepared during the 
procedure and be transferred to the wound as soon as possible or if stored, 
requires the need for specialised equipment (Dohan Ehrenfest et al, 2010c). 
With increased complexity of different procedures, this often meant that 
phlebotomy had to be carried out whilst the patient was sedated and dressed 
with sterile drapes. This increased the likelihood of contamination of the surgical 
area, especially if the phlebotomy was carried out by someone not directly 
involved in the surgical procedure. We therefore sought to examine whether 
storage or L-PRF (using a modified preparation method), for a period of longer 
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than 15 minutes, in its blood collecting tube,had a negative effect on the 
biomaterial, with specific reference to its platelet concentration. The 
measurement of platelet concentration was used as an indirect measurement of 
L-PRF breakdown, since platelets adhere to the fibrin network of the biomaterial 
and are released upon its dissolution. This investigation formed part of a 
Masters Degree, with parts of the results obtained being submitted as a thesis 
(Peck, 2011). The resultant data was gathered and formulated into a scientific 
paper that was subsequently published in the South African Dental Journal of 
November of 2015.  
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Title: Platelet- Rich Fibrin (PRF) - The effect of storage time on platelet 
concentration 
Abstract 
The aim of this study was to determine whether storage time had a significant 
effect on the platelet concentration of platelet-rich fibrin (PRF). Three blood 
samples were drawn from each participant into a sterile (non-anticoagulant 
containing) blood sampling tube. Two of the blood samples were centrifuged to 
form PRF. The third non-centrifuged sample was used to measure the baseline 
blood platelet concentration. After PRF had formed, it was removed from the 
respective test tubes at different time intervals i.e. immediately after 
centrifugation (Group A) and after 60 min of storage in the blood collecting tube 
(Group B). The residual blood from each group was tested for platelet 
concentration and compared to the baseline reading (as an indirect measure of 
the platelet concentrate of PRF). The PRF produced in Group A (PRF A) had a 
mean platelet concentration of 274 ± 57.8 × 109/L, whereas the PRF of Group B 
(PRF B) was 278 ± 58.2 × 109/L. A statistically significant difference was seen 
between the groups (p < 0.001). Conclusions: Storage time has a significant 
effect on the platelet concentration of PRF. Further research is required to 
determine whether this has any clinical relevance. 
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Introduction 
Wound healing is a complex process characterised by the repair and 
reconstitution of lost or damaged tissue. Identification of the pathological and 
biochemical mechanisms that regulate tissue repair and homeostasis has long 
been regarded as central to their therapeutic exploitation in the clinical setting. 
By the mid-1990s, several methods were proposed to enhance wound healing, 
including the administration of high concentrations of human platelets to 
affected areas 1-6. It was assumed that platelets optimised wound healing by 
promoting the secretion of growth factors (GFs) necessary for tissue repair 7-9. 
The most common platelet concentrate used in these procedures is platelet-
rich-plasma (PRP) and by the early part of the 21st century, its use in various 
surgical procedures was commonplace 1, 4, 10, 11. However, the preparation of 
PRP often requires the use of specialised equipment, chemicals and animal-
derived additives. This increases the risk for complications secondary to allergic 
reactions to certain animal-derived additives 12-14.  As a result, researchers have 
sought more efficient and safer methods of concentrating platelets for surgical 
use 1.  This led to the production of platelet-rich-fibrin (PRF), a platelet 
concentrate that neither contained additives nor required the use of specialised 
equipment during its preparation. First introduced by Choukroun et al (2001), 
PRF has been studied extensively and is now regarded as a biological scaffold 
different to PRP 15. However, even though the use of PRF is gaining 
widespread clinical acceptance, several questions regarding its biological 
stability remain unanswered 16, 17. The aim of this this study was to analyse the 
effect of storage time on the platelet concentration of this unique biomaterial. 
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Materials and Methods  
The study was conducted under the principles outlined by the “World Medical 
Association Declaration of Helsinki, Ethical Principles for Medical Research 
Involving Human Subjects” of 2008. Ethical approval was obtained from the 
Ethics Committee of the University of the Western Cape (Registration number 
11/4/29). All participants were fully informed of the research protocol and had to 
sign a declaration of informed consent before being allowed to participate in this 
cohort analytical study. A total of 30 healthy participants (16 females and 14 
males) were enrolled into the study. Participants were drawn from the current 
patient pool as well as staff members based at the Dental Faculty, University of 
the Western Cape.  All participants had 3 separate blood samples collected by 
venipuncture. Two of the samples were acquired using tubes containing clot 
activators, i.e., Vacuette® 10 ml serum tubes with Z Serum Clot Activator 
(Greiner BioOne International AG, Germany), whereas the remaining blood 
sample was drawn into a 10 ml BD Vacutainer® tube that contained 
dipotassium-EDTA, an anticoagulant (BD Diagnostics, New Jersey USA).  
All the blood samples collected in the anticoagulant containing tubes were used 
to measure baseline platelet concentrations, whereas the remaining blood 
samples (collected in the Clot Activator containing tubes) were used to prepare 
PRF by centrifugation (400g for 12 minutes) in a standard benchtop centrifuge 
(PLC-03, Hicare International, Taiwan) (Figure 1).  Therefore, from each study 
participant, 2 samples of PRF were obtained (Figure 2). The 2 PRF samples 
were then randomly allocated into either group (Groups A or B) using a simple 
coin toss.  
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Figure 1: Benchtop centrifuge 
 
Figure 2: Prepared PRF 
For Group A, the PRF was removed from the tube immediately after preparation 
(0 min), whereas for Group B, the PRF remained in the tube and was only 
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removed after 60 minutes. The PRF produced from each group was designated 
PRF A and PRF B respectively.  Because a direct measurement of platelet 
concentration of PRF is not yet possible, we calculated the PRF concentration 
for each group indirectly, by determining the numerical difference between the 
residual platelet concentration (of the remaining serum after removal of PRF) 
and the baseline platelet concentration for each specific study participant. In this 
study, platelet concentration analysis was carried out using an electronic 
automated cell counter (Advia 2120, Siemens AG, Erglangen, Germany). 
Data was collected and entered into a spreadsheet (Microsoft Office 2010 
Excel, Microsoft Corporation, Washington). The results were compared and 
analysed statistically using SPSS® Version 13 for Windows.   
Results and Discussion 
A total of 30 participants (16 females and 14 males) were entered into the 
study. The mean age of the participants was 41.7 years, with male subjects 
being slightly younger than their female counterparts (41.3 years for males vs 
42 years for females). The youngest participant was 24 years old and the oldest 
58 years old. 
Platelet concentrations obtained from analysis of all 30 participants were within 
the normal laboratory reference range of 170-400 × 109/L of circulating blood. 
None of the participants displayed any significant haematological disease. The 
mean blood platelet concentration was 282.8 × 109/L (Table 1). There was no 
significant difference between the genders.  
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Table 1: Mean baseline platelet concentration in cells x 
109/l of blood 
 Baseline 
 Mean SD 
Males 275.14 43.13 
Females 289.50 69.64 
 
After removal of formed PRF from Group A, the residual serum yielded minimal 
concentrations of platelets. The mean concentration of remaining platelets was 
7.9 × 109/L (Table 2). For Group B, serum platelet concentrations were also 
minimal after removal of the prepared PRF with the mean concentration of the 
platelets being 4.0 × 109/L (Table 2).  
The residual mean platelet concentration of Group A was higher than that 
determined for Group B with the mean difference in platelet concentrates 
between the 2 groups being 3.90 × 109/L. Using a non-parametric Signed Rank 
Test, the statistical significance of the differences in platelet concentrates 
between the Groups A and B was analysed. The difference between the 2 
groups was statistically significant (p < 0.001). 
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Table 2: Mean baseline platelet concentration of residual blood in cells 
x 109/L 
 Mean N Std. Deviation Std. Error Mean 
Group A 7.9 30 3.03 0.55 
Group B 4 30 1.93 0.35 
 
The platelet concentration of PRF for both groups was calculated using the 
difference between baseline and residual platelet concentrations (Table 3). A 
paired t-test showed a statistically significant difference between the 2 groups (p 
< 0.001) (Table 4).  
Table 3: Mean calculated PRF platelet concentration in cells x 109/L of 
blood 
 Mean Std. Deviation Minimum Maximum 
PRF A  274.9 57.8 169 387 
PRF B  278.8 58.2 171 390 
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Table 4: Statistical analysis of PRF A and PRF B 
Mea
n 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
t df Significanc
e (2-tailed) 
   Lower Upper    
-3.9 3.133 0.572 -5.07 -2.73 -
6.81
8 
29 0.001 
* Paired t-test performed, P value is significant  
 
Discussion 
The purpose of this study was to determine whether storage time had any 
significant effect on the platelet concentration of PRF. Because the structural 
properties of the PRF clot does not allow for a direct measurement of its platelet 
concentration, we used the residual platelet values left in the blood tube after 
removal of the PRF clot as an indirect measurement of the platelet 
concentration in the PRF clot. This was in accordance with a previously 
published method 18. Higher residual values indicate that less platelets were 
contained in the removed clot whereas lower residual values would indicate that 
more platelets were transferred to the clot. The results from this study indicate 
that there is a significant difference in the mean platelet concentration of PRF 
when stored for 0 and 60 minutes. 
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From the platelet counts obtained in both test groups it was clear that a 
significant proportion of platelets had been removed from the blood after 
extraction of the PRF clots. In fact, when differences between the test groups 
and the baseline blood sample were compared, it was evident that 97-98% of 
the platelets were concentrated in the PRF clot (Table 3). This observation is 
similar to results published for previous studies (97%) 19. The natural process of 
fibrin and clot formation that occurs in the blood collecting tubes results in the 
entrapment of the majority of the available platelets in a fibrin matrix. This acts 
as a reservoir for a concentration of growth factors (GFs) required in the initial 
stages of wound healing 20. 
Although the physiology of PRF has been studied extensively, very few reports 
adequately document the ability of this platelet concentrate to be stored 21. 
Previous research has indicated that storing PRF under certain conditions may 
affect its ability to clinically yield positive results. In fact, it is not recommended 
to store the platelet concentrate in its blood collecting tube since it is assumed 
that it may disintegrate into an unusable form after about 15 minutes of storage 
22. Instead, several authors recommend storing the biomaterial in a metal dish 
or a proprietary designed storage box 17. Data regarding the maximal storage 
time and ideal storage temperature of PRF are largely lacking.  
In this study, we used standard blood collecting tubes with clot activators to 
store PRF for at least 60 minutes at room temperature. This particular duration 
of time was chosen based on the average time of typical periodontal surgical 
procedures at the Faculty of Dentistry, University of the Western Cape. The 
results of the study indicate that by using the presented protocol for platelet 
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concentrate preparation, it was possible to concentrate more than 97% of the 
available blood platelets into a readily usable form. This study also showed that 
by using the blood collecting tubes as a storage medium, that there was no 
detrimental effect on the platelet concentration of PRF. Indeed, storing the 
concentrate for 60 minutes resulted in a form of PRF that had significantly 
higher concentrations of platelets compared to non-stored PRF. The reason for 
this phenomenon is unclear, but may be related to the “clot activators” that line 
these tubes. Clot activators are often silica based and are used in plastic tubes 
to mimic the clotting effect of glass based blood tubes 22. As a result, a longer 
contact time between blood and these activators may enhance fibrin activation 
and clot formation, with subsequent platelet entrapment 18.  
Another reason for variation in platelet concentration seen in this study may be 
due to the fact that the recommended centrifuge time is too short to allow for 
complete clot formation to occur. Therefore, allowing the PRF clot to remain in 
the tube for a period longer than the recommended time, may result in a more 
complete physiological reaction taking place. 
The ability of PRF to sustain its platelet concentrate over the tested time may 
have significant clinical implications 8, 9, 22-24. Rather than drawing blood during 
the surgical procedure, it allows for blood to be drawn before the start of the 
procedure, thereby improving patient comfort and operator time. The ability to 
store the PRF in the same tubes in which it was formed, negates exposure to 
other environmental factors that may contaminate the sample. It is also cost-
effective, since no specialised equipment or storage facilities are required. This 
may be significant in resource poor settings.  
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PRF has been recognised as a biomaterial that includes living cells 18,19. In 
order to sustain cell viability over time, an isotonic solution is required for their 
storage. The blood collecting tubes, although not designed to store blood, act 
as containers for the PRF and the remaining formed elements and serum. 
Consequently, by storing PRF in the blood that it was derived from, the 
remaining serum, after PRF has formed, acts as a natural isotonic solution that 
sustains cell survival. 
The release of growth factors is a significant property of blood platelets [24]. 
Previous studies indicate that several of these factors play an essential role in 
osteogenesis and periodontal regeneration 20, 25. By using PRF, the release of 
these growth factors appears to be constant, and over a longer period of time 
when compared that seen by PRP 23. In a direct comparison between the two, 
PRP was shown to have an initial larger release of growth factors after 
activation. However, these high concentrations were not stable and decreased 
over time. On the other hand, PRF releases less growth factors initially, but 
sustains this release for a longer duration 23. A number of authors speculate that 
this may be due to the fibrin clot that forms a network and acts as a reservoir for 
the trapped platelets 18,19, 26. In the present study, it was shown that the platelet 
concentration of PRF improved over a period of 60 minutes of storage. We 
assume that this may be due to prolonged fibrin clot maturation. It is therefore 
reasonable to speculate that if PRF is stored until optimal fibrin formation is 
achieved, then higher concentrations of growth factors may be available from 
the PRF during wound healing. Whether this has any clinical significance 
requires further investigation. 
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Temperature may affect the storage potential of PRF and it has been suggested 
that storing it in near-freezing temperatures is not advisable. In this study, all the 
samples were stored at room temperature. It was clear that storage under these 
conditions had no detrimental effect on the platelet concentration of the PRF 
clot. 
Although the present study showed statistically significant differences between 
the two groups tested, some limitations were also evident. These include the 
limited number of study participants as well as the inability to directly measure 
the platelet concentration of PRF. Other factors include the small difference 
between the platelet concentrations of the groups tested. Although statistically 
significant, a mean difference of only 3.9 × 109 cells/L may not be clinically 
relevant and therefore warrants further research to validate the clinical 
significance of these findings. 
Conclusions 
The viability of storing PRF in its own blood collecting tubes has not yet been 
reported. This study showed that by using the above method of platelet 
preparation, it is possible to concentrate more than 97% of the available 
platelets into a PRF clot. The study also indicated that, unlike previous reports, 
clot disintegration does not take place after 15 minutes of storage, but rather 
remains stable over a period of at least 60 minutes and may in fact increase in 
platelet concentration during that time. Further investigations are warranted to 
determine whether this has any clinical implications. 
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5.3 Conclusion 
The above investigation examined the effect of storage time on the platelet 
concentration of L-PRF. To the author’s knowledge, this was the first paper 
published concerning this parameter. A significant finding was that 97% of 
platelets could be concentrated into a viable biomaterial using the method 
proposed by the author. It was also shown that storage of this specific L-PRF 
was possible for at least 60 min after preparation without any physical 
deterioration. Furthermore, the platelet concentration increased over that period 
of time, therefore rejecting the hypothesis that L-PRF would breakdown and 
release platelets if it was not used within 15 minutes of preparation. This implies 
that the biomaterial can be prepared before the surgical procedure, without 
increasing surgical treatment time. Because the investigation was limited to 
platelet concentration, further analysis was carried out on the efficacy of the 
biomaterial to stimulate cellular growth. The results are presented in a 
subsequent chapter of this thesis.   
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Chapter 6  
6.1 The effect of L-PRF (prepared by a modified protocol) on cellular 
activity  
The biological effects of L-PRF, has been extensively commented upon in the 
literature (Dohan et al, 2006a; Miron et al, 2017a; Miron et al, 2017c; Draganos 
et al, 2018). The biomaterial has been compared to other platelet concentrates 
and found to have a distinct morphology as well as have a stimulatory effect on 
various cells types (Dohan Ehrenfest et al, 2010a). Although the initial research 
was limited to cells of the oral region, L-PRF has proven to have similar effects 
on extra-oral tissues such as cartilage, ocular tissue, adipose tissue, meniscal 
tissue, periosteal cells, tympanic membrane tissue and salivary gland cells, 
amongst others (Verma et al, 2017; Arbildo et al, 2017; Miron et al, 2017c). A 
large proportion of the research investigating the effect of L-PRF, use the MTT 
assay as measurement of how L-PRF affects cell proliferation and viability. MTT 
is a standard laboratory assay that measures these parameters. It reflects the 
capacity of the mitochondria in living cells to convert MTT to purple formazan 
crystals that can be solubilized with dimethylsulphoxide (DMSO) or isopropanol. 
This effect is directly proportional to the cell number and is measured with a 
spectrophotometer at a wavelength of 540 nm. Rapidly dividing cells i.e. cells 
which show high rates of proliferation, reduce MTT at a faster rate than cells 
with low proliferative potential. The MTT assay therefore measures the ability of 
the cell to reduce MTT (viability) as well as the rate of cell division 
(proliferation). As a result, the MTT assay can also be used to measure 
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cytotoxicity (loss of viable cells) and cytostatic activity (shift from proliferation to 
quiescence).  
Previous research indicates that L-PRF has a direct positive effect on cellular 
growth (Dohan et al, 2006). This is commonly seen during the early phase of L-
PRF and cell interaction, with an initial proliferative burst often noted during the 
first few days of exposure (Dohan Ehrenfest et al, 2012a). The exact 
mechanism of how L-PRF interacts with these various cells is unknown but is 
speculated to involve the high concentration of GFs that the biomaterial brings 
to the site (Miron et al, 2017c, Miron et al, 2018). The L-PRF tested in this study 
is prepared using modified parameters that were initially developed by 
Choukroun et al (2001). These parameters may influence the biological 
properties of the material, as has been mentioned previously (I). The effects of 
diverting from the original protocol have increasingly become a point of 
contention, with many study results recently being called to questioned (Miron 
et al, 2018). It was therefore prudent that the L-PRF as prepared by the author 
be investigated for its biological effects on cells. The following published paper 
presents the results from an in-vitro investigation of the effect of L-PRF 
(prepared, using the authors method), either alone or in combination with 
another biomaterial, on living cells. Results from the study were published in the 
South African Dental Journal of 2018.  
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List of abbreviations 
 
3T3 cells mouse fibroblast cell line 
bFGF  basic fibroblast growth factor 
clHA  cross-linked Hyaluronic acid 
DMEM Dulbecco’s Modified Eagles Medium 
EDTA  ethylene-diamine-tetra-acetic acid 
EGF  epidermal growth factor 
FBS  foetal bovine serum 
HA  hyaluronic acid 
HGF  human gingival fibroblasts 
L-PRF  leukocyte- and platelet-rich fibrin 
PDGF-AB platelet-derived growth factor 
TGF-β1 transforming growth factor beta 1 
VEGF  vascular endothelial growth factor 
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Abstract 
Introduction. Leukocyte- and platelet-rich fibrin (L-PRF), an autologous derived 
platelet and leukocyte concentrate, was first introduced by Choukroun et al. in 
2001 and is currently used for several oral and maxillofacial procedures. 
Hyaluronic acid (HA) is an anionic, glycosaminoglycan that shows a wide range 
of physiological actions, acting as a cellular scaffold, stimulating cell adhesion 
and migration, as well as having anti-inflammatory effects. Aims and 
Objectives: To investigate the effect of cross-linked HA and L-PRF on 
fibroblast viability and proliferation. Methods: An in vitro laboratory study was 
conducted at The University of the Western Cape. L-PRF was prepared from a 
single healthy volunteer and cross-linked HA was obtained from a commercially 
available product. Analysis was carried out on 3T3 cells using MTT assay. 
Results: Both L-PRF and cross-linked HA are associated with cell viability and 
increased cell proliferation. L-PRF had it strongest proliferative effect after 24 
hours whereas HA had it strongest effect after eight days (p < 0.05). The 
combination of HA and L-PRF was not significantly better than the control (p > 
0.05). Conclusions: L-PRF prepared in a specific manner as outlined, as well 
as commercially available cross-linked HA, is compatible with cell growth and 
proliferation.  
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Introduction 
Leukocyte- and platelet-rich fibrin (L-PRF), an autologous derived platelet and 
leukocyte concentrate, was first introduced by Choukroun et al. in 2001 and is 
currently used for a number of oral and maxillofacial procedures.1 The use of L-
PRF has gained popularity in the field of surgical implantology, specifically for 
procedures involving soft and hard tissue augmentation.2-5 The preparation of L-
PRF differs from those of previous platelet concentrates in that it involves the 
use of a single spin protocol that results in an easily manipulated biomaterial 
that can be applied directly to the site of surgery.1 It is assumed that the 
concentrated growth factors associated with L-PRF optimize wound healing and 
decrease surgical recovery time.2,5 Consequently, L-PRF has been used in 
various fields, including dermatology and periodontal regeneration .2-5  
Hyaluronic acid (HA) is an anionic, glycosaminoglycan.6,7 It is a naturally 
occurring molecule that is found in high concentrations in the extracellular 
matrix of skin, cartilage, bone and periodontal ligament.7 Even though the exact 
function of HA has not yet been established, the molecule shows a wide range 
of physiological actions, acting as a cellular scaffold, stimulating cell adhesion 
and migration, as well as having anti-inflammatory effects.7 Commercially 
synthesized HA, in various forms, has been used in tissue engineering, 
dermatology, orthopaedics, and more recently, periodontal regeneration.7-10 
Traditionally, two forms of commercially synthesized HA exist, i.e., non-cross-
linked HA, and cross-linked-HA, resulting in different properties and indications 
for each form of HA.  
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The aim of the study was to investigate the effect of cross-linked HA and L-PRF 
on fibroblast viability and proliferation. 
Materials and methods 
The study was conducted at The University of the Western Cape, Cape Town, 
South Africa, in 2017. Ethical clearance was obtained from the Research Ethics 
Committee of the above university (reference number: BM 16/3/31). Informed 
consent was obtained from the blood donor. 
Preparation of the L-PRF  
Thirty six milliliters of blood was obtained from a single 56 year old healthy 
female volunteer. The blood samples were collected in blood collecting tubes 
that contained clot activator i.e., Vacuette® 9-ml serum tubes with Z Serum Clot 
Activator (Greiner BioOne International AG, Germany). These were then 
immediately centrifuged at 400xg for 12 minutes in a standard benchtop 
centrifuge (PLC-03, Hicare International, Taiwan) as has been previously 
described.11   Centrifugation separated the blood into three distinct layers (Fig 
1). The layers could be distinguished as a topmost layer consisting of platelet 
poor plasma, L-PRF in the middle, and red blood cells below. L-PRF was then 
removed with a sterile forceps, separated from the underlying red blood cells 
and shredded into smaller fragments using surgical scissors. 
Hyaluronic Acid (HA) 
A commercially available cross-linked HA (hyaDent BG, Bioscience GmbH) was 
used in the present study. It is sold as a clear gel contained in a dental 
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anaesthetic-type cartridge and is applied using a dental syringe and a 
specifically supplied needle. This specific formulation contains 2.0 mg/ml of 
sodium hyaluronate that is cross-linked with butanediol digylcidyl ether, 
resulting in a HA molecule with a unique chemical structure.  
Cells and Cell Culture 
In this investigation, the 3T3 fibroblast cell line was obtained from The National 
Repository for Biological Materials (Sandringham, South Africa). The 3T3 cells 
were incubated at 37°C in 5% carbon dioxide and 95% humidity in Dulbecco’s 
Modified Eagle’s medium (DMEM) with 10% foetal bovine serum (FBS) and 1% 
penicillin– streptomycin mix. Cells were grown to about 80% confluence and 
then trypsinized using trypsin-ethylene-diamine-tetra-acetic acid (EDTA). The 
cells were then seeded into 3 x 96-well plates and treated as follows; 
• Plate 1 – 1 drop of HA (HA group) 
• Plate 2 – 1 drop of HA added to a 1 mm x 1 mm fragment of L-PRF (HA 
+ L-PRF group) 
• Plate 3 – 1 mm x 1 mm fragment of L-PRF (L-PRF group) 
All the plates had an equal number of controls containing only DMEM. After a 
culture period of 24 hours to 10 days, each group was removed and 
proliferation and viability evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay.12 A minimum of 5 replicate 
experiments for each group was performed to ensure reproducibility. 
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Cell Viability and Proliferation Assay 
Cell viability (the metabolic activity of the cell) and cell proliferation (rate of cell 
division) were measured using the standard MTT assay (MTT, Sigma Chemical 
Co., Baltimore, MD, USA). The MTT assay or test is a sensitive and quantitative 
colorimetric assay that measures these parameters.12 It reflects the capacity of 
the mitochondria in living cells to convert MTT to purple formazan crystals that 
can be solubilized with dimethylsulphoxide (DMSO) or isopropanol.12 This effect 
is directly proportional to the cell number and is measured with a 
spectrophotometer at a wavelength of 540 nm. Rapidly dividing cells i.e. cells 
which show high rates of proliferation, reduce MTT at a faster rate than cells 
with low proliferative potential. The MTT assay therefore measures the ability of 
the cell to reduce MTT (viability) as well as the rate of cell division 
(proliferation). As a result, the MTT assay can also be used to measure 
cytotoxicity (loss of viable cells) and cytostatic activity (shift from proliferation to 
quiescence). For the current study, readings were taken from all groups with the 
control group set at 100%. 
Data Analysis 
Data from the MTT assay were captured using Microsoft Excel 2010 (Microsoft 
Corporation, Washington, USA) and statistically analyzed using the one-way 
ANOVA and Tukey’s test. 
Results 
With the control group set at 100%, the mean optical densities of each of the 
test groups were divided by that of the control group and expressed as a 
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percentage of the control value. The data from the MTT assay was correlated, 
and is presented in Figures 1-4. Statistical analysis is represented by Tables 1 
and 2. 
According to the results obtained, both L-PRF and cross-linked HA (clHA) as 
well as the combination of the two materials were compatible with cell viability 
and proliferation (i.e. none of the tested biomaterials tested displayed evidence 
of being cytotoxic or cytostatic). Cross-linked HA showed a statistically 
significant reduction in cell number when compared with the control group at 24 
hours (89.98% ± 9.83, p < 0.05). Thereafter cell viability steadily increased, 
reaching 100.88% ± 6.46 at day 10. Peak cell proliferation associated with HA 
was seen on day 8 and recorded as 112.20% ± 9.69. This was significantly 
greater than the proliferation seen in both other test groups for the same time 
period (p < 0.05). The HA + L-PRF group showed a cell viability of 85.44% ± 
12.35 at 24 hours. This was statistically significant (p < 0.05) when compared 
with the control group, indicating a negative effect on cellular proliferation in the 
first 24 hours. This difference was not significant for days 2, 5 and 7, but was 
again recorded on days 8 and 10 (p < 0.05). 
The L-PRF group showed the highest cell viability and proliferation after 24 
hours (108.99% ± 5.43). This was significantly higher than the other groups 
tested as well as higher than the control group (p < 0.05). At day 10, no 
significant differences were seen between all the test groups, however the HA + 
L-PRF group showed a significantly reduced number of cells as compared with 
the control (p < 0.05).   
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A comparison of the proliferative effects of the test groups indicate that both 
groups containing clHA showed a pattern of cellular proliferation that steadily 
increased from day 1 to peak at day 8 (clHA group) and day 7 (HA+L-PRF 
group) respectively. This was different to that observed for the L-PRF group 
where peak cell proliferation was seen after 24 hours and steadily decreased 
over the test period (Fig 4.) 
Discussion and Conclusions 
The results from the current study indicate that both L-PRF and cross-linked HA 
are biocompatible and induce cellular proliferation of fibroblasts in vitro.  
L-PRF 
It appears as if the effect of L-PRF used in this study is most pronounced in the 
first 24 hours when compared with any of the other materials tested. This may 
be due to the high concentration of growth factors present in the material. 
These include substances such as vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF-AB), 
transforming growth factor beta 1 (TGF-β1) and epidermal growth factor (EGF), 
released from platelets as well as leukocytes.13-16 This initial “proliferative burst” 
is similar to that seen by Vahabi et al. who reported a statistically significant 
increase in cellular proliferation of human gingival fibroblasts (HGFs) after 24 
hours.17 However, unlike the Vahabi et al. study, which showed a reduction of 
cell viability of up to 60% after 72 hours, the present study showed sustained 
cellular viability and proliferation that was statistically similar to the control group 
for all subsequent test days. The difference in observations in the two studies is 
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difficult to explain without a direct comparison between the two biomaterials 
associated with each investigation. Dohan Ehrenfest et al. showed that no 
significant differences were seen in cell viability and proliferation when 
measured using the MTT assay over 21 days for HGFs cultured with L-PRF 13. 
However, the MTT assay was only reported after day three, thereby possibly 
failing to record any earlier significant findings. Similar to the Dohan Ehrenfest 
et al  investigation, the present study showed no statistically significant 
differences when L-PRF was compared to the control group at day 7, and for 
subsequent days thereafter.13 A recent study investigating the in vitro effect of a 
modified protocol to produce L-PRF, also showed no significant cell proliferation 
after 24 hours compared with the control group, suggesting that the protocol 
used to produce L-PRF in the current study may result in a L-PRF with a 
different biological effect compared with the abovementioned reports.16 A 
previous investigation by Peck et al. showed that the L-PRF used in this study 
has a distinct fibrin architecture with most of the fibers being of a “larger” 
diameter.18 Whether this characteristic is significant in the biological behaviour 
of the biomaterial is still unclear. 
Cross-linked HA 
A limited number of studies have reported on the cell stimulating potential of the 
specific high molecular weight clHA used in the present study.6,7 Previous 
research indicates that this formulation is biocompatible and is able to positively 
stimulate the proliferation of periodontal ligament cells in vitro.6 These results 
were statistically significant when the biomaterial was diluted at ratios of 1:100 
and 1:10. The authors can provide no conceivable reason why the diluted 
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material evoked a higher proliferation rate than the undiluted material. We 
speculate, however, that this may possibly be due to the reduced viscosity of 
the material after dilution, thereby allowing better interaction with the growth 
medium and cell culture. 
In the present study we showed that undiluted clHA resulted in a reduction of 
cellular proliferation for the first few days after cell culture. This was similar to 
what was observed by Fujioko- Kubayashee et al and colleagues. At day 5, 
cellular proliferation approximated that of the control group, and, by day 8, was 
significantly higher than that of the control group (p < 0.05). Therefore an 
augmented proliferative effect was noticed for the present study. Although HA 
has well-established water retention properties, the exact mechanism of HA and 
fibroblast interaction is unclear with “fibroblast stretching” cited as the most 
likely cause.19 In a recent study evaluating the effect of both clHA and non-cross 
linked HA on dermal fibroblasts, it was shown that the molecular structure, 
particularly the type and density of the cross-linkages, play  a significant role in 
the ability of HA to stimulate fibroblast proliferation.19 Any biological effect of 
synthesized HA is product dependent and the results of each study should 
therefore be interpreted with this in mind. This might also explain the variations 
in clinical efficacy of dental related HA that are reported in the literature.  
Hyaluronic Acid and L-PRF     
Because HA has previously been used for tissue engineering and is 
commercially available for the management of several inflammatory-related 
conditions, the authors evaluated the cell viability and proliferative potential of a 
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combination of clHA and L-PRF on fibroblasts. As L-PRF has an inherently high 
concentration of growth factors related to wound healing, it was assumed that 
the combination of the two biomaterials would stimulate cellular proliferation. 
The results from the current study indicate that the combined formulation was 
biocompatible, but had a varied effect on cell proliferation. Similar to clHA, the 
clHA+ L-PRF mixture showed a significant reduction in cell proliferation after 24 
hours. Proliferation then increased over time, and on day 7, it peaked, showing 
results similar to those of the control group (p > 0.05). This proliferation was 
opposite to that seen for the L-PRF group. It is interesting to note that the 
clHA+L-PRF combination showed consistently lower cell proliferation when 
compared with the control group throughout the time period of the study. 
Although L-PRF on its own stimulated cell proliferation significantly after 24 
hours, it seems the addition of clHA constrained this initial stimulatory effect. 
Whether this is related to the viscosity of the clHA or its concentration is critical 
to debate. It is known that diluted forms of clHA seem to better stimulate cell 
growth, and this might therefore explain the results seen in the present study 6. 
Conclusion 
L-PRF and clHA are unique biomaterials that are being used in tissue 
engineering. In the present study, we show that these materials on their own, or 
in combination, are biocompatible and stimulate cell growth. Interestingly, it 
appears that this specific method of L-PRF preparation results in a material that 
has a stimulatory effect that peaks within the first 24 hours. Cross-linked HA 
also stimulates growth positively, but unlike L-PRF this effect is prolonged over 
8 days, implying a different, as yet unknown, mechanism of action. The 
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combination of L-PRF and clHA seems to provide no further advantage to 
cellular growth when compared with using either of the materials on their own. 
Based on the above, we can speculate that although L-PRF results in an almost 
immediate stimulatory effect, that clHA, as a sole treatment choice, might be 
beneficial in the management of wounds that require more prolonged 
stimulation. Further research is required to determine the clinical implications of 
the above findings.  
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Figures and Tables 
 
Figure 1: Proliferation and viability assay (MTT) of 3T3 cells. Control is taken as 
100% 
 
Figure 2: HA vs control (MTT assay) 
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Fig 3: HA + L-PRF vs Control (MTT assay) 
 
 
Fig 4: L-PRF vs control (MTT assay) 
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Table 1: Comparison between the test groups (one way ANOVA) 
 HA  HA + 
PRF 
 PRF   
 Mean SD Mean SD Mean  SD P value 
Day 1 89.98 9.83 85.44 12.35 108.99 5.43 0.005 * 
Day 2 91.41 8.79 94.72 9.89 96.27 4.34 0.632 
Day 5 100.08 8.79 95.18 7.29 101.01 7.26 0.47 
Day 7 97.47 8.92 98.6 6.15 100.79 5.77 0.757 
Day 8 112.2 9.69 94.57 4.09 94.78 9.66 0.007 * 
Day 10 100.88 6.46 96.15 2.62 99.15 7.64 0.439 
(* p<0.05)  
Table 2: Comparison between the test groups (Tukey test) 
 HA vs Control HA-PRF vs Control PRF vs Control 
Day 1 0.02* 
0.03* 
0.49 
0.27 
0.01* 
0.38 
0.01* 
0.13 
0.08 
0.31 
0.009* 
0.005* 
0.003* 
0.045* 
0.38 
0.08 
0.13 
0.49 
Day 2 
Day 5 
Day 7 
Day 8 
Day 10 
(* p< 0.05)   
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6.3 Conclusion 
The current study highlights several previously unknown properties of a L-PRF 
prepared using a modified protocol. It demonstrated a direct stimulatory effect of 
the biomaterial on living cells, with a significant increase in cellular growth 
observed during the first day. It also showed no negative effect on cell viability, 
thereby indicating no cytotoxic effect to the cells. The fact that it significantly 
stimulated cellular proliferation independently, may explain the rapid healing 
results that were documented in the reported clinical cases (VI and VII). 
Interestingly, although hyaluronic acid is a known biostimulator (as was seen in 
this study), the combination of the two biomaterials (HA and L-PRF) does not 
appear to demonstrate any benefit on cellular proliferation when compared to 
using either of the materials on their own. The exact reason for this is unknown, 
but may be due to a number of factors, one of those being the high water 
absorption capacity of HA. HA, because of its unique ability to absorb large 
amounts of water, when combined with L-PRF, may result in absorbing its 
associated growth factors, thereby neutralizing their effect on the surrounding 
cells. Although not cytotoxic, this combination may explain the lower than 
normal growth rate of the cells seen in the early part of the investigation. This 
hypothesis is however speculative and requires further rigorous scientific 
examination.  
Within the limitations of the laboratory-based study, this is the first scientific 
published evidence that demonstrates that L-PRF (as prepared by the author), 
has a direct proliferative effect on cellular growth and is not cytotoxic. This may 
have significant implications for the future of this biomaterial.      
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Chapter 7  
7.1 The duration of antibiotic release from leukocyte- and platelet-rich 
fibrin (L-PRF)  
Leukocyte- and platelet- rich fibrin (L-PRF) was initially developed as a simple 
method of concentrating platelet associated growth factors (Choukroun et al, 
2001). These growth factors were then easily transferred to wound sites, due to 
the platelets being intimately dispersed within the fibrin fiber meshwork of the L-
PRF clot (Dohan et al, 2006). This structural configuration had resulted in 
advantages of L-PRF over previous generations of similar platelet concentrates 
such as platelet- rich plasma (PRP) in that the growth factors were released 
over a longer period of time, thereby potentially optimizing wound healing 
(Dohan et al 2006). Because of its dense concentration of fibrin fibers, we 
hypothesized that this would facilitate L-PRF as a potential drug delivery 
system. This was based on the fact that previous studies have successfully 
used fibrin as a drug carrier. The potential to deliver drugs locally via this 
method, with specific reference to antimicrobials, would allow for wound sites to 
resist postoperative infection and therefore optimize the healing. Because the 
structural properties of L-PRF (as prepared by the author) had already been 
described (II), we investigated its ability to release a systemically ingested 
antibiotic over time. The findings were formulated into a scientific article and 
published in the South African Dental Journal in May of 2018.  
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Abstract 
Introduction: Leukocyte- and platelet-rich fibrin (L-PRF), an autologous derived 
platelet and leukocyte concentrate, was first introduced by Choukroun et al. in 
2001 and is currently used in a wide range of medical procedures. Although 
various biological properties have been attributed to L-PRF, nevertheless, when 
tested for inherent antimicrobial activity, the biomaterial fails to demonstrate a 
clear and significant effect against a range of oral microbiota. Aims and 
objectives: To determine whether L-PRF prepared after a single oral dose of 
antibiotic had any significant antimicrobial effect over a 48 hour period.   
Methods: An in vitro laboratory study for which L-PRF was prepared from a 
single healthy volunteer who had previously ingested oral antibiotics. The 
resultant prepared L-PRF was tested for antimicrobial activity against 
Streptococcus mutans (ATCC 35668) using standard laboratory methods. 
Results: For all samples tested, measurable zones of inhibition were clearly 
visible after 24 hours, but were absent after 48 hours. Conclusions: L-PRF 
prepared after a single dose of oral antibiotic results in a measurable 
antimicrobial effect that is sustainable for 24 hours. Although L-PRF will remain 
structurally intact for a few days, it does not appear to influence the duration of 
the antimicrobial activity. 
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Introduction 
Leukocyte- and platelet-rich fibrin (L-PRF), an autologous blood-derived 
biomaterial, was first introduced by Choukroun et al. in 2001 as a simple 
method of introducing autogenous growth factors to a wound site.1 Since then, 
L-PRF has been utilized for a number of medical procedures, including the 
management of diabetic wounds, soft and hard tissue augmentation and 
dermatological lesions.2-5 L-PRF is prepared using a single spin protocol that 
results in an easily manipulated biomaterial that can be applied directly to the 
site of surgery.1 The structure of this biomatrix, which consists of a platelet and 
leukocyte concentrate interwoven within a fibrin mesh, is claimed to be one of 
the major factors that contribute to its clinical success. Previous studies indicate 
that the unique characteristic of fibrin make it an ideal drug delivery system that 
allows the distribution of an active agent directly to the site required.6 The fact 
that fibrin undergoes fibrinolysis over a period of time, has the potential of 
prolonging the drug release and may therefore influence the clinical outcome. 
Previous studies have combined antibiotics with fibrin (mostly fibrin sealants) for 
the management of various conditions such as osteomyelitis, endocarditis, and 
other “difficult to treat” infections.7-11     
Although various biological properties have been attributed to L-PRF, 
nevertheless, when tested for inherent antimicrobial activity, the biomaterial 
failed to demonstrate a clear and significant antimicrobial effect against a range 
of oral microbiota.12 We hypothesize that incorporating antibiotics into L-PRF 
may enhance its antimicrobial profile and that the structure of the L-PRF would 
allow for a prolonged release of the drug. The aim of this in-vitro pilot study was 
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to determine whether L-PRF prepared after a single oral dose of antibiotic had 
any significant antimicrobial effect over a 48 hour period.    
Materials and methods 
The study was conducted at The University of the Western Cape, Cape Town, 
South Africa, in 2017. Ethical clearance was obtained from the University 
Research Ethics Committee (reference number: BM 16/3/31). Informed consent 
was obtained from the blood donor. 
Preparation of the L-PRF  
Thirty six milliliters of blood were obtained from a 24 year old healthy female 
volunteer who had undergone dental implant surgery. She had ingested a single 
dose of antibiotics, as surgical prophylaxis (Amoxicillin, 2 g orally), one hour 
prior to the surgical procedure. One hour after antibiotic ingestion, blood 
samples were collected in blood collecting tubes that contained clot activator, 
i.e., Vacuette® 9-ml serum tubes with Z Serum Clot Activator (Greiner BioOne 
International AG, Germany). These were then immediately centrifuged at 400 x 
g for 12 minutes in a standard benchtop centrifuge (PLC-03, HiCare 
International, Taiwan) as previously described.12   Some of the resultant L-PRF 
clots were then used during the surgical procedure, whilst the remaining clots 
were used for the current study. These L-PRF clots were then compressed 
using the PRF Box ™ (Process for PRF, Nice, France) to obtain uniform 
thickness of the sample specimens, two of which were selected and designated 
as Sample One and Sample Two respectively. 
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Microbial Culture 
The Oral and Dental Research Laboratory (Faculty of Dentistry, University of 
the Western Cape) sponsored samples of Streptococcus mutans (ATCC 35668, 
Quantum Biotechnologies, South Africa) for the study. The authenticity of the 
bacteria was confirmed via Gram stain, growth morphology on blood agar and 
API STREP 20 system (bioMerieux).  Cultures were grown for 24 hours at 37°C. 
Two colonies were adjusted to 0.5 McFarland’s standard (DensiCHEK Plus, 
bioMerieux) in sterile physiological saline.  One millilitre (1 ml) of the adjusted 
colonies was then spread plated on CASO agar (Merk Life Science GmbH, 
Germany).  
Antimicrobial activity 
The samples of prepared L-PRF were of comparable size and thickness due to 
the standardized protocol used in preparation. Each sample was placed in the 
centre of a bacteria-streaked agar plate and then incubated for 37°C in a 
standard laboratory incubation chamber for 24 hours. At that stage the plates 
were removed and the clear zones surrounding each L-PRF sample (zones of 
microbial inhibition), were repeatedly measured using a digital vernier caliper 
(Mastercraft, South Africa). In order to test the antimicrobial efficacy over the 
subsequent 24 hours, the samples were removed and placed in a fresh 
bacteria-impregnated agar plate. The plate was incubated for 24 hours as 
before and the inhibition zones again measured.    
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Data analysis 
Data from the test samples were captured using Microsoft Excel 2010 
(Microsoft Corporation, Washington, USA) and statistically analyzed using one-
way ANOVA and Tukey’s test. 
Results 
The 24 and 48 hour results were recorded as the observable zones of inhibition 
in millimeters and are represented in Table 1.  
Table 1. Zones of inhibition measured in millimeters 
24 Hours 
(Sample 1) 
24 Hours 
(Sample 2) 
48 Hours 
(Sample 1) 
48 Hours 
(Sample 1) 
33.97 29.41 0 0 
41.57 42.70 0 0 
32.20 31.22 0 0 
29.53 44.03 0 0 
32.90 31.99 0 0 
32.91 47.15 0 0 
39.65 47.06 0 0 
40.75 31.82 0 0 
35.11 42.82 0 0 
41.33 31.60 0 0 
 
Zones of inhibition were noted for both L-PRF samples after 24 hours. 
According to statistical analysis using one-way ANOVA and Tukey HSD Test, 
no significant differences were noted for the sizes of inhibition zones when the 
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two samples were compared after 24 and 48 hours, i.e., similar results were 
recorded at both 24 and 48 hours. No measurable inhibition zones were seen 
for either sample after 48 hours (Table 2), indicating that all antimicrobial activity 
had been lost at that time. A statistically significant difference was seen in the 
data between the two time points.  
 
Table 2: Tukey HSD results 
 
 
 
 
Samples Tukey Q stat Tukey p-value Tukey inference 
S1 (24hrs) vs S2 
(24hrs) 1.4702 0.7058178 insignificant 
S1 (24hrs) vs S1 
(48hrs) 26.6181 0.0010053 p<0.01 
S1 (24hrs) vs S2 
(48hrs)  26.6181 0.0010053 p<0.01 
S2 (24hrs) vs S1 
(48hrs) 28.0883 0.0010053 p<0.01 
S2 (24hrs) vs S2 
(48hrs) 28.0883 0.0010053 p<0.01 
S1 (48hrs) vs s2 
(48hrs) 0 0.8999947 insignificant 
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Discussion and Conclusions 
Repeated systemic use of antibiotics to treat or minimize localized infection has 
its limitations, especially in areas with constrained blood supply. Furthermore, 
localized drug delivery systems often require specialized carriers to allow for the 
delivery of therapeutically sustainable doses of the active agent. In the present 
study we attempted to determine whether using an antibiotic- laden autologous 
blood-derived concentrate had any significant antimicrobial effect over a period 
of time. The results from the current study indicates that L-PRF prepared after a 
single dose of antibiotics provides measurable antimicrobial activity for at least 
24 hours against specific oral microbiota. After 48 hours, the antimicrobial effect 
is markedly reduced, with no statistically relevant antimicrobial effect seen. This 
may suggest that although L-PRF has a unique structure, its ability to 
concentrate antibiotics and release them over time, may be limited.  This has 
been seen in previous studies in which fibrin sealants directly supplemented 
with antibiotics showed a rapid antibiotic release over a short period of time 
(85% over 72 hours).14-16  Woolverton et al. (2001) attributed this to rapid 
diffusion as a result of the antimicrobial molecules being small, ionic, and 
designed for oral and parenteral delivery.6 However, antibiotics having a less 
soluble nature,  unlike the current study,  have been shown to exhibit a much 
longer sustained release from fibrin sealants.17 Another reason for the rapid 
diffusion of antibiotics from L-PRF may be the limited binding capacity of the 
antibiotic used in the present study.  Amoxicillin, when orally ingested, is 20% 
protein bound in the blood and about 60% of the drug is excreted in the urine 
within 6-8 hours.18 The protein binding is mostly to albumin (the most abundant 
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plasma protein) which has a specific binding site but a relatively low affinity for 
the antibiotic.18 The drug has no known affinity to fibrin and this may explain the 
limited antimicrobial effect observed in the present study. It is therefore 
assumed that the drug was concentrated in the plasma component of the L-
PRF and not directly bound to the fibrin or cells associated with the L-PRF 
matrix.      
Unlike previous studies that have directly combined the antibiotic with the fibrin 
matrix, we attempted to incorporate antibiotics that were already in the blood (at 
peak plasma concentration) during the process of preparing the L-PRF matrix. 
This has the advantage of not requiring any additional materials or steps in 
incorporating the antibiotic into the L-PRF. Interestingly, certain clinical studies 
involving the use of L-PRF for dental surgical procedures have made use of oral 
antibiotic surgical prophylaxis prior to preparing L-PRF. 19 In these studies, no 
mention was made of the influence of antibiotic ingestion in the healing 
outcomes of the site treated with the L-PRF. The present study indicates that 
antibiotics are presumably incorporated into L-PRF after a single oral dose and 
may be active for at least 24 hours. We can therefore presume that the clinical 
studies that have administered antibiotics prior to surgery, have indeed 
incorporated antibiotics into the L-PRF, if the L-PRF was prepared at least one 
hour after antibiotic prophylaxis. A further investigation into the influence of pre-
operative antibiotics as a factor influencing the clinical behaviour of L-PRF is 
therefore required.      
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Conclusion 
L-PRF has restricted intrinsic antimicrobial activity. Within the limitations of the 
present study, we have shown that L-PRF prepared after a single dose of oral 
antibiotic, results in a measurable antimicriobial effect that is sustainable for 24 
hours. Although L-PRF will remain structurally intact for a few days, this does 
not appear to influence the duration of the antimicrobial activity. We therefore 
assume 
that the antibiotic is mostly concentrated in the plasma and is not directly bound 
to the structural components of the L-PRF matrix. Further research is required 
to determine the significance of these preliminary findings.     
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7.2 Conclusion 
L-PRF has previously been shown to accelerate wound healing by delivering 
high concentrations of platelet associated growth factors to the site (Miron et al, 
2017c). Patients undergoing oral surgery routinely ingest oral antimicrobial 
agents as surgical prophylaxis, as a result we hypothesised that L-PRF 
prepared after the ingestion of antibiotics, could potentially result in 
incorporating these agents into the biomaterial itself. Because of the slow 
dissolution of L-PRF, this provided and ideal potential for prolonged local drug 
delivery. Based on the findings of the above study, it was shown that a single 
dose of antibiotics, ingested one hour before L-PRF preparation, could be 
incorporated into the biomaterial and remain active for at least 24 hours after 
the procedure. It is unknown whether this property is common to all L-PRF 
variants or whether it influenced previous clinical reports. However, this finding 
may provide a method of localised antimicrobial protection during the immediate 
post-operative healing period. This is important, especially in cases where there 
is a potential for wound dehiscence or when a wound is left open or exposed 
e.g. an extraction socket. Other potential benefits may include using L-PRF 
laden with antibiotics in sites of bone grafting, or periodontal regeneration. This 
allows both growth factors as well as antimicrobials to be delivered directly at 
the intended site. Based on the above the need for the post-operative use of 
antibiotics and the adverse effects associated with it, may be negated. This may 
be relevant to both oral and systemic wound care for difficult to treat conditions 
such as diabetic ulcers. Even though the current study focussed on the ability of 
L-PRF to store and release antimicrobial agents, it should be considered that 
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the biomaterial may have the ability to concentrate and release other drugs. 
Whether this has any clinical significance, requires further research. 
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Chapter 8  
8.1 The clinical efficacy of L-PRF, prepared using a modified protocol 
Platelet concentrates have been used to accelerate healing for several decades 
(Miron et al, 2017c, Miron et al, 2018). Many of these concentrates require the 
use of specific equipment and involve several steps to ensure the viability of the 
final biomaterial (I). Since the introduction of PRP, which was initially used for 
maxillofacial procedures, platelet- rich concentrates have undergone an 
expanded scope of clinical use, and are now used in most surgical disciplines. 
L-PRF which was introduced as a simplified method of producing platelet 
concentrates, gained popularity after its initial introduction and appears to 
currently be the preferred method of concentrating platelets.  By 2009, L-PRF 
had gained limited popularity, mostly in Europe, with specific equipment being 
designed and developed to produce the biomaterial (I). However, at that time, 
these machines were not available in South Africa. As a result, the authors 
sought to use locally available equipment to produce L-PRF-like material, using 
the parameters that were previously published in the literature. Consequently, 
we were able to produce a biomaterial using a single spin centrifuge protocol 
that physically resembled L-PRF, as was described in the literature. The 
material was successfully used in several oral surgical procedures, the results 
of which were published as case reports in peer reviewed scientific journals. 
The following are reproductions of those publications;    
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8.2 Published article 1 
Case Reports in Dentistry 2011 (2011): 3450480 
Title  
Alveolar Ridge Preservation (ARP) using leukocyte and platelet-rich fibrin (L-
PRF): A report of a case 
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Abstract 
In order for a dental implant to be restored optimally, it must be placed in an 
ideal anatomic position. However this is not always possible, since physiological 
wound healing after tooth removal, often results in hard and soft tissue changes 
which ultimately compromises ideal implant placement. With the aim of 
minimising the need for tissue augmentation, several alveolar ridge preservation 
(ARP) techniques have been developed. These often require the use of grafting 
material and therefore increases the risk of disease transmission. Leukocyte 
and platelet-rich fibrin (L-PRF) is a newly developed platelet concentrate that is 
prepared from the patient’s own blood. Clinical research has indicated that it 
improves wound healing and stimulates bone formation. We present a case 
where L-PRF was successfully used in an ARP procedure to facilitate implant 
placement in a compromised extraction socket. 
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Introduction 
In order for a dental implant to be restored optimally, it must be placed in an 
ideal anatomic position. However this is not always possible, since physiological 
wound healing following either tooth extraction, trauma, or pathology, often 
results in a deficiency of both hard and soft tissue. Unless augmentation 
procedures are carried out, placing an implant in these tissue deficient sites 
would ultimately compromise the functional and aesthetic results [1]. Although 
several different augmentation procedures have been developed, many of them 
are associated with a number of disadvantages such as increased overall cost, 
the requirement for a second surgical site, and the use of animal derived 
products [2]. 
With the aim of minimising the need for tissue augmentation, several authors 
have proposed techniques to preserve the anatomy of the alveolar ridge after 
tooth extraction. These procedures have collectively been termed alveolar ridge 
preservation (ARP) or socket preservation [2]. Several different ARP techniques 
exist, most of which include the use of a foreign graft materials. Because ARP is 
a relatively new procedure, no long term studies regarding the technique have 
been published and even though several cases reports have been presented, 
there is no evidence to support the superiority of one technique over the other. 
Recently, Choukroun introduced leukocyte and platelet-rich fibrin (L-PRF), a 
second generation platelet concentrate that improves healing of the both hard 
and soft tissues [3]. We present a case where L-PRF was used in an ARP 
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procedure to limit ridge resorption after tooth extraction, in-order to maximise 
the tissue available for ideal implant placement 
Case presentation 
 A 43 year old healthy female presented for the restoration of her dentition in the 
upper right jaw. Upon clinical examination, it was noted that several posterior 
teeth were missing from the 1st quadrant and that the only remaining multi-
rooted tooth (the upper right first molar), was severely periodontally 
compromised (Fig 1). The radiographic examination revealed the presence of 
unextracted roots in the areas immediately mesial and distal to the remaining 
molar (Fig 2). Based on the poor prognosis of the molar as well as the presence 
of the unextracted roots, a treatment plan that involved the extraction of the 
remaining tooth and roots, and subsequently replacing them with an implant-
supported prosthesis, was deemed the best long-term restorative solution. In 
order to maximise the amount of available bone for implant placement, an ARP 
procedure was indicated at the time of extraction. 
Initial visit 
After local anaesthesia had been obtained, the upper right molar together with 
the residual tooth roots were extracted atraumatically by using a 5mm dental 
luxator (Dentsply® Ltd, Surrey, United Kingdom). The remaining tooth sockets 
were curetted and all granulation tissue and socket debris, removed (Fig 3). At 
the same time, 30ml of blood was drawn from the antecubital fossa of the 
patient into three separate blood collecting tubes (Vacuette® with Z Serum Clot 
Activator, Greiner Bio One International AG, Germany).These were then 
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immediately centrifuged at 400g for 12 minutes, using a standard tabletop 
laboratory centrifuge (PLC-03®, Hi-care international, Taiwan). Using this 
method, the blood in the tubes separated into three visible layers i.e. a red 
blood cell layer (RBC) that occupied the lowermost part of the tube, a cell free 
layer that occupied the uppermost part of the tube, and a L-PRF layer, that was 
located between the two (Fig 4). For each tube, the L-PRF layer was removed, 
and compressed between saline soaked sterile gauze to form a “ L-PRF 
membrane” (Fig 5). A total of three L-PRF membranes were formed and 
inserted into the extraction socket site. These were then stabilised using 4-0 
braided resorbable sutures (Clinisut®, Port Elizabeth, South Africa) that was 
sutured over the wound site. Oral analgesics and a chlorhexidine 0.2% 
mouthrinse was prescribed during the healing period and the patient was 
followed up two weeks later. 
Follow-up visit 
On the follow up visit, the extraction site showed signs of healing with no 
evidence of residual inflammation. The site was free of infection and the L-PRF 
membrane was still clearly visible (Fig 6). Even though it remained exposed to 
the oral environment, there were no signs of membrane disintegration or 
infection. The patient also reported minimal pain during the postoperative 
period. Because of the positive response to treatment, she was scheduled for 
implant placement four weeks later. 
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Implant placement 
A radiograph taken prior to implant placement confirmed new bone formation in 
the extraction area (Fig 7). Upon surgical flap reflection, the underlying alveolar 
ridge was clearly visible. The ridge had retained its morphology with no signs of 
bone resorption or of the residual socket. At implant insertion, the quality of the 
newly formed bone was such that it allowed for the implant to be inserted at an 
insertion torque of more than 35Ncm. 
Prosthetic management 
Eight weeks after implant placement, the implant was restored with a cement 
retained crown and has since then remained in function without any 
complications. At the 3 month follow up after the restorative treatment had been 
completed, radiographic evidence of bone maturation was present at the peri-
implant sites (Fig 9). 
Discussion 
The healing of an extraction socket is characterised by both internal and 
external changes that ultimately effects the shape of the alveolar ridge [2]. 
Studies indicate that during healing, bone does not regenerate to the level of 
bone crest or to the level of the neighbouring teeth and therefore 100% socket 
fill does not occur. Using an animal model, Araujo and Lindhe showed that in 
the first 8 weeks following extraction, there is marked osteoclastic activity, 
resulting in the resorption of the facial and lingual bone walls, especially in the 
crestal region [4]. They also noted that bone resorption was greater on the facial 
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wall and that any loss of ridge height was accompanied by a horizontal loss on 
both facial and lingual walls of the extraction site. 
Alveolar ridge preservation is a relatively new surgical procedure aimed at 
retaining maximum bone and soft tissue after a tooth has been removed [2]. By 
maintaining the original ridge morphology, there will a minimal need for 
augmentation procedures thereby allowing the resultant restoration to be placed 
in an aesthetically and functionally ideal position. 
During the last decade several different ARP techniques have been developed, 
most of which include the use of a graft material that is placed into the 
extraction socket [2]. This increases the treatment cost as well as increases the 
risk of disease transmission. Studies also indicate that in many cases, the graft 
material is not totally incorporated into the newly formed bone and when 
compared to sites without graft material, show less vital bone formation. In 
some cases ARP requires the use of collagen membranes. In these cases a 
25% membrane exposure rate has been reported, and this directly affects the 
amount of bone fill that takes place within the socket [2]. 
Leukocyte and platelet-rich fibrin (L-PRF) was first described by Choukroun in 
2000 [5]. It is considered a second generation platelet concentrate and has 
been used in various surgical procedures in an attempt to enhance wound 
healing. It is prepared from the patient’s own blood thereby eliminating the 
possibility of disease transmission or foreign body reactions. 
The preparation technique of L-PRF is simple and requires no special 
equipment. Blood is drawn into standard glass/silica coated blood collection 
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tubes and centrifuged at a predetermined speed to ensure cell separation. No 
anti-coagulants are used during the procedure and natural coagulation can 
therefore take place. This unique preparation technique allows L-PRF to trap at 
least 95% of the platelets of the collected blood into a fibrin mesh [6]. The fibrin 
mesh can then be easily manipulated into a membrane that allows it to be 
transferred to any surgical site. Here, high concentrations of the collected 
platelets allow for the slow release of growth factors (GFs) from the platelet 
granules [7]. These GFs include vascular endothelium growth factor (VEGF), 
platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), epidermal 
growth factor (EGF), hepatocyte growth factor (HGF), insulin-like growth factor 
(IGF) and transforming-growth factor-beta (TGF-beta). All of these play a role in 
replacing lost tissue, resurfacing of the wound, and restoring vascular integrity. 
Compared to other platelet concentrates, L-PRF releases these factors at a 
sustained rate over a longer period, thereby optimising wound healing [8]. 
Recently L-PRF it has also been shown to stimulate the growth of osteoblasts 
and periodontal ligament cells, both of which are significant for the regeneration 
of periodontal defects [6], [8-11]. 
Because of the in-vitro efficacy of L-PRF, several clinical studies have been 
carried out to determine its clinical potential. Currently, L-PRF has been 
successfully tested in a number of procedures including maxillofacial surgery, 
periodontal surgery and implantology [9]. Mazor et al successfully used L-PRF 
as the only grafting material in a series of sinus augmentation procedures [10]. 
With this technique Mazor et al was able to demonstrate that L-PRF could 
stimulate new bone formation in areas that were previously deficient of the 
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amount of bone required for implant placement [10]. In a similar 6 year follow up 
study, Simonpeiri et al was able to demonstrate that using L-PRF as a sole 
grafting agent was a viable long term option in sinus augmentation procedures 
[11]. 
L-PRF has also been used successfully to treat periodontal defects. In-vitro 
studies have confirmed that L-PRF selectively stimulates the growth of 
osteoblasts and gingival cells [12]. In a series of clinical trials conducted by 
Pradeep et al is was shown that L-PRF could be used as a guided-tissue-
regeneration (GTR) membrane to affect periodontal regeneration in 3-wall bony 
defects and degree II furcation lesions [9], [13]. Del Corso et al published 
several case reports showing the successful use of L-PRF membranes in the 
management of both single and multiple gingival recession defects [14]. The 
clinical results were maintained successfully for at least one year. Anilkumar et 
al confirmed this observation and showed that L-PRF could be used for root 
coverage procedures [15]. 
Conclusion 
In the above case report, we demonstrated the successful use of L-PRF in an 
ARP procedure. The biomaterial acts by releasing high concentration growth 
factors to the wound site, thereby stimulating healing and new bone formation 
[16]. Unlike other ARP procedures, the use of L-PRF is a simple method that 
requires minimal cost and reduces the need for specialised grafting material. 
Because it is a completely autologous product, the risk of disease transmission 
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and graft rejection is negated. Further long-term research is required to 
determine whether ARP procedures would benefit from the use of L-PRF. 
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Figure 1: Initial presentation 
 
 
Figure 2: Radiograph shows hopeless upper molar with retained roots both 
mesial and distal to the tooth 
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Figure 3: Extraction site immediately after tooth removal. 
 
Figure 4: Formation of L-PRF. 
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Figure 5: L-PRF membrane. 
 
Figure 6: Extraction site healing 1 week after tooth removal (note 
the visibility of the L-PRF membrane). 
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Figure 7: Radiograph showing new bone formation. 
 
Figure 8: Flap reflection. 
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Figure 9: Radiograph showing stable peri-implant bone 3 months after 
restoration. 
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ABSTRACT 
Successful dental implant treatment usually requires that the implant be placed 
in the ideal anatomic position, so that it will readily facilitate the placement of a 
functional and aesthetically acceptable restoration. However, this is not always 
possible, and in many cases augmentation procedures may be required to 
compensate for lost tissue structures. These interventions often require more 
complex surgery, as well as the use of graft material derived from animal 
sources. Leukocyte- and platelet-rich fibrin (L-PRF) is a newly developed 
platelet concentrate that has successfully been used in a number of surgical 
procedures to optimise wound healing. Several studies indicate that it may also 
have the ability to stimulate bone formation. In this article we present two cases 
where L-PRF was used to stimulate bone formation to facilitate ideal placement 
of implants. 
Keywords: Leukocyte- and platelet-rich fibrin (L-PRF), bone augmentation, 
osseous regeneration 
  
173 
INTRODUCTION 
The use of implant-supported restorations to replace missing teeth has become 
widely accepted as a viable treatment option in modern restorative dentistry. 
However, once teeth are lost due to pathology or trauma, the remaining alveolar 
bone anatomy is often compromised and there may be insufficient bone volume 
to allow placement of an implant that would be functional. Frequently, aesthetics 
are also compromised. Several techniques have been developed to overcome 
this problem, including one or more combinations of guided bone regeneration, 
osteoconduction, osteo-induction, distraction osteogenesis, and revascularised 
bone grafts.1 In this article we present two cases where a novel biomaterial, 
“leukocyte- and platelet rich fibrin (L-PRF)”,2 was used with the intention to 
enhance osseous regeneration and to enable the placement of dental implants 
in previously deficient bony sites.3 
CASE 1 
A 45-year-old female patient presented with complaints of “difficulty when 
chewing” on her right side. Both upper-right premolars had been extracted by 
her dentist due to failed endodontic treatment and since then she had not been 
able to adapt to a removable partial denture. She therefore requested a “fixed” 
restorative option. Her medical history was unremarkable and she had no 
history of smoking or evidence of periodontal disease. It was decided that two 
implant-supported crowns in the region of teeth 14 and 15 would offer her the 
most stable, long-term restorative solution.  
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The clinical examination indicated a buccal bony defect in the area of 14 and 
15, but the affected area was otherwise healthy and free from signs of 
pathology. 
The pre-operative radiographic examination revealed insufficient bone height 
secondary to maxillary sinus pneumatisation in the area of extracted tooth 15, 
with only 2-3mm of vertical bone remaining (Figure 1). A sinus augmentation 
procedure was indicated to increase the bone available so there may be 
adequate support for the length of the intended implant. 
The two implant sites were prepared simultaneously, as follows: 
Surgical management of site 14 (upper right first premolar) 
A midcrestal incision was made and a full-thickness mucoperiosteal flap was 
raised. No vertical releasing incisions were made. The bone in site 14 was 
judged to be sufficient for implant placement without any additional 
augmentation procedures, and therefore was prepared according to the 
standard protocol. During the procedure, intra-oral radiographs were repeatedly 
taken to confirm the correct depth and direction of the osteotomy site. Once the 
final width and depth had been reached, a 3.7mm by 10mm dental implant 
(Uniti®, Equinox, Holland) was inserted into the prepared site and torqued to 
35Ncm. 
Surgical management of site 15 (upper right second premolar) 
As the residual vertical bone was less than 4mm in the 15 area, a 2mm pilot drill 
was used to prepare the osteotomy site to within 1mm of the sinus floor (Figure 
2). A 3mm drill was then used to the same depth so as to allow for the insertion 
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of osteotomes. Sixty millilitres of blood was then drawn from the antecubital vein 
of the patient and collected into six 10ml anti-coagulant-free blood collecting 
tubes (Vacuette® with Z Serum Clot Activator, Greiner Bio One International 
AG, Germany). These were then centrifuged at 400g for 12 minutes, using a 
standard laboratory table-top centrifuge (PLC-03®, Hi-care International, 
Taiwan). Immediately after being centrifuged, one L-PRF clot was separated 
from the underlying red blood cell layer and introduced into the 15 osteotomy 
site (Figure 3). The floor of the sinus was in-fractured using a 3mm osteotome 
(Southern Implants®, Irene, South Africa), and the lining was raised. Once the 
integrity of the sinus membrane was confirmed using the Valsalva manoeuvre, 
four more L-PRF clots were then introduced into the sinus with the osteotome to 
elevate the floor to the desired height. A 3.7mm by 13mm implant (Uniti®, 
Equinox, Holland) was then inserted, with the previously introduced L-PRF clots 
acting as a “protective layer” for the sinus lining. 
After primary stability had been reached, titanium cover screws were placed on 
both implants and the remaining LPRF was then applied to the lateral aspect of 
the alveolar ridge. The site was closed using 4-0 synthetic absorbable braided 
sutures (Clinisut®, Port Elizabeth, South Africa). An immediate post-operative 
radiograph was then taken that depicted the 10mm rise in sinus membrane 
height (Figure 4). 
Post-operative healing was uneventful, and after two weeks the sutures were 
removed. The patient returned after six months having encountered no 
complications associated with the initial surgery. At this time, the implants were 
surgically exposed and the healing abutments were placed. No movement or 
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pain was associated with implant 15 and the radiographic examination revealed 
evidence of new bone formation extending to the tip of the implant (Figure 5). 
The implants were subsequently successfully restored with two cement-retained 
splinted porcelain-fused-to-metal (PFM) crowns (Figure 6). 
CASE 2 
A 48-year-old healthy male presented with complaints of a pain on the left side 
of his mouth that was associated with an unrestored dental implant (Mistral®, 
MIS implants, Tel Aviv, Israel) placed three months previously (Figure 7). 
Clinically, the patient experienced pain on percussion at the implant in the 27 
area. Further clinical investigation revealed that the implant was mobile and had 
failed to osseointegrate. It was decided to remove the failing implant and to 
subsequently replace it with another, once adequate healing had taken place. 
Taking into account the previous history of implant failure together with the risk 
of potential bone resorption, it was decided that an alveolar ridge preservation 
(ARP) procedure was to be carried out immediately after removal of the failed 
implant at the same operative procedure. 
Surgical procedure for simultaneous implant removal and ARP procedure 
Under local anaesthesia, the implant in the area of 27 was removed and the 
resulting bony socket thoroughly curetted to remove all granulation tissue and 
fibrous debris. Blood was then drawn from the vein of the antecubital fossa and 
L-PRF prepared in a similar manner as described above. Three (3) L-PRF clots 
were then inserted into the 27 socket site and secured in place using 4-0 
synthetic absorbable braided sutures (Clinisut®, Port Elizabeth, South Africa). 
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Implant placement 
Healing was uneventful and three months after initial introduction of the L-PRF 
clot into the failed implant site, a follow-up radiograph revealed substantial new 
bone formation that was more radio-opaque compared with the immediate 
adjacent bone (Figure 8). The patient was then scheduled for implant surgery 
one week later to replace the initial failed implant. At surgical exposure of the 27 
area, substantial new bone formation was evident with only minimal signs of the 
failed implant site still visible (Figure 9). A 4.2mm by 10mm dental implant 
(Screwvent®, Zimmer, California, USA) was then placed into the area without 
any complications being noted. 
DISCUSSION 
Leukocyte- and platelet-rich fibrin (L-PRF), a second generation platelet-rich-
plasma (PRP) concentrate, was first described by Choukroun in the early part of 
the 21st century.2 It is considered a biomaterial that actively promotes wound 
healing in both hard and soft tissues.3 It is prepared from the patient’s own 
blood and requires no additional additives or specialised equipment for its 
preparation.4-8 Blood is drawn from the patient directly into glass or silica 
coated plastic blood-collecting tubes and centrifuged at low speed to separate 
the platelets from the red blood cells (RBCs).6 The absence of any 
anticoagulant during the centrifuge process allows for the unimpeded activation 
of platelets, thus triggering the coagulation cascade.5 This results in the 
formation of a fibrin clot that contains a high concentration of leukocytes and 
platelets.9 This L-PRF clot can then be moulded into a usable “membrane” that 
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acts as a simple method of transferring high concentrations of platelets to any 
wound site. A three dimensional analysis of the L-PRF membrane indicates that 
it has a unique structure that traps platelets, leukocytes and cytokines in a mesh 
of fibrin strands. This imparts structural integrity to the biomaterial and allows it 
to be manipulated for use in variety of clinical procedures.3 
The L-PRF membrane traps at least 95% of the platelets of the collected blood, 
allowing for the natural release of several growth factors (GFs) to the surgical 
area.3,10,11 These GFs are released from the platelet granules, and include 
vascular endothelium growth factor (VEGF), platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platelet-
derived-growth factor (PDGF) and transforming-growth factor-beta (TGF-beta), 
all of which play a role in replacing lost tissue, resurfacing of the wound, and 
restoring vascular integrity.4,12 PDGF stimulates the replication of stem cells 
associated with fibroblasts and endothelial cells (thereby promoting 
angiogenesis) as well as the production of fibronectin – a cell-adhesion 
molecule required for proper cellular proliferation and migration during healing. 
PDGF also induces osteoconduction and promotes the production of hyaluronic 
acid, an essential component for wound contraction and remodelling. Although 
similar GFs may be released by platelet-rich plasma (PRP), the unique structure 
of L-PRF allows it to release these factors over a longer period of time, 
potentially optimising wound healing.12,13 The presence of leukocytes (absent 
from PRP) also contributes to the release of TGF-beta and VEGF, further 
increasing the concentration of available GFs.3,13 
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L-PFR has been exploited in various clinical procedures including maxillofacial 
surgery, periodontal surgery, implantology and plastic surgery.14,15 In a clinical 
study of maxillary sinus lift procedures in which L-PRF clots and L-PRF 
membranes were used as the only augmentation material, Mazor et al showed 
that L-PRF was capable of stimulating complete bone regeneration in the areas 
that initially had inadequate vertical bone height.8 In a similar six-year follow-up 
study, Simonpeiri et al were able to demonstrate that using L-PRF as a sole 
grafting agent was a viable long-term option in sinus augmentation 
procedures.16 
Case 1 demonstrated the use of L-PRF in osteotome mediated sinus 
augmentation procedures. By applying L-PRF to the osteotomy site, before 
fracturing the sinus floor, the biomaterial acts as a “protective cushion” that 
facilitates the safe upward displacement of the sinus membrane.9 Studies 
indicate that using L-PRF in osteotome sinus floor elevation techniques, 
together with immediate implant placement, reduces the healing time between 
surgical placement and prosthetic restoration of the implants.9 
L-PRF has been used to treat periodontal hard and soft tissue defects.14,15 In 
vitro studies have confirmed that L-PRF selectively stimulates the growth of 
osteoblasts and gingival cells.17 In a series of clinical trials conducted by 
Pradeep et al, it was shown that L-PRF could be used as a guided-tissue-
regeneration (GTR) membrane to effect periodontal regeneration in three-wall 
bony defects and degree II furcation lesions.14,15 Del Corso et al published 
several case reports showing the successful use of L-PRF membranes in the 
management of both single and multiple gingival recession defects.18 Using 
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multiple L-PRF membranes instead of connective tissue grafts, it was shown 
that the lost soft tissue could effectively be restored by layering the L-PRF 
membranes over each other, thereby increasing gingival height and thickness. 
The clinical results were maintained for at least one year.18 Ramakrishnan et al 
confirmed this observation and showed that L-PRF could be used for root 
coverage procedures.5 
L-PR F vs PRP (Where is the evidence?) 
Since the initial development of PRP in the late 1990’s, the platelet concentrate 
has undergone significant research, especially in the field of oral and 
maxillofacial surgery.19 Although widely used in a variety of clinical fields, the 
ability of PRP to enhance wound healing has recently been questioned.20 A 
systematic review of more than 100 papers concluded that significant evidence 
existed for the use of PRP in periodontal defects. However, the same study 
concluded that the effect of PRP on sinus augmentation was less than 10% 
when compared with controls and suggested that no substantial evidence 
existed for its use in other dental procedures.19 The heterogeneity in studies 
that have examined PRP is regarded as a major reason for the lack of 
conclusive evidence supporting its use. 
L-PRF is a new form of platelet concentrate which has features that are 
distinctly unique when compared with PRP and therefore cannot be regarded as 
the same biomaterial.4,6,10 However, as with PRP, there is a lack of long-term 
controlled trials that would endorse the use of L-PRF in routine surgical 
procedures. Recently, though, five-year follow-up reports have been published 
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which demonstrate the clinical safety and efficacy of using this new biomaterial. 
Further reports are awaited. 
CONCLUSIONS 
In the cases presented above, the clinical application of L-PRF in bone 
regeneration procedures was demonstrated. These potential effects are directly 
related to the biological properties of the material, which allow it to act as a 
“membrane-laden leukocyte- and platelet-rich concentrate”. Its preparation is 
inexpensive, requires no specialised equipment or the addition of animal 
derived products, and it could promise a new era in the field of wound healing. 
Further research is required to fully explore the broad potential of this 
biomaterial. 
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Figure 1: Initial presentation 
 
 
 
 
Figure 2: Osteotomy site preparation for the placement of two implants 
in 14, 15 area. 
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Figure 4: Immediate post-operative radiograph showing the distal implant in 
the maxillary sinus surrounded by L-PRF. 
 
Figure 3: Leukocyte- and platelet-rich fibrin (L-PRF) clot obtained from 
patient’s blood. 
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Figure 5: Although taken at a slightly different angle, this six month 
postoperative radiograph reveals increased radio-opacity indicating the 
presence of new bone extending to the tip of the implant. 
 
 
 
 
Figure 6: Cement-retained implant-supported PFM crowns (14, 15) in place. 
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Figure 7: Initial presentation of patient with a painful, failed implant in 27 area. 
 
 
Figure 8: Radiograph indicating increased opacity at the failed implant site 
3months after the implant removal and placement of L-PRF clot in the area. 
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Figure 9: Presence of new bone formation as seen clinically at the time of 
implant placement in 27 area.  
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8.4 Conclusion 
The publications that are presented, are according to the authors knowledge, 
some of the first English scientific peer reviewed reports of the use of L-PRF 
(prepared using a modified protocol), for alveolar ridge preservation. The 
significance of the above findings indicate that this method of preparing L-PRF 
can result in positive clinical outcomes for both alveolar ridge preservation and 
sinus augmentation. Since this protocol was developed, the biomaterial has 
successfully been used to treat a variety of clinical cases involving oral surgical 
procedures over the past eight years. This implies that a clinically effective 
platelet concentrate can be produced using standard equipment and a simple 
cost-effective protocol.  
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Chapter 9  
9.1 Discussion and conclusions 
The use of platelet concentrates in order to accelerate or stimulate wound 
healing has become a common technique used in the management of a range 
of medical procedures. This is based on the biological principle that platelets 
contain a large number of growth factors and cytokines that play a crucial role in 
wound healing. Nevertheless, the practice remains controversial with several 
contradictory reports either advocating or criticising the procedure. Since the 
introduction of Choukroun’s method of concentrating autologous platelet 
concentrates, the process has been widely adopted, especially in the field of 
oral surgery (Dragonas et al, 2018). The fact that specific parameters are 
required to prepare L-PRF via Choukroun’s method, did not dissuade others 
from attempting to duplicate the procedure using non-standard techniques 
(Miron et al, 2018). With this in mind, we sought to analyse whether an 
alternative method of producing a human leukocyte and platelet- rich 
concentrate, using standard laboratory equipment, could result in a biomaterial 
that was biologically stable and clinically effective. From a review of the 
literature as well taking into consideration of the limitations associated with the 
studies presented, the following comments can be made; 
• Variation from the original protocol developed by Choukroun et al (2001), 
results in variants of the original biomaterial and hence,  
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• L-PRF, as presented in the literature, is not a single entity but represents 
a spectrum of leukocyte and platelet rich concentrates that have the 
following features in common (I); 
a. They are all autologous i.e. derived from the host 
b. They all are prepared using a single spin protocol i.e. whole blood 
is centrifuged once to obtain the desired biomaterial 
c. No added chemicals are used in the process of preparing the 
biomaterial 
d. They all appear macroscopically similar i.e. a yellow fibrin clot  
e. The can all be compressed mechanically to yield various shapes  
• Technical variations of preparation method mean that a single universally 
accepted protocol for preparing L-PRF does not exist (I). 
• Variation from the original protocol has a direct effect on the microscopic 
structure and biological properties of the final biomaterial (II). 
• L-PRF variants have shown both positive and neutral clinical results (I).  
• The variation of preparation methods may explain contradictory clinical 
results (I). 
• Clinical comparisons between variants are difficult due to the heterogony 
of preparation methods that exist (I). 
• L-PRF prepared the way the candidate proposes; 
a. concentrates 97% of plasma platelets (Peck, 2011)  
b. is not cytotoxic to living cells in-vitro (III) 
c. can be stored for at least 1 hour after preparation, within the blood 
collecting tube (IV). 
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d. has a unique morphological structure but has similarities to 
classical L-PRF as presented by Choukroun (II). 
e. has an early accelerative effect on cellular proliferation that lasts 
for at least 24 hours in-vitro (IV). 
f. can contribute to the localized release of systemic antibiotics for at 
least 24 hours in-vitro (V). 
g. has been proven to be clinically effective for the management of 
alveolar bone defects and sinus augmentation procedures (VI and 
VII) 
h. is cost effect  
i. is easy to produce (II). 
j. requires no specialised equipment (II – VII) 
k. may be a way of producing L-PRF in resource-poor healthcare 
settings. 
 
The fact that our research has shown that a biologically effective platelet 
concentrate can easily be produced, has a direct important implication for 
clinical practice. It allows the technology to be made available to wide range of 
health care practitioners who do not have access to specialised equipment, as 
well as reduces the burden on them for purchasing new equipment. Platelet 
concentrates can now also be available not only for oral surgical procedures, 
but also for those seeking to use the biomaterial in the management of other 
conditions  such as diabetic ulcers or chronic slow healing wounds (Pinto, et al, 
2018). Although this specific biomaterial has not been tested in these scenarios, 
the evidence presented here suggests that it has the potential to accelerate 
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wound healing and cell growth (IV, VI-VII). Further large scale clinical trials are 
therefore required to verify the findings presented in this thesis.   
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ABSTRACT
Platelet-rich fibrin (PRF) was first introduced by 
Choukroun et al, in 2001 as a method of concentrating 
autologous human leukocytes, platelets and fibrin 
for autotransplantation into surgical wound sites to 
accelerate healing. Even though several clinical reports 
have documented the use of L-PRF, controversy still exists 
with regards to many aspects of this biomaterial. Diverse 
publications report the use of non-standardised methods 
to prepare L-PRF, resulting in variable clinical results. The 
impact of the type of centrifuge, as well as of the growth 
factor release kinetics, have recently been studied and 
have yielded new insights into the structure and function 
of L-PRF. The presence of bone morphogenetic proteins 
as well as stem cells has also been documented. In 
this report we analyse various factors affecting L-PRF 
preparation and its constituents and highlight some of the 
controversies surrounding the biomaterial.
INTRODUCTION
Platelet-rich fibrin (PRF) was first introduced by 
Choukroun et al. in 2001 as a method of concentrating 
autologous human leukocytes, platelets and fibrin for 
autotransplantation into surgical wound sites to accelerate 
healing.1 This method of concentrating blood platelets was 
different to previous techniques in that it centrifuged the 
collected blood only once, no anticoagulant agents were 
added, and leukocytes and fibrin were deliberately included 
in the final product. Previous similar techniques had sought 
to concentrate platelets only, with little consideration for 
the other constituents.2,3 Choukroun’s protocol (Process 
protocol, Nice, France) was simple and essentially consisted 
of collecting venous blood into dry glass tubes, after which 
the tubes would be spun at a low centrifuge speed to allow 
the blood to separate into the constituents.4 This resulted 
in three distinct layers forming in the blood collecting 
tube, i.e. a red blood cell layer at the bottom of the tube, 
an acellular layer at the uppermost part of the tube, and a 
leukocyte- and platelet-rich fibrin (L-PRF) layer formed in 
the middle of the tube.4 The L-PRF layer was considered as 
the active biomaterial and has, since its development, been 
promoted as an agent that accelerates wound healing and 
tissue regeneration.5 Even though several clinical reports 
have documented the use of L-PRF in oral and extra-oral 
surgical procedures, controversy still exists with regards to 
several aspects of this biomaterial. In this report we set out 
to highlight some of these debates.
The terminology and classification of L-PRF
In an attempt to distinguish various platelet concentrates 
from each other, Dohan Ehrenfest et al. used three key pa-
rameters i.e; the preparation process, the pharmacological 
properties, and the characteristics of the final material to 
establish a functional classification.6 By applying specific cri-
teria to these parameters, the authors were able to classify 
platelet concentrates into four distinct categories (Table 1).6 
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Although this classification elucidates and simplifies the 
distinction of various platelet concentrates, it is not the 
only existing proposed system to classify platelet concen-
trates.7 However, Dohan Ehrenfest’s classification is widely 
quoted in the literature and at the time of its publication, in 
2009, Choukroun’s PRF was the only platelet concentrate 
included in the category of L-PRF.
As the popularity of Choukroun’s protocol for the produc-
tion of L-PRF grew, publications appeared describing proc-
esses that purported to produce L-PRF. However, none 
had applied the exact criteria as described by Choukroun 
(Process protocol, Nice, France).8-11 It is unclear whether 
L-PRF produced by other than the Choukroun method 
can be classified as a true L-PRF.4 Publications incor-
rectly use the terms L-PRF and Choukroun’s PRF inter-
changeably, even though the exact method as described 
by Choukroun has not been used to produce the platelet 
concentrate.12 This has lead to incorrect assumptions and 
a clear, unequivocal, classification of platelet concentrates 
that is universally accepted is therefore sought. For the 
purposes of clarity, the following proposed terminology 
will be used throughout this article:
L-PRF – Leukocyte- and platelet-rich fibrin. Defined as •	
a broad and all-inclusive category that is used to de-
scribe a mixed platelet, leukocyte and fibrin concen-
trate prepared using no-anticoagulants and a single 
spin centrifuge technique. 
L-PRF (C) – Leukocyte- and platelet-rich fibrin (Choukroun •	
type). Defined as a specific leukocyte and platelet-rich fi-
brin prepared using Choukroun’s protocol i.e. (the equip-
ment and the preparation method follows the exact rec-
ommended protocol as outlined by Choukroun1). 
L- PRF (I/E) – Leukocyte- and platelet-rich fibrin (In-•	
traspin/ EBA 20 type). Defined as a specific leukocyte 
and platelet-rich fibrin prepared using either an Intra-
spin (Intra-Lock International, Boca-Raton, FL, USA), or 
EBA 20 (Andreas Hettich GmbH & Co KG, Tuttlingen, 
Germany) centrifuge and following the recommended 
protocol as outlined by Dohan Ehrenfest et al.4 
L-PRF (O) – Leukocyte- and platelet-rich fibrin (Other). •	
Defined as a leukocyte- and platelet-rich fibrin prepared 
in a manner similar to L-PRF (I/E) and L-PRF(C) produc-
tion, but using a non-purpose-built centrifuge.
TECHNIQUES AND METHODS OF 
PRODUCING L-PRF
Choukroun’s method of producing L-PRF was intended to 
be a simple technique that would allow for the production 
of high quality platelet and leukocyte concentrates, which 
could be prepared easily and used in everyday healthcare 
facilities.4 This method specified the use of a PC-02 table 
centrifuge and a collection kit from Process (Nice, France).4 
Further, the blood sample was to be taken without antico-
agulant in 10-mL blood collecting tubes which were then im-
mediately centrifuged at 3000 revolutions per minute (RPM) 
(approximately 400g of relative centrifugal force (RCF)) for 10 
minutes. The formed L-PRF clot could then be removed from 
the blood collecting tube and used as required.
The influence of centrifuge type and RCF on L-PRF
Even though Choukroun’s protocol was clearly outlined, 
a number of  publications were subsequently produced 
that reported on procedures which did not follow the pre-
scribed methods.13-15 Key to these differences was the fail-
ure to use a specific centrifuge (PC-O2, Process, Nice, 
France) and a specific RCF (400g). In many publications, 
the RCF was not reported, and instead the centrifuge 
speed and time was quoted.13-15 This is a significant devia-
tion from the protocol since the influence of the RCF is 
underestimated and not considered.
Relative centrifugal force (RCF) can be defined as the 
amount of accelerative force applied to a sample in a cen-
trifuge.16 It is not equivalent to revolutions per minute (RPM) 
and the terms cannot be used interchangeably. Centrifuges 
work by putting samples in rotation around a fixed axis, 
thereby applying an accelerative force perpendicular to the 
axis.16 This resultant force causes the separation of vari-
ous elements in the sample based on the individual weight 
of the sample elements and is the basis for blood separa-
tion techniques carried out by laboratory centrifuges. RCF 
is measured in multiples of the standard acceleration due 
to gravity at the Earth’s surface (x g) and is based on two 
specific variables i.e. how wide the rotor is and how fast it 
is moving.16 The radius of the centrifuge or rotor is as critical 
to the process of producing a specific RCF as is the RPM. 
Only those processes where the RPM and the rotor radius 
are identical are comparable and any deviations from these 
criteria may result in inaccuracies. Consequently, RCF will 
only be constant for centrifuges with the same rotor radii. 
Results derived from investigations using centrifuges with 
different radii will produce differing RCF’s.16 Therefore one 
cannot assume that all centrifuges used for producing L-
PRF and spinning at 3000 RPM will produce an RCF of 
400g. This is a significant parameter that is often misun-
derstood. RCF is critical to the production of L-PRF and 
must be calculated for each centrifuge used, especially if 
this parameter is not pre-set on the machine.
 
The effect of varying RCF’s during platelet concentrate 
preparation was recently reported.17 Amable, Carias, Teix-
eira et al. analysed various factors affecting the preparation 
of Platelet-rich plasma (PRP), and showed that changes in 
RCF significantly influenced the platelet yield even though 
other parameters such as period of centrifuge time as well 
as temperature remained constant. Dhurat and Sukesh 
reviewed several PRP preparation methods.18 Based on 
their analysis, it was shown that the use by authors of dif-
ferent RCF parameters resulted in variations in the platelet 
yields of the PRP produced. More pertinently, scrutiny of 
the literature reveals that although PRP has been clini-
cally used for several years, no standardised preparation 
protocol has yet been documented. With regards to the 
preparation methods of L-PRF that are published in the 
literature, similar inconsistencies exist.
 
Other centrifuge parameters that may influence 
L-PRF preparation.
A series of articles recently published by a team of authors 
reported on investigations into the effect of various 
parameters on the quality of the resultant L-PRF’s.19-21 
Using the same centrifugal force (400g) as well as the 
same type of blood collecting tubes, the authors tested 
four different commercially available L-PRF centrifuges. 
The results indicated that centrifuge vibration as well as 
centrifuge type significantly affect the quality and quantity 
Table 1: Categories of platelet concentrates as proposed by 
Dohan Ehrenfest et al,6
1. Pure platelet-rich plasma (P-PRP)
2. Leucocyte- and platelet-rich plasma (L-PRP)
3. Pure platelet-rich fibrin (P-PRF)
4. Leukocyte- and platelet-rich fibrin (L-PRF)
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of the L-PRF clot produced. Under scanning electron 
microscope (SEM) analysis, the L-PRF clots produced 
from the different centrifuges showed variations in cell 
morphology and fibrin architecture, with some cells 
showing signs of significant damage. These differences 
were attributed to the type of centrifuge used.19-21 The 
Intra-Spin L-PRF centrifuge (Intra-Lock International, Boca-
Raton, FL, USA) produced clots displaying cells with the 
most stable and normal shape.20 It is therefore critical that 
identical processes should be followed if the biomaterial 
product is to be standardised. Researchers cannot simply 
recreate the biomaterial by using any centrifuge with a 
setting of 400g RCF even at the appropriate spin time. 
Growth factors and their release kinetics 
The preferred use of L-PRF in clinical practice is largely due 
to its reported release of autogenous growth factors. It is 
assumed that the high concentration of these growth fac-
tors results in reduced healing time as well as the stimu-
lation of tissue regeneration.8 These growth factors have 
been well documented in the literature.22 Recently however, 
the release kinetics of these growth factors has been ques-
tioned.23 Schär et al. prepared L-PRF (I/E) with a single spin 
protocol at 400g for 12 minutes using an EBA 20 (Andreas 
Hettich GmbH & Co KG, Tuttlingen, Germany) centrifuge.23 
This is the same machine, recently upgraded, as the Intra-
Spin L-PRF centrifuge (Intra-Lock International, Boca-Raton, 
FL, USA).24-26 The authors compared the release of various 
growth factors from L-PRF, L-PRP and a coagulated blood 
clot. The results demonstrated that the total growth factor 
release of vascular endothelial growth factor (VEGF) as well 
as of interleukin-1β (IL-1β) was higher from the blood clot 
than from any of the platelet concentrates. Furthermore, no 
statistically significant differences could be established be-
tween the blood clot and the various platelet concentrates 
as regards the amounts of insulin-like growth factor-1 (IGF-
1) and of platelet-derived growth factor AB (PDGF-AB) that 
were released. The L-PRF (I/E) clot released the highest 
concentrations of transforming growth factor β1 (TGF-β1). 
When the release kinetics of L-PRF (I/E), L-PRP and the 
blood clot were investigated, the researchers found that the 
various growth factors were released at different times as 
well as for different lengths of time. An examination of this 
effect on the migration on human bone marrow-derived 
mesenchymal stem cells (MSC) and human umbilical vein 
endothelial cells (HUVEC) found no significant differences 
in the overall patterns of migration for any of the groups 
tested. However it was reported that IGF-1 had a positive 
correlation with the migration of both cell types whereas 
PDGF-AB had a negative correlation with both cell types 
i.e. MSC and HUVEC. It may be of relevance that IGF-1 had 
the highest concentration in the blood clot and that there 
were no differences in the release kinetics of this growth 
factor when compared with those of L-PRF and L-PRP.23 
In a similar study, in which the release of growth factors 
as well as the effect of platelet concentrates on tendon 
cells were compared with those of a whole blood clot, it 
was shown that the platelet concentrates had the ability to 
significantly increase cell proliferation as compared with 
that of the blood clot.27 However, it must be pointed out 
that the techniques of preparing these platelet concen-
trates were completely different between the two studies, 
thereby influencing the final architecture and possible bio-
logical properties of the various concentrates.
Bone morphogenic proteins
Bone morphogenic proteins (BMPs) are low molecular 
weight glycoproteins that are responsible for ectopic bone 
formation.28 First described in the 1960’s, these proteins 
play a critical role in various aspects of cell function, dif-
ferentiation and tissue repair. More significantly, they are 
crucial in the maintenance of skeletal integrity and bone 
fracture healing. BMPs are released and synthesised by 
a number of cells including osteoblasts, osteoprogenitor 
cells, chondrocytes, platelets and macrophages.28,29 It is 
therefore clear that the synthesis of these key proteins is 
not restricted to bone forming cells.
 
It has recently been shown that L-PRF (I/E) releases BMP-2 
over a period of seven days, but that the amounts released 
are relatively small.21 Dohan Ehrenfest et al. found it difficult 
to explain the exact origin of these BMPs, but suggested it 
was related to the presence of leukocytes in the platelet con-
centrate.21 However it had been shown previously that the 
platelets themselves contain significant amounts of BMP-2 
and that the release of these proteins is pH dependent.30 As 
a result, it has been suggested that the release of BMP-2 
by platelets may play a significant role in the initial stages 
of bone fracture healing, since the pH in this environment is 
optimal for platelet activation.30 
Other researchers have found that other BMPs such as 
BMP-6, BMP-7 and BMP-4 are also released by platelets, 
and, further, that the concentration of BMPs contained in 
platelets is patient dependent.31,32 It has also been shown, 
by genome-wide micro analysis, that lysed platelets have 
the ability to upregulate proliferative pathways of osteob-
last like cells in-vitro.33 
The potentially ground-breaking findings from various stud-
ies investigating the BMP potential of L-PRF as well as its 
variants must be seen in the light of patient variation as well 
as the pH of the test environment.21,28,30,32 Further research 
into these factors may have clinical implications and could 
explain the reasons for the inconsistent clinical outcomes 
experienced when using platelet-rich concentrates for bone 
grafting or regeneration. By implication then, it would cur-
rently be difficult to control the amounts of BMP’s released 
from platelets when used in a clinical setting.  
Stem cells
Stem cells are undifferentiated cells that can differentiate 
into specialized cells, including more stem cells or other 
cell types during development.34 Recently, a variant of L-
PRF(C) has been analysed, thought to contain haemat-
opoetic stem cells (HSC).35 The presence of these HSC 
cells is mostly determined using immunohistochemical 
analysis for the detection of specific cell markers, in this 
case, CD34. This is a transmembrane phosphoglycopro-
tein that is predominantly used as a marker for HSC as 
well as haematopoetic progenitor cells.36 Although tradi-
tionally linked to cells of haematopoetic cell origin, CD34 
has recently been linked to other non-haematopoetic cells 
types such as mesenchymal stem cells (MSC), endothelial 
progenitor cells and interstitial dendritic cells.36 Therefore, 
the mere presence of CD34 positive cells does not allow 
the assumption that a specific cell type such as HSC, ex-
ists. In order to verify the existence of HSC, the cells should, 
in addition to the proven presence of CD34, display other 
traits such as a low expression of CD90, a lack of expres-
sion of CD38 and human leukocyte antigen-DR (HLA-DR), 
as well as a panel of mature lineage markers (lin-).36
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The potential of CD34 positive cell types in L-PRF(C) and 
its variants appears promising, but requires further inves-
tigation due to the variation in CD34 detection methods. 
Almost all CD34 detection methods use antigen-antibody 
interactions. These interactions are non-covalent and are 
reversible, with the potential of affecting the detection of the 
CD34 marker. Because of this, it is suggested that multiple 
methods be used to verify the presence of CD34.36
 
Although peripheral blood has been used as a source for 
CD34 positive cells in many forms of therapy, the baseline 
concentration of these cells in peripheral blood is relatively 
low.37,38 As such, most therapies that require the use of 
CD34 positive cells enrich the presence of these cells in the 
vasculature by using granulocyte colony-stimulating factor 
(G-CSF).39 This allows for an adequate amount of cells to 
be harvested for local or systemic transplantation. Whether 
the levels of CD34 positive cells in L-PRF and its variants are 
at therapeutic concentrations, requires further analysis.
Clinical results from studies using L-PRF 
Several randomised controlled trials have been published 
that involve the use of L-PRF in the clinical management 
of a variety of disorders.40-43 These trials have contradic-
tory results, which may be related to a variation in the 
techniques and equipment used to prepare L-PRF.41-45 
Nevertheless, several articles report positive clinical out-
comes even when standardised preparation techniques 
have not been used.46-49 Whilst most of these publications 
are in fact case reports, nevertheless even randomised 
controlled trials where the RCF has not been verified, 
have shown positive clinical outcomes.43 This is similar to 
reports about the use of PRP, which show a variety of 
clinical results based on the various methods of producing 
PRP.18 Further research is therefore required to verify clini-
cal differences which may be associated with the various 
methods of preparing L-PRF. 
Does generic L-PRF exist?
L-PRF (O) is prepared using standard blood collecting 
tubes and a non-purpose built table top centrifuge deliver-
ing an RCF of 400g with a centrifuge time of 12 minutes. 
This method allows for the preparation of a platelet and 
leukocyte concentrate without the need for specialised 
equipment. Several case reports have demonstrated posi-
tive clinical results when using this preparation method.50,51 
However one cannot assume that this generic type of L-PRF 
has properties similar to those of L-PRF(C) or to L-PRF(I/E) 
since it has previously been shown that the centrifuge type 
may play a significant role in the final morphological fea-
tures of the end product.19,20 Further analysis of this bioma-
terial is therefore required to determine equivalence to the 
established protocols for L-PRF preparation.
  
CONCLUSIONS
The concept of L-PRF as a bioactive material with possi-
ble regenerative properties has resulted in it being adopted 
for use in various clinical procedures. However, the wide-
spread use of this material has resulted in the production 
of several variants. Whether the biological properties of all 
these variants are similar, is unknown. Contradictory clini-
cal results are reported in the literature with several generic 
types of L-PRF showing diverse results. In order to minimise 
the controversies associated with L-PRF, further research 
is required to determine which factors affect the biological 
properties of the material and whether these factors are 
clinically beneficial and relevant.
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ABSTRACT 
Introduction 
The use of leukocyte and platelet- r1ch flbr1n (L:PRF) In regenerative 
surgery has increased exponentially in the last decade. That 
success has lead various centres to have introduced the 
biomaterial as a routine inclusion in oral grafting procedures. 
Evidence suggests that the physical properties of fibrin play an 
essential role in homeostasis of blood clots. Only a limited number 
of studies have investigated the features of fibrin fibre diameter of 
L-PRF concentrates. 
Aims and objectives 
To investigate and compare the fibrin network and fibrin fibre 
diameter of L-PRF prepared by two different methods. 
Methods 
Blood was collected from a single volunteer using established 
protocols. The resultant L:PRF clots were then prepared and 
examined using scanning electron microscopy. The results ware 
subjected to statistical analysis. 
Results 
L-PRF prepared using the modified method had larger diameter 
fibrin fibres than that prepared using the official protocol. The 
difference was statistically significant (P=0.001). There was also 
a larger amount of thicker fibrin fibres observed in the modified 
L-PRF group. 
Conclusions 
Preparation methods affect the fibrin fibre diameter of l.:PRF. This 
may have consequences that Influence the blologlcal properties 
of the blomater1al. 
INTRODUCTION 
The use of leukocyte and platelet- rich fibrin (l.:PRF) in regenerative 
medicine has increased exponentially in the last decade.' First 
Introduced by Choukroun et al. In 2001,2 this autologous, blood 
derived platelet concentrate that has been extensively used In 
oral surgical procedures, with clinical success in the fields of 
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surgical implantology and regenerative periodontology.u Because 
of its popularity, various centers centres have introduced the 
biomaterial as a routine inclusion in oral grafting procedures'. 
Although Choukroun had speclned the original method of L-PRF 
preparadon, this protocol had been modified overtime, with several 
variants of L-PRF now being made available.3. 4 The modification 
of the original protocol included updating the equipment and 
materials used, as well as varying the centrifuge time and force.4 
This resulted in two further variants of L:PRF being introduced i.e. 
advanced PRF (A-PRF) and advanced PRF+ (A-PRF+).4 Both of 
these variants use a lower centrifugal force when compared to the 
original protocol and this is thought to have distinct advantages 
over the original preparation method.a. 4 
Figura 1: Modified L-PRF and A-PRF (right} 
194 > RESEARCH 
An important component of the biological advantages of l.:PAF 
concentrates, is its specific structure which comprises a dense 
fibrin network, with high concentrations of platelets and leukocytes 
interspersed within the mesh of fibrin fibres.6 It is thought that this 
allows growth factors to be trapped, and released over a prolonged 
period thereby enhancing healing and regeneration.8•7 Recently, 
the role of fibrin structure has been researched for its role in blood 
c1ots.8•11 Evidence suggests that the physical properties of fibrin fibres 
play an essential role in homeostasis of blood clots by affecting their 
mechanical and biological contribution properties. s. 12 However, only 
a limited number of studies have investigated the features of fibrin 
fibre diameter of L:PRF concentrates.'3"4 
With the increase in popularity of l.:PRF, several authors have 
reported positive clinical results using l.:PRF that is prepared using 
non-standardised equipment or materials.15-17 All example of this 
type of "modified" l:PAF has been clinically documented in previous 
publications by Peck et a1.1s. 19 This deviation from the proposed 
protocol may result in structural and functional changes to the 
consequences to the biomaterial that is being produced.20-22 In this 
report, using scanning electron microscopy (SEM), we analyse and 
compare the fibrin network and fibrin fibre diameter of two different 
methods of L:PRF preparation i.e. our modified protocol for the 
preparation of l.:PRF as previously described by Peck et al, and 
A-PRF+, prepared via the recommended protocol as previously 
ouUined in the literature."' 1e. 19 
Figure 2. PRF Box with prepared L-PRF before compression 
Figure 3: Modified L-PRF and A-PRF+ (Low magnification) 
MATERIALS AND METHODS 
The studly was conducted at the Dental Faculty, University of 
the Western Cape, Gape Town, South Africa in 2017. Ethical 
clearance was obtained from the Research Ethics Committee of 
the university with the following reference number: BM 16/3131 
Preparation of the L:PRF samples 
Thirty six milliliters of blood was obtained from a single 30-year-old 
healthy male volunteer via venipuncture of the left antecubital vein. 
Two methods were used to prepare L-PRF, i.e. : 
1. Modified L:PRF: Blood samples were collected in 9ml blood 
collecting tubes that contain clot activator i.e., Vacuette® 9ml 
serum tubes with Z Serum Clot Activator (Greiner BioOne 
International MJ, Germany). The blood samples were then 
centrifuged at 400g for 12 minutes in a standard benchtop 
centrifuge (PLC-03, Hicare International, Taiwan). 
2. A-PRF+:Blood samples were collected in 10 ml A-PRF+™ 
tubes (Process for PRF, Nice, France), and centrifuged for 
1300RPM for B minutes, using a dedicated tabletop centrifuge 
(PRF DUO™, Process For PRF, Nice, France). 
After being centrifuged, the blood from both groups separated 
into 3 distinct layers (Fig 1). From previous reports, the layers could 
be distinguished as a topmost layer consisting of acellular platelet 
poor plasma, Modified L:PRF/A-PRF+ in the middle, and red blood 
cells at the bottom of the test tube. s. 8 In order to standardise 
L:PRF thickness, the resultant L-PRF clots from both groups were 
removed from the tubes, and subjected to controlled compression, 
using a specifically designed tool i.e., the PRF Box® (Process for 
PRF, Nice, France) (Rg 2). 23 All the samples were then transferred 
for preparation for scanning electron microscopy analysis. 
Preparation for scanning electron microscopy (SEM) 
All the samples were fixed using 2.5% gluteraldehyde in phosphate 
buffered saline (PBS) for 1 hour. Each specimen was removed and 
washed in PBS for 5 minutes (twice) and thereafter distilled water 
for 5 minutes (twice). The specimens were then dehydrated serially 
with 50%, 70%, 90% and 100% ethanol, with each dehydration 
step taking 10 minutes. The samples were then transferred to the 
Electron Microscope Unit, Department of Physics, University of 
the Western Cape, for critical point drying, gold-palladium coating, 
and mounting for SEM analysis. 
Scanning electron microscope observation 
The surface microstructure of each specimen was analysed 
using the same scanning electron microscope (AURIGA Reid 
Emission High resolution SEM, Gari Zeiss Microscopy GmbH, 
Jena, Germany). All measurements of the fibrin networks were 
carried out at 10 000 times magnification. At least 200 fibres 
were randomly selected from each group and measured for 
WO• imm Mag • 10.00KX 
Figure 4: Modified L-PRF (High magnification) 
Figure 5: A-PRF + (High magnification) 
analysis using lmageJ version 1.510 software developed by 
Wayne Rasband (National Institutes of Health, USA). The data 
was captured using Microsoft Excel 2010 (Microsoft Corporation, 
Washington, USA) and statistically analysed using the Mann-
Whitney U and Wilcoxon W tests. 
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Figure 8: The distribution of fibrin fibre diameters for Modified 
L-PRF (group 1) and A-PRF+ (group 2) measured as leng1h in nm 
RESULTS 
Descriptive analysis of Modified 1..:-PRF and A-PRF+ Fibrin fibre 
networks 
Under low magnification (1000 times) both samples show similar 
morphological characteristics. A dense mesh of fibres was evident 
with scatteracl cells seen on the surface for each sample (Fig 
3). For the Modified L-PRF sample, more irregular bodies were 
present, possibly signifying the presence of platelets (Fig 3). 24 
This may be characteristic of the region observed and may not 
be representativa of 1he sample as a whole.8 No distinction in fibre 
architecture for the 2 groups was seen at this level of magntncatlon. 
When observing 1he samples at higher magnification (10 000 
times), 1he fibre mesh showed distinct characteristics (Figs 4 
and 5). For both groups, the fibres were densely arranged In a 
netlike structure with clear spacing and crosslinking seen. Distinct 
differences could be noted with regards to fibre diameter, with 
both groups showing non-uniform flbre thickness. Thicker flbras 
were interweaved with thinner fibres and many of the fibres 
showed irregular surface characteristics indicative of platelet-fibrin 
fibre lnteractlon.24 The presence of cellular bodies could be noted 
for both groups. Distinguishing between both groups solely on the 
basis of SEM analysis, was difficult. 
Length_ M,PRF 23'1 
nm A-PRF+ 206 
Total 437 
Table2 ._ .... Ill 
- Mann,WllltMr U WilcoxonW 
z 
Asymp. Sig. (2-tailed) ... B 7 ....... , .... 
238.06 
238.08 
54882.00 
40711.00 
Lenglh_nm 
-
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-
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Analysis of Modttled L-PRF and A-PRF+ fibrin fibre thickness 
A total of 437 fibrin fibre samples were analysed from both groups. 
The fibres were measured in nanometres (nm) with a range of 100-
808nm and a mean of 281 nm being observed for the Modified 
L-PRF group. For the A-PRF+ group, fibre diameters ranged from 
43-742nm with a mean diameter of 256nm. For both 1he groups, 
statlstlcal analysis revealed that the mean flbre diameter was not a 
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clear reflection of the various fibre groups present. It also showed 
that the flbr1n fibre diameters were not equally distributed In each of 
the groups and that a wide range of fibre diameters were present 
(Fig 6). These fibre groups were present in both Modified L:-PRF 
and A-PRF+, but were slgnlflcantly different In 1helr distribution 
for the two versions of L-PRF. Of the two groups tested, Modified 
L:-PRF was characterized by larger diameter fibres and had a 
higher amount of thicker flbres when compared to A-PRF+ (Ag 6). 
Because of the wide range of fibre diameters noted in each of 
the sample groups tested, arbitrary size classes were selected to 
better Illustrate the range of fibre diameters seen. This size selection 
was based on a previously published model which analysed 
human fibrin networks. M Consequently the fibre diameters were 
categorised Into 3 groups based on "thickness• I.e. thin Oowest 
thickness to 85nm), intermediate (86 - 202nm), and thick (203nm 
to highest). This is represented by histogram A. 
l:i' c . .. 
2 
l1ngth_c1t 
Histogram A: The distribution of "thin, Intermediate and thick" 
fiberfibres of Modified L-PRF (group1) and A-PRF+ (group 2) 
DISCUSSION 
L:-PRF In Its various forms has shown promising results In both 
in-vitro and in-vivo studias.1• i 5-1u This is attributed to the s1ructural 
integrity of the biomaterial which results in a matrix1hat contributes 
to the prolonged release of various growth factors as well as 
provides a network for the migration of cellular components.:i-0 
The process of preparing L-PRF was initially documented by 
Choukroun In 2001.2 However since the or1glnal protocol was 
introduced, several authors have attempted to replicate the platelet 
concentrate using non-standardized methods.111-19 Although 
clinically successful, the ultrastructure of these 1..:-PRF variants has 
not been reported upon extensively. 
The data from this study Indicates that using both 1he A-PRF+ 
protocol as well as the modified protocol for 1he preparation of 
L:-PRF that we used, may yield L-PRF clots that appear similar 
macroscopically. Both preparation methods resulted In separation 
of the centrifuged blood into 31hree distinct layers as previously 
described. When examining L-PRF clot size, 1he resultant L:-PRF 
clots appeared smaller for 1he Modified L-PRF group, however 
this was not quantified statistically. We speculate this may be 
due to using a 9ml blood collecting tube as opposed to 10ml in 
the A-PRF+ group. However, the size of the collectlng tube may 
not be 1he only factor affecting l:-PRF size, since recant research 
indicates that using different centrifuges may affect L-PRF clot 
size. 21>-22 
Compressed L:-PRF clots from both groups appeared similar 
under low magntflcatlon (X1000), with a dense flbre network and 
large range of fibre diameters being seen. The density of the fibre 
networks seen in this study has previously been reported upon 
and Is thought to be related to 1he compression of 1he clots In 
the PRF-Box™.23 When the fibre diameters were analysed as thin, 
intermediate, and thick, 1he majority of fibres in both groups were 
classified as thick. This differs from the findings of Vieira et al. 
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2009,25 who reported that the predominant fibre patterns were 
thin. 
Previous studies that have examined the features of fibrin 
associated with L-PRF, have often used the mean diameter of the 
fibres to describe the characteristics of the L-PRF clot or are limited 
to a subjective description of the fibre diameter.18• 21> In the present 
study, statistical analysis revealed that using the mean diameter, 
did not reflect the range and frequency of the fibra types observed. 
Therefore when analyzing fibre diameters for Modified L-PRF 
and A-PRF+, we identified clear groupings (Fig 6). These were 
statistically significantly different for the two L-PRF groups, with 
the Modified L-PRF showing a higher number of larger diameter 
fibres as compared to A-PRF+ (Table 1). The exact reasons for 
this difference in not known, but is probably due to differences 
in the centrifugal force, centrifuge time, centrifuge make, agents 
present in the blood collecting tubes and shape of the blood 
collecting tubes.20, 26 Because all the samples were taken from 
the same individual in a 15 minute period, the above may serve 
as an adequate explanation for the differences in fibre diameters 
seen. However one must consider that for different individuals or 
in instances where blood is collected from the same individual 
at different times, that other factors such as pH, the presence of 
zinc, ionic strength, concentrations of calcium, polyphosphate, 
fibrinogen, fibrinogen binding proteins and thrombin, may also 
influence fibre thickness and network density. 11.12 
The tubes used to collect blood to prepare Modified L-PRF, are 
coated with silica. Silica is a known procoagulant. It binds to 
plasma proteins and has the ability to cause reversible structural 
changes to these molecules. 27•28 This is dependent on the size of 
the silica particle, with smaller silica particles demonstrating the 
ability to shorten coagulation time and increase the activation of 
factor X, whilst at the same time activate platelats.28 The fact that 
silica coated tubes were used in the preparation of the Modified 
L-PRF, may further contribute to the morphological differences 
seen between the 2 groups. 
The individual fibre diameters seen in the samples tested may 
have implications for the mechanical stability of each L-PRF clot.29 
Clots with thicker fibres tend to be less elastic than those with 
thinner fibres and may be more readily degraded by the fibrinolytic 
system.8• 29 This may have consequences for the biological 
behaviour of L-PRF since structural integrity and the controlled 
release of growth factors is thought to be a major contributing 
factor to its c linical success. Therefore, one might assume that 
because A-PRF+ has a lower amount of thick fibres than Modified 
L-PRF, that its rate of dissolution may be slower than that of 
the Modified L-PRF. As such, its ability to remain intact may be 
prolonged as compared with other platelet concentrates and 
may explain the extended release of growth factors as recently 
reported. 3•4 
CONCLUSIONS 
To the author's knowledge, this is the first presentation of the 
morphological fibre characteristics of an L-PRF clot prepared 
using a specific modified protocol as previously described 
by the authors. When compared to an established protocol, 
the resultant L-PRF clot appears morphologically similar to its 
A-PRF+ counterpart with a dense fibrin network interspersed with 
platelets and other blood cells. However, clear differences are 
noted for the fibrin fibre diameter with Modified L-PRF showing a 
higher proportion of larger diameter fibres. The reason for these 
differences is speculated to be associated with the different 
protocols used to prepare the platelet concentrates. One might 
therefore assume that changes in the protocol of preparation of 
L-PRF may directly affect it morphological structure. Whether 
these differences affect the clinical efficacy of these biomaterials 
is unclear, and warrants further research. 
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ABSTRACT
The aim of this study was to determine whether storage 
time had a significant effect on the platelet concentration of 
platelet-rich fibrin (PRF). Three blood samples were drawn 
from each participant into a sterile blood sampling tube. 
Two of the blood samples were centrifuged to form PRF. 
The third non-centrifuged sample was used to measure 
the baseline blood platelet concentration. After PRF had 
formed, it was removed from the respective test tubes at 
different time intervals i.e. immediately after centrifugation 
(Group A) and after 60 min of storage time in the blood 
collecting tube (Group B). The residual blood from each 
group was tested for platelet concentration and compared 
with the baseline reading (as an indirect measure of the 
platelet concentrate of PRF). The PRF produced in Group 
A (PRF A) had a mean platelet concentration of 274 
±57.8×109/L, whereas the PRF of Group B (PRF B) was 
278 ± 58.2×109/L. A statistically significant difference was 
seen between the groups (p < 0.001). 
Conclusions: Storage time has a significant effect on the 
platelet concentration of PRF. Further research is required to 
determine whether this has any clinical relevance.
INTRODUCTION
Wound healing is a complex process characterised 
by the repair and reconstitution of lost or damaged 
tissue. Identification of the pathological and biochemical 
mechanisms that regulate tissue repair and homeostasis has 
long been regarded as central to their therapeutic exploitation 
in the clinical setting. By the mid-1990s, several methods 
were proposed to enhance wound healing, including the 
administration of high concentrations of human platelets to 
affected areas.1-6 It was assumed that platelets optimised 
wound healing by promoting the secretion of growth factors 
(GFs) necessary for tissue repair.7-9 The most common 
platelet concentrate used in these procedures is platelet-rich-
plasma (PRP) and by the early part of the 21st century, its 
use in various surgical procedures was commonplace.1,4,10,11 
However, the preparation of PRP often requires the use 
of specialised equipment, chemicals and animal-derived 
additives. This increases the risk for complications secondary 
to allergic reactions to certain animal-derived additives.12-14 
As a result, researchers have sought more efficient and safer 
methods of concentrating platelets for surgical use.1 This 
led to the production of platelet-rich-fibrin (PRF), a platelet 
concentrate that neither contained additives nor required 
the use of specialised equipment during its preparation. First 
introduced by Choukroun et al (2001), PRF has been studied 
extensively and is now regarded as a biological scaffold 
different to PRP.15 However, even though the use of PRF is 
gaining widespread clinical acceptance, several questions 
regarding its biological stability remain unanswered.16,17 The 
aim of this this study was to analyse the effect of storage time 
on the platelet concentration of this unique biomaterial.
MATERIALS AND METHODS 
The study was conducted under the principles outlined 
by the “World Medical Association Declaration of Helsinki, 
Ethical Principles for Medical Research Involving Human 
Subjects” of 2008. Ethical approval was obtained from the 
Ethics Committee of the University of the Western Cape 
(Registration number 11/4/29). All participants were fully 
informed of the research protocol and were required to sign 
a declaration of informed consent before being allowed to 
participate in this cohort analytical study. A total of 30 healthy 
participants (16 females and 14 males) were enrolled into 
the study. Participants were drawn from the current patient 
pool as well as staff members based at the Dental Faculty, 
University of the Western Cape. All participants had three 
separate blood samples collected by venipuncture. Two 
of the samples were acquired using tubes containing clot 
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activators, i.e., Vacuette® 10ml serum tubes with Z Serum 
Clot Activator (Greiner BioOne International AG, Germany), 
whereas the remaining blood sample was drawn into a 10ml 
BD Vacutainer® tube that contained dipotassium-EDTA, an 
anticoagulant (BD Diagnostics, New Jersey USA).
 
All the blood samples collected in the anticoagulant-
containing tubes were used to measure baseline platelet 
concentrations, whereas the remaining blood samples 
(collected in the Clot Activator containing tubes) were used 
to prepare PRF by centrifugation (400g for 12 minutes) 
in a standard benchtop centrifuge (PLC-03, Hicare 
International, Taiwan) (Figure 1). Therefore, from each study 
participant, two samples of PRF were obtained (Figure 2). 
The two PRF samples were then randomly allocated into 
either Group A or Group B, using a simple coin toss. 
For Group A, the PRF was removed from the tube 
immediately after preparation (0min), whereas for Group 
B, the PRF remained in the tube and was only removed 
after 60 minutes. The PRF produced from each group 
was designated PRF A and PRF B respectively.  Because 
a direct measurement of platelet concentration of PRF 
is not yet possible, we calculated the PRF concentration 
for each group indirectly, by determining the numerical 
difference between the residual platelet concentration (of 
the remaining serum after removal of PRF) and the baseline 
platelet concentration for each specific study participant. In 
this study, platelet concentration analysis was carried out 
using an electronic automated cell counter (Advia 2120, 
Siemens AG, Erglangen, Germany).
Data was collected and entered into a spreadsheet 
(Microsoft Office 2010 Excel, Microsoft Corporation, 
Washington). The results were compared and analysed 
statistically using SPSS® Version 13 for Windows.  
RESULTS AND DISCUSSION
A total of 30 participants (16 females and 14 males) were 
entered into the study. The mean age of the participants 
was 41.7 years, with male sub-
jects being slightly younger than 
their female counterparts (41.3 
years for males vs 42 years for 
females). The youngest partici-
pant was 24 years old and the 
oldest, 58 years old.
Platelet concentrations obtained 
from analysis of all 30 participants 
were within the normal laboratory 
reference range of 170-400×109L 
of circulating blood. None of the 
participants displayed any sig-
nificant haematological disease. 
The mean blood platelet concen-
tration was 282.8×109/L (Table 1). 
There was no significant differ-
ence between the genders. 
After removal of formed PRF from 
Group A, the residual serum yield-
ed minimal concentrations of platelets. The mean concentra-
tion of remaining platelets was 7.9×109/L (Table 2). For Group 
B, serum platelet concentrations were also minimal after re-
moval of the prepared PRF with the mean concentration of 
the platelets being 4.0×109/L (Table 2). 
The residual mean platelet concentration of Group A was 
higher than that determined for Group B with the mean 
difference in platelet concentrates between the two 
groups being 3.90 × 109/L. Using a non-parametric Signed 
Rank Test, the statistical significance of the differences in 
platelet concentrates between the Groups A and B was 
analysed. The difference between the two groups was 
statistically significant (p < 0.001).
The platelet concentration of PRF for both groups was cal-
culated using the difference between baseline and residual 
platelet concentrations (Table 3). A paired t-test showed a 
statistically significant difference between the two groups 
(p < 0.001) (Table 4).
Figure 1: Benchtop centrifuge Figure 2: Prepared PRF
Table 1: Mean baseline platelet concentration in cells x 109/l of blood
Baseline
Mean SD
Males 275.14 43.13
Females 289.50 69.64
Table 2: Mean baseline platelet concentration of residual blood 
in cells x  109/l of blood
Mean N Std. Deviation Std. Error Mean
Group A 7.9 30 3.03 0.55
Group B 4 30 1.93 0.35
Table 3: Mean calculated PRF platelet concentration in cells x 
109/l of blood
Mean Std. Deviation Minimum Maximum
PRF A 274.9 57.8 169 387
PRF B 278.8 58.2 171 390
Table 4: Statistical analysis of PRF A and PRF B
Mean Std. Deviation Std. Error Mean 95% Confidence Interval of the Difference t df Significance (2-tailed)
Lower Upper
-3.9 3.133 0.572 -5.07 -2.73 -6.818 29 0.001
* Paired t-test performed, P value is significant
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DISCUSSION
The purpose of this study was to determine whether stor-
age time had any significant effect on the platelet concen-
tration of PRF. Because the structural properties of the 
PRF clot does not allow for a direct measurement of its 
platelet concentration, we used the residual platelet values 
left in the blood tube after removal of the PRF clot as an 
indirect measurement of the platelet concentration in the 
PRF clot. This is in accordance with a previously published 
method.18 Higher residual values indicate that less platelets 
were contained in the removed clot whereas lower residual 
values would indicate that more platelets were transferred 
to the clot. The results from this study indicate that there is 
a significant difference in the mean platelet concentration of 
PRF when stored for 0 and 60 minutes.
From the platelet counts obtained in both test groups it 
was clear that a significant proportion of platelets had 
been removed from the blood after extraction of the PRF 
clots. In fact, when differences between the test groups 
and the baseline blood sample were compared, it was evi-
dent that 97%-98% of the platelets were concentrated in 
the PRF clot (Table 3). This observation is similar to results 
published for previous studies (97%).19 The natural proc-
ess of fibrin and clot formation that occurs in the blood 
collecting tubes results in the entrapment of the majority 
of the available platelets in a fibrin matrix. This acts as a 
reservoir for a concentration of growth factors (GFs) re-
quired in the initial stages of wound healing.20
Although the physiology of PRF has been studied extensive-
ly, very few reports adequately document the ability of this 
platelet concentrate to be stored.21 Previous research has in-
dicated that storing PRF under certain conditions may affect 
its ability to clinically yield positive results.22 In fact, it is not 
recommended to store the platelet concentrate in its blood 
collecting tube since it is assumed that it may disintegrate 
into an unusable form after about 15 minutes of storage.22 
Instead, several authors propose storing the biomaterial in 
a metal dish or a proprietary designed storage box.17 Data 
regarding the maximal storage time and ideal storage tem-
perature of PRF are, however, largely lacking. 
In this study, we used standard blood collecting tubes 
with clot activators to store PRF for at least 60 minutes 
at room temperature. This particular duration of time 
was chosen based on the average time of typical peri-
odontal surgical procedures at the Faculty of Dentistry, 
University of the Western Cape. The results of the study 
indicate that by using the presented protocol for platelet 
concentrate preparation, it was possible to concentrate 
more than 97% of the available blood platelets into a read-
ily usable form. This study also showed that by using the 
blood collecting tubes as a storage medium, there was 
no detrimental effect on the platelet concentration of PRF. 
Indeed, storing the concentrate for 60 minutes resulted in 
a form of PRF that had significantly higher concentrations 
of platelets compared with non-stored PRF. The reason 
for this phenomenon is unclear, but may be related to the 
“clot activators” that line these tubes. Clot activators are 
often silica based and are used in plastic tubes to mimic 
the clotting effect of glass based blood tubes.22 As a re-
sult, a longer contact time between blood and these ac-
tivators may enhance fibrin activation and clot formation, 
with subsequent platelet entrapment.18 
Another reason for the variation in platelet concentration 
seen in this study may be that the recommended centri-
fuge time is too short to allow for complete clot forma-
tion to occur. Therefore, allowing the PRF clot to remain 
in the tube for a period longer than the recommended 
time, may result in a more complete physiological reac-
tion taking place.
The ability of PRF to sustain its platelet concentrate over 
the tested time may have significant clinical implica-
tions.8,9,22-24 Rather than having to draw blood during the 
surgical procedure, it allows for blood to be drawn before 
the start of the procedure, thereby improving patient com-
fort and saving operator time. The option to store the PRF 
in the same tubes in which it was formed negates expo-
sure to other environmental factors that may contaminate 
the sample. It is also cost-effective, since no specialised 
equipment or storage facilities are required. This may be 
significant in resource-poor settings. 
PRF has been recognised as a biomaterial that includes 
living cells.18,19 In order to sustain cell viability over time, an 
isotonic solution is required for storage. The blood collect-
ing tubes, although not designed to store blood, act as 
containers for the PRF and the remaining formed elements 
and serum. Consequently, when PRF is stored in the blood 
that it was derived from, the remaining serum acts as a 
natural isotonic solution that sustains cell survival.
The release of growth factors is a significant property of 
blood platelets.24 Previous studies indicate that several of 
these factors play an essential role in osteogenesis and 
periodontal regeneration.20,25 When PRF is used, the re-
lease of these growth factors appears to be constant, 
and over a longer period of time when compared with 
that seen with PRP.23 In a direct comparison between the 
two, PRP was shown to have an initial larger release of 
growth factors after activation. However, these high con-
centrations were not stable and decreased over time. On 
the other hand, PRF releases less growth factors initially, 
but sustains this release for a longer duration.23 A number 
of authors speculate that this may be due to the fibrin 
clot that forms a network and acts as a reservoir for the 
trapped platelets.18,19,26 In the present study, it was shown 
that the platelet concentration of PRF improved over a pe-
riod of 60 minutes of storage. We assume that this may 
be due to prolonged fibrin clot maturation. It is therefore 
reasonable to speculate that if PRF is stored until optimal 
fibrin formation is achieved, then higher concentrations 
of growth factors may be available from the PRF during 
wound healing. Whether this has any clinical significance 
requires further investigation.
Temperature may affect the storage potential of PRF and 
it has been suggested that storing it in near-freezing tem-
peratures is not advisable. In this study, all the samples 
were stored at room temperature. It was clear that storage 
under these conditions had no detrimental effect on the 
platelet concentration of the PRF clot.
Although the present study showed statistically significant 
differences between the two groups tested, some limita-
tions were also evident. These include the limited number 
of study participants as well as the inability to directly meas-
ure the platelet concentration of PRF. Other factors include 
the small difference between the platelet concentrations of 
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the groups tested. Although statistically significant, a mean 
difference of only 3.9 × 109 cells/L may not be clinically rel-
evant and therefore further research is warranted to deter-
mine the clinical significance of these findings.
CONCLUSIONS
The viability of storing PRF in its own blood collecting 
tubes has not yet been reported. This study showed that 
by using the above method of platelet preparation, it is 
possible to concentrate more than 97% of the available 
platelets into a PRF clot. The study also indicated that, un-
like in previous reports, clot disintegration does not take 
place after 15 minutes of storage, but rather remains sta-
ble over a period of at least 60 minutes and may in fact 
increase in platelet concentration during that time. Further 
investigations are warranted to determine whether this 
has any clinical implications.
Disclosure policy: The authors declare no conflict of interest re-
garding the publication of this paper. This paper forms part of the 
requirements of partial fulfilment towards the degree PhD.  
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ABSTRACT 
Introduction: Leukocyte- and platelet-rich fibrin (L-PRF), 
an autologous derived platelet and leukocyte concentrate, 
was first introduced by Choukroun et al. in 2001 and is 
currently used for several oral and maxillofacial procedures. 
Hyaluronic acid (HA) is an anionic, glycosaminoglycan that 
shows a wide range of physiological actions, acting as a 
cellular scaffold, stimulating cell adhesion and migration, 
as well as having anti-inflammatory effects. 
Aims and objectives: To investigate the effect of cross-
linked HA and L-PRF on fibroblast viability and proliferation. 
Methods: An in vitro laboratory study was conducted at 
The University of the Western Cape. L-PRF was prepared 
from a single healthy volunteer and cross-linked HA was 
obtained from a commercially available product. Analysis 
was carried out on 3T3 cells using MTT assay. 
Results: Both L-PRF and cross-linked HA are associated 
with cell viability and increased cell proliferation. L-PRF 
had it strongest proliferative effect after 24 hours whereas 
HA had it strongest effect after eight days (p < 0.05). The 
combination of HA and L-PRF was not significantly better 
than the control (p > 0.05). 
Conclusions: L-PRF prepared in a specific manner as 
outlined, as well as commercially available cross-linked 
HA, is compatible with cell growth and proliferation. 
NTRODUCTION
Leukocyte- and platelet-rich fibrin (L-PRF), an autologous 
derived platelet and leukocyte concentrate, was first 
introduced by Choukroun et al. in 2001 and is currently 
used for a number of oral and maxillofacial procedures.1 
The use of L-PRF has gained popularity in the field of 
surgical implantology, specifically for procedures involving 
soft and hard tissue augmentation.2-5 The preparation of 
L-PRF differs from those of previous platelet concentrates 
in that it involves the use of a single spin protocol that 
results in an easily manipulated biomaterial that can be 
applied directly to the site of surgery.1 It is assumed that 
the concentrated growth factors associated with L-PRF 
optimize wound healing and decrease surgical recovery 
time.2,5 Consequently, L-PRF has been used in various fields, 
including dermatology and periodontal regeneration.2-5
 
Hyaluronic acid (HA) is an anionic, glycosaminoglycan.6,7 
It is a naturally occurring molecule that is found in high 
concentrations in the extracellular matrix of skin, cartilage, 
bone and periodontal ligament.7 Even though the exact 
function of HA has not yet been established, the molecule 
shows a wide range of physiological actions, acting as a 
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ACRONYMS
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cellular scaffold, stimulating cell adhesion and migration, 
as well as having anti-inflammatory effects.7 Commercially 
synthesized HA, in various forms, has been used in tissue 
engineering, dermatology, orthopaedics, and more recently, 
periodontal regeneration.7-10 Traditionally, two forms of 
commercially synthesized HA exist, i.e., non-cross-linked 
HA, and cross-linked-HA, resulting in different properties 
and indications for each form of HA. 
The aim of the study was to investigate the effect of 
cross-linked HA and L-PRF on fibroblast viability and 
proliferation.
MATERIALS AND METHODS
The study was conducted at The University of the Western 
Cape, Cape Town, South Africa, in 2017. Ethical clearance 
was obtained from the Research Ethics Committee of 
the above university (reference number: BM 16/3/31). 
Informed consent was obtained from the blood donor.
Preparation of the L-PRF 
Thirty six milliliters of blood was obtained from a single 56 
year old healthy female volunteer. The blood samples were 
collected in blood collecting tubes that contained clot 
activator i.e., Vacuette® 9-ml serum tubes with Z Serum 
Clot Activator (Greiner BioOne International AG, Germany). 
These were then immediately centrifuged at 400xg for 
12 minutes in a standard benchtop centrifuge (PLC-
03, Hicare International, Taiwan) as has been previously 
described.11 Centrifugation separated the blood into three 
distinct layers (Figure 1). The layers could be distinguished 
as a topmost layer consisting of platelet poor plasma, 
L-PRF in the middle, and red blood cells below. L-PRF 
was then removed with a sterile forceps, separated from 
the underlying red blood cells and shredded into smaller 
fragments using surgical scissors.
Hyaluronic Acid (HA)
A commercially available cross-linked HA (hyaDent BG, 
Bioscience GmbH) was used in the present study. It is 
sold as a clear gel contained in a dental anaesthetic-
type cartridge and is applied using a dental syringe and 
a specifically supplied needle. This specific formulation 
contains 2.0 mg/ml of sodium hyaluronate that is cross-
linked with butanediol digylcidyl ether, resulting in a HA 
molecule with a unique chemical structure. 
Cells and Cell Culture
In this investigation, the 3T3 fibroblast cell line was 
obtained from The National Repository for Biological 
Materials (Sandringham, South Africa). The 3T3 cells were 
incubated at 37°C in 5% carbon dioxide and 95% humidity 
in Dulbecco’s Modified Eagle’s medium (DMEM) with 10% 
foetal bovine serum (FBS) and 1% penicillin– streptomycin 
mix. Cells were grown to about 80% confluence and then 
trypsinized using trypsin-ethylene-diamine-tetra-acetic 
acid (EDTA). The cells were then seeded into 3 x 96-well 
plates and treated as follows;
•	 Plate 1 – 1 drop of HA (HA group)
•	 Plate 2 – 1 drop of HA added to a 1 mm x 1 mm fragment 
of L-PRF (HA + L-PRF group)
•	 Plate 3 – 1 mm x 1 mm fragment of L-PRF (L-PRF group)
All the plates had an equal number of controls containing 
only DMEM. After a culture period of 24 hours to 10 days, 
each group was removed and proliferation and viability 
evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay.12 A minimum 
of 5 replicate experiments for each group was performed 
to ensure reproducibility.
Cell Viability and Proliferation Assay
Cell viability (the metabolic activity of the cell) and cell 
proliferation (rate of cell division) were measured using 
the standard MTT assay (MTT, Sigma Chemical Co., 
Baltimore, MD, USA). The MTT assay or test is a sensitive 
and quantitative colorimetric assay that measures these 
parameters.12 It reflects the capacity of the mitochondria 
in living cells to convert MTT to purple formazan crystals 
that can be solubilized with dimethylsulphoxide (DMSO) 
or isopropanol.12 This effect is directly proportional to the 
cell number and is measured with a spectrophotometer 
at a wavelength of 540 nm. Rapidly dividing cells i.e. cells 
which show high rates of proliferation, reduce MTT at a 
faster rate than cells with low proliferative potential. The 
MTT assay therefore measures the ability of the cell to 
reduce MTT (viability) as well as the rate of cell division 
(proliferation). As a result, the MTT assay can also be used 
to measure cytotoxicity (loss of viable cells) and cytostatic 
activity (shift from proliferation to quiescence). For the 
current study, readings were taken from all groups with 
the control group set at 100%.
Data Analysis
Data from the MTT assay were captured using Microsoft 
Excel 2010 (Microsoft Corporation, Washington, USA) 
and statistically analyzed using the one-way ANOVA and 
Tukey’s test.
Figure 1: Proliferation and viability assay (MTT) of 3T3 cells. Control is 
taken as 100% Figure 2: HA vs control (MTT assay).
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RESULTS
With the control group set at 100%, the mean optical 
densities of each of the test groups were divided by that 
of the control group and expressed as a percentage 
of the control value. The data from the MTT assay was 
correlated, and is presented in Figures 1-4. Statistical 
analysis is represented by Tables 1 and 2.
According to the results obtained, both L-PRF and 
cross-linked HA (clHA) as well as the combination of the 
two materials were compatible with cell viability and 
proliferation (i.e. none of the tested biomaterials tested 
displayed evidence of being cytotoxic or cytostatic). Cross-
linked HA showed a statistically significant reduction in cell 
number when compared with the control group at 24 hours 
(89.98% ± 9.83, p < 0.05). Thereafter cell viability steadily 
increased, reaching 100.88% ± 6.46 at day 10. Peak cell 
proliferation associated with HA was seen on day 8 and 
recorded as 112.20% ± 9.69. This was significantly greater 
than the proliferation seen in both other test groups for 
the same time period (p < 0.05). The HA + L-PRF group 
showed a cell viability of 85.44% ± 12.35 at 24 hours. This 
was statistically significant (p < 0.05) when compared with 
the control group, indicating a negative effect on cellular 
proliferation in the first 24 hours. This difference was not 
significant for days 2, 5 and 7, but was again recorded on 
days 8 and 10 (p < 0.05).
The L-PRF group showed the highest cell viability and 
proliferation after 24 hours (108.99% ± 5.43). This was 
significantly higher than the other groups tested as 
well as higher than the control group (p < 0.05). At 
day 10, no significant differences were seen between 
all the test groups, however the HA + L-PRF group 
showed a significantly reduced number of cells as 
compared with the control (p < 0.05).
  
A comparison of the proliferative effects of the 
test groups indicate that both groups containing 
clHA showed a pattern of cellular proliferation 
that steadily increased from day 1 to peak at 
day 8 (clHA group) and day 7 (HA+L-PRF group) 
respectively. This was different to that observed for 
the L-PRF group where peak cell proliferation was 
seen after 24 hours and steadily decreased over 
the test period (Figure 4.)
DISCUSSION AND CONCLUSIONS
The results from the current study indicate that both 
L-PRF and cross-linked HA are biocompatible and 
induce cellular proliferation of fibroblasts in vitro. 
L-PRF
It appears as if the effect of L-PRF used in this study 
is most pronounced in the first 24 hours when 
compared with any of the other materials tested. 
This may be due to the high concentration of growth 
factors present in the material. These include 
substances such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), platelet-
derived growth factor (PDGF-AB), transforming growth 
factor beta 1 (TGF-β1) and epidermal growth factor (EGF), 
released from platelets as well as leukocytes.13-16 This initial 
“proliferative burst” is similar to that seen by Vahabi et al. 
who reported a statistically significant increase in cellular 
proliferation of human gingival fibroblasts (HGFs) after 24 
hours.17 However, unlike the Vahabi et al. study, which 
showed a reduction of cell viability of up to 60% after 
72 hours, the present study showed sustained cellular 
viability and proliferation that was statistically similar to the 
control group for all subsequent test days. The difference 
in observations in the two studies is difficult to explain 
without a direct comparison between the two biomaterials 
Table 1: Comparison between the test groups (one way ANOVA) 
HA HA + PRF PRF
Mean SD Mean SD Mean SD P value
Day 1 89.98 9.83 85.44 12.35 108.99 5.43 0.005 *
Day 2 91.41 8.79 94.72 9.89 96.27 4.34 0.632
Day 5 100.08 8.79 95.18 7.29 101.01 7.26 0.47
Day 7 97.47 8.92 98.6 6.15 100.79 5.77 0.757
Day 8 112.2 9.69 94.57 4.09 94.78 9.66 0.007 *
Day 10 100.88 6.46 96.15 2.62 99.15 7.64 0.439
(* p<0.05)
Figure 3: HA + L-PRF vs Control (MTT assay). Figure 4: L-PRF vs control (MTT assay).
Table 2: Comparison between the test groups (Tukey test)
HA vs Control HA-PRF vs Control PRF vs Control
Day 1 0.02* 0.01* 0.003*
Day 2 0.03* 0.13 0.045*
Day 5 0.49 0.08 0.38
Day 7 0.27 0.31 0.08
Day 8 0.01* 0.009* 0.13
Day 10 0.38 0.005* 0.49
(* p<0.05)
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associated with each investigation. Dohan Ehrenfest et 
al. showed that no significant differences were seen in 
cell viability and proliferation when measured using the 
MTT assay over 21 days for HGFs cultured with L-PRF 
13. However, the MTT assay was only reported after 
day three, thereby possibly failing to record any earlier 
significant findings. Similar to the Dohan Ehrenfest et al 
investigation, the present study showed no statistically 
significant differences when L-PRF was compared to 
the control group at day 7, and for subsequent days 
thereafter.13 A recent study investigating the in vitro effect 
of a modified protocol to produce L-PRF, also showed 
no significant cell proliferation after 24 hours compared 
with the control group, suggesting that the protocol used 
to produce L-PRF in the current study may result in a 
L-PRF with a different biological effect compared with 
the abovementioned reports.16 A previous investigation 
by Peck et al. showed that the L-PRF used in this study 
has a distinct fibrin architecture with most of the fibres 
being of a “larger” diameter.18 Whether this characteristic 
is significant in the biological behaviour of the biomaterial 
is still unclear.
Cross-linked HA
A limited number of studies have reported on the cell 
stimulating potential of the specific high molecular weight 
clHA used in the present study.6,7 Previous research 
indicates that this formulation is biocompatible and is able to 
positively stimulate the proliferation of periodontal ligament 
cells in vitro.6 These results were statistically significant 
when the biomaterial was diluted at ratios of 1:100 and 1:10. 
The authors can provide no conceivable reason why the 
diluted material evoked a higher proliferation rate than the 
undiluted material. We speculate, however,  that this may 
possibly be due to the reduced viscosity of the material 
after dilution, thereby allowing better interaction with the 
growth medium and cell culture.
In the present study we showed that undiluted clHA 
resulted in a reduction of cellular proliferation for the first 
few days after cell culture. This was similar to what was 
observed by Fujioko- Kubayashee et al and colleagues. 
At day 5, cellular proliferation approximated that of the 
control group, and, by day 8, was significantly higher 
than that of the control group (p < 0.05). Therefore an 
augmented proliferative effect was noticed for the present 
study. Although HA has well-established water retention 
properties, the exact mechanism of HA and fibroblast 
interaction is unclear with “fibroblast stretching” cited as 
the most likely cause.19 In a recent study evaluating the 
effect of both clHA and non-cross linked HA on dermal 
fibroblasts, it was shown that the molecular structure, 
particularly the type and density of the cross-linkages, play 
a significant role in the ability of HA to stimulate fibroblast 
proliferation.19 Any biological effect of synthesized HA is 
product dependent and the results of each study should 
therefore be interpreted with this in mind. This might also 
explain the variations in clinical efficacy of dental related 
HA that are reported in the literature. 
Hyaluronic Acid and L-PRF    
Because HA has previously been used for tissue 
engineering and is commercially available for the 
management of several inflammatory-related conditions, 
the authors evaluated the cell viability and proliferative 
potential of a combination of clHA and L-PRF on 
fibroblasts. As L-PRF has an inherently high concentration 
of growth factors related to wound healing, it was 
assumed that the combination of the two biomaterials 
would stimulate cellular proliferation. The results from 
the current study indicate that the combined formulation 
was biocompatible, but had a varied effect on cell 
proliferation. Similar to clHA, the clHA+ L-PRF mixture 
showed a significant reduction in cell proliferation after 
24 hours. Proliferation then increased over time, and on 
day 7, it peaked, showing results similar to those of the 
control group (p > 0.05). This proliferation was opposite to 
that seen for the L-PRF group. It is interesting to note that 
the clHA+L-PRF combination showed consistently lower 
cell proliferation when compared with the control group 
throughout the time period of the study. Although L-PRF 
on its own stimulated cell proliferation significantly after 24 
hours, it seems the addition of clHA constrained this initial 
stimulatory effect. Whether this is related to the viscosity 
of the clHA or its concentration is critical to debate. It is 
known that diluted forms of clHA seem to better stimulate 
cell growth, and this might therefore explain the results 
seen in the present study 6.
CONCLUSION
L-PRF and clHA are unique biomaterials that are being 
used in tissue engineering. In the present study, we show 
that these materials on their own, or in combination, are 
biocompatible and stimulate cell growth. Interestingly, it 
appears that this specific method of L-PRF preparation 
results in a material that has a stimulatory effect that 
peaks within the first 24 hours. Cross-linked HA also 
stimulates growth positively, but unlike L-PRF this effect 
is prolonged over 8 days, implying a different, as yet 
unknown, mechanism of action. The combination of 
L-PRF and clHA seems to provide no further advantage 
to cellular growth when compared with using either of 
the materials on their own. Based on the above, we 
can speculate that although L-PRF results in an almost 
immediate stimulatory effect, that clHA, as a sole 
treatment choice, might be beneficial in the management 
of wounds that require more prolonged stimulation. 
Further research is required to determine the clinical 
implications of the above findings. 
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ABSTRACT 
Introduction 
Leukocyte- and platelet-rich fibrin (L.:-PRF), an autologous derived 
platelet and leukocyte concentrate, was first introduced by 
Choukroun et al. in 2001 and is currently used in a wide range of 
medical procedures. Although various biological properties have 
been attributed to L-PRF, nevertheless, when tested for inherent 
antimicrobial activity, the biomaterial fails to demonstrate a clear 
and significant effect against a range of oral microbiota. Aims 
and objectives: To determine whether L-PRF prepared after a 
single oral dose of antibiotic had any significant antimicrobial 
effect over a 48 hour period. Methods: An in vitro laboratory 
study for which L-PRF was prepared from a single healthy 
volunteer who had previously ingested oral antibiotics. The 
resultant prepared L-PRF was tested for antimicrobial activity 
against Streptococcus mutans (ATCC 36668) using standard 
laboratory methods. Results: For all samples tested, measurable 
zones of Inhibition were clearly vlslble after 24 hours, but were 
absent after 48 hours. Conclusions: L-PRF prepared after a 
single dose of oral antibiotic results in a measurable antimicrobial 
effect that is sustainable for 24 hours. Although L-PRF will remain 
structurally intact for a few days, it does not appear to influence 
the duration of the antimicrobial activity. 
Introduction 
Leukocyte- and platelet-rich fibrin (L-PRF), an autologous blood-
derived biomaterial, was first introduced by Choukroun et al. 
in 2001 as a simple method of introducing autogenous growth 
factors to a wound site.' Since then, L-PRF has been utilized for 
a number of medical procedures, including the management 
of diabetic wounds, soft and hard tissue augmentation and 
dermatological L-PRF is prepared using a single spin 
protocol that results in an easily manipulated biomaterial that can 
be applied directly to the site of surgery.1 The structure of this 
biomatrix, which consists of a platelet and leukocyte concentrate 
interwoven within a fibrin mesh, is claimed to be one of the major 
factors that contribute to Its cllnlcal success. Previous studies 
Indicate that the unique characteristic of fibrin make It an Ideal 
drug delivery system that allows the distribution of an active 
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agent directly to the site required.8 The fact that fibrin undergoes 
flbrlnolysls over a period of time, has the potential of prolonging 
the drug release and may therefore Influence the cllnlcal 
outcome. Previous studies have combined antibiotics with fibrin 
(mostly fibrin sealants) for the management of various conditions 
such as osteomyelitis, endocarditis, and other "difficult to treat" 
infections.1-11 
Although various biological properties have been attributed 
to L-PRF, nevertheless, when tested for inherent antimicrobial 
activity, the biomaterial failed to demonstrate a clear and 
significant antimicrobial effect against a range of oral microbiota.12 
We hypothesize that incorporating antibiotics into L-PRF may 
enhance its antimicrobial profile and that the structure of the 
L-PRF would allow for a prolonged release of the drug. The 
aim of this in-vitro pilot study was to determine whether L-PRF 
prepared after a sing le oral dose of antibiotic had any significant 
antlmlcroblal effect over a 48 hour period. 
MATERIALS AND METHODS 
The study was conducted at The University of the Western 
Cape, Cape Town, South Africa, In 2017. Ethical clearance 
was obtained from the University Research Ethics Committee 
(reference number: BM 1613/31). Informed consent was obtained 
from the blood donor. 
Preparation of the L-PRF 
Thirty six milliliters of blood were obtained from a 24 year old 
healthy female volunteer who had undergone dental implant 
surgery. She had ingested a single dose of antibiotics, as 
surgical prophylaxis (Amoxicillin, 2 g orally), one hour prior to 
the surgical procedure. One hour after antibiotic ingestion, blood 
samples were collected in blood collecting tubes that contained 
clot activator, i.e., Vacuette® 9ml serum tubes with Z Serum Clot 
Activator (Greiner BioOne International AG, Germany). These 
were then immediately centrifuged at 400 x g for 12 minutes in 
a standard benchtop centrifuge (PLC-03, HICare lntematlonal, 
Taiwan) as prevlously descr1bed.'2 Some of the resultant L-PRF 
clots were then used during the surgical procedure, whilst the 
remaining clots were used for the current study. These l.:PRF 
clots were then compressed using the PRF Box TM (Process for 
PRF, Nice, France) to obtain uniform thickness of the sample 
specimens, two of which were selected and designated as 
Sample and Sample Two respectively. 
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Microbial Culture 
The Oral and Dental Research Laboratory (Faculty of Dentistry, 
University of the Western Cape) sponsored samples of 
Streptococcus mutans (ATCC 35668, Quantum Biotechnologies, 
South Africa) for the study. The authenticity of the bacteria was 
confirmed via Gram stain, growth morphology on blood agar and 
API STREP 20 system (bioMerieux). Cultures were grown for 24 
hours at 37°C. Two colonies were adjusted to 0.5 McFarland's 
standard (DensiCHEK Plus, bioMerieux) in sterile physiological 
saline. One mil litre (1 ml) of the adjusted colonies was then spread 
plated on CASO agar (Merk Life Science GmbH, Germany). 
Antimicrobial activity 
The samples of prepared L-PRF were of comparable size and 
thickness due to the standardized protocol used in preparation. 
Each sample was placed in the centre of a bacteria-streaked 
agar plate and then incubated for 37°C in a standard laboratory 
incubation chamber for 24 hours. At that stage the plates were 
removed and the clear zones surrounding each L-PRF sample 
(zones of microbial inhibition), were repeatedly measured using 
a digital vernier caliper (Mastercraft, South Africa). In order to 
test the antimicrobial efficacy over the subsequent 24 hours, 
the samples were removed and placed in a fresh bacteria-
impregnated agar plate. The plate was incubated for 24 hours as 
before and the inhibition zones again measured. 
DATA ANALYSIS 
Data from the test samples were captured using Microsoft Excel 
2010 (Microsoft Corporation, Washington, USA) and statistically 
analyzed using one-way ANOVA and Tukey's test. 
33.97 29.41 0 0 
41.57 42.70 0 0 
32.20 31.22 0 0 
29.53 44.03 0 0 
32.90 31.99 0 0 
32.91 47.15 0 0 
39.65 47.06 0 0 
40.75 31.82 0 0 
35.11 42.82 0 0 
41.33 31.eo 0 0 
RESULTS 
The 24 and 48 hour results were recorded as the observable 
zones of inhibition in millimeters and are represented in Table 1. 
Zones of inhibition were noted for both L-PRF samples after 24 
hours. According to statistical analysis using one-way ANOVA 
and Tukey HSD Test, no significant differences were noted for the 
sizes of inhibition zones when the two samples ware compared 
after 24 and 48 hours, i.e., similar results were recorded at both 
24 and 48 hours. No measurable inhibition zones were seen 
for either sample after 48 hours (Table 2), indicating that all 
antimicrobial activity had been lost at that time. A statistically 
significant difference was seen in the data between the two time 
points. 
DISCUSSION AND CONCLUSIONS 
Repeated systemic use of antibiotics to treat or minimize 
localized infection has its limitations, especially in areas with 
constrained blood supply. Furthermore, localized drug delivery 
systems often require specialized carriers to allow for the delivery 
of therapeutically sustainable doses of the active agent. In the 
present study we attempted to determine whether using an 
antibiotic- laden autologous blood-derived concentrate had any 
significant antimicrobial effect over a period of time. The results 
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81 l,24hrs) VB 1.4702 0.7058178 Insignificant 
S2 (24hrs) 
81 (24hrs) VS 26.6181 0.0010053 JX().01 
81 (48hrs) 
81 (24hra) VB 26.6181 0.0010053 p<0.01 
S2 (48hra) 
82 (24hrs) VS 28.0883 0.0010053 JX().01 
S1 (4Bhrs) 
S2 (24hrs) VB 28.0883 0.0010053 P<0.01 
S2 (48hrs) 
81 (4Bhrs) vs 0 0.8999947 lnslgnlllcant 
s2 (48hrs) 
from the currant study indicates that L-PRF prepared after a 
single dose of antibiotics provides measurable antimicrobial 
activity for at least 24 hours against specific oral microbiota. 
Attar 48 hours, the antimicrobial effect is markedly reduced, 
with no statistically relevant antimicrobial affect seen. This may 
suggest that although L-PRF has a unique structure, its ability 
to concentrate antibiotics and release them over time, may be 
limited. This has been seen in previous studies in which fibrin 
sealants directly supplemented with antibiotics showed a 
rapid antibiotic release over a short period of time (85% over 
72 hours).14-1e Woolverton et al. (2001) attributed this to rapid 
diffusion as a result of the antimicrobial molecules being small, 
ionic, and designed for oral and parenteral delivery. 8 However, 
antibiotics having a lass soluble nature, unlike the current study, 
have been shown to exhibit a much longer sustained release 
from fibrin sealants.11 Another reason for the rapid diffusion of 
antibiotics from L-PRF may be the limited binding capacity of 
the antibiotic used in the present study. Amoxicillin, when orally 
ingested, is 20% protein bound in the blood and about 60% of 
the drug is excreted in the urine within 6-8 hours.18 The protein 
binding is mostly to albumin (the most abundant plasma protein) 
which has a specific binding site but a relatively low affinity for the 
antibiotic.18 The drug has no known affinity to fibrin and this may 
explain the limited antimicrobial effect observed in the present 
study. It is therefore assumed that the drug was concentrated in 
the plasma component of the L-PRF and not directly bound to 
the fibrin or cells associated with the L-PRF matrix. 
Unlike previous studies that have directly combined the antibiotic 
with the fibrin matrix, we attempted to incorporate antibiotics 
that were already in the blood (at peak plasma concentration) 
during the process of preparing the L-PRF matrix. This has the 
advantage of not requiring any additional materials or steps in 
incorporating the antibiotic into the L-PRF. Interestingly, certain 
clinical studies involving the use of L-PRF for dental surgical 
procedures have made use of oral antibiotic surgical prophylaxis 
prior to preparing L-PRF.19 In these studies, no mention was made 
of the influence of antibiotic ingestion in the healing outcomes 
of the site treated with the L-PRF. The present study indicates 
that antibiotics are presumably incorporated into L-PRF after a 
single oral dose and may be active for at least 24 hours. We can 
therefore presume that the clinical studies that have administered 
antibiotics prior to surgery, have indeed incorporated antibiotics 
into the L-PRF, if the L-PRF was prepared at least one hour after 
antibiotic prophylaxis. A further investigation into the influence 
of pre-operative antibiotics as a factor influencing the clinical 
behaviour of L-PRF is therefore required. 
CONCLUSION 
1..:-PRF has restricted intrinsic antimicrobial activity. Within the 
limitations of the present study, we have shown that L-PRF 
prepared after a single dose of oral antibiotic, results in a 
measurable antimicriobial effect that is sustainable for 24 hours. 
Although 1..:-PRF will remain structurally intact for a few days, this 
does not appear to influence the duration of the antimicrobial 
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activity. We therefore assume that the antibiotic is mostly 
concentrated in the plasma and is not directly bound to the 
structural components of the L-PRF matrix. Further research 
is required to determine the significance of these preliminary 
findings. 
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The use of leukocyte- and platelet-
rich fibrin (L-PRF) to facilitate implant 
placement in bone-deficient sites:  
a report of two cases 
ABSTRACT
Successful dental implant treatment usually requires that the 
implant be placed in the ideal anatomic position, so that it 
will readily facilitate the placement of a functional and aes-
thetically acceptable restoration. However, this is not always 
possible, and in many cases augmentation procedures may 
be required to compensate for lost tissue structures. These 
interventions often require more complex surgery, as well 
as the use of graft material derived from animal sources. 
Leukocyte- and platelet-rich fibrin (L-PRF) is a newly devel-
oped platelet concentrate that has successfully been used 
in a number of surgical procedures to optimise wound heal-
ing. Several studies indicate that it may also have the ability 
to stimulate bone formation. In this article we present two 
cases where L-PRF was used to stimulate bone formation to 
facilitate ideal placement of implants.
Keywords: Leukocyte- and platelet-rich fibrin (L-PRF), bone 
augmentation, osseous regeneration
INTRODUCTION
The use of implant-supported restorations to replace miss-
ing teeth has become widely accepted as a viable treatment 
option in modern restorative dentistry. However, once teeth 
are lost due to pathology or trauma, the remaining alveo-
lar bone anatomy is often compromised and there may be 
insufficient bone volume to allow placement of an implant 
that would be functional. Frequently, aesthetics are also 
compromised. Several techniques have been developed to 
overcome this problem, including one or more combinations 
of guided bone regeneration, osteoconduction, osteo-in-
duction, distraction osteogenesis, and revascularised bone 
grafts.1 In this article we present two cases where a novel 
biomaterial, “leukocyte- and platelet rich fibrin (L-PRF)”,2 was 
used with the intention to enhance osseous regeneration 
and to enable the placement of dental implants in previously 
deficient bony sites.3
CASE 1
A 45-year-old female patient presented with complaints of 
“difficulty when chewing” on her right side. Both upper-right 
premolars had been extracted by her dentist due to failed en-
Figure 1: Pre-operative orthopantomograph showing the amount of bone avail-
able at the proposed implant sites in first quadrant (14, 15 area).
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dodontic treatment and since then she had not been able to 
adapt to a removable partial denture. She therefore requested 
a “fixed” restorative option. Her medical history was unremark-
able and she had no history of smoking or evidence of peri-
odontal disease. It was decided that two implant-supported 
crowns in the region of teeth 14 and 15 would offer her the 
most stable, long-term restorative solution. 
The clinical examination indicated a buccal bony defect in 
the area of 14 and 15, but the affected area was otherwise 
healthy and free from signs of pathology.
The pre-operative radiographic examination revealed insuffi-
cient bone height secondary to maxillary sinus pneumatisation 
in the area of extracted tooth 15, with only 2-3mm of vertical 
bone remaining (Figure 1). A sinus augmentation procedure 
was indicated to increase the bone available so there may be 
adequate support for the length of the intended implant. 
The two implant sites were prepared simultaneously, 
as follows:
Surgical management of site 14 (upper right first premolar) 
A midcrestal incision was made and a full-thickness muco-
periosteal flap was raised. No vertical releasing incisions were 
made. The bone in site 14 was judged to be sufficient for implant 
placement without any additional augmentation procedures, and 
therefore was prepared according to the standard protocol. Dur-
ing the procedure, intra-oral radiographs were repeatedly taken 
to confirm the correct depth and direction of the osteotomy site. 
Once the final width and depth had been reached, a 3.7mm by 
10mm dental implant (Uniti®, Equinox, Holland) was inserted into 
the prepared site and torqued to 35Ncm. 
Surgical management of site 15 (upper right second 
premolar) 
As the residual vertical bone was less than 4mm in the 15 
area, a 2mm pilot drill was used to prepare the osteotomy site 
to within 1mm of the sinus floor (Figure 2). A 3mm drill was 
then used to the same depth so as to allow for the insertion 
of osteotomes. Sixty millilitres of blood was then drawn from 
the antecubital vein of the patient and collected into six 10ml 
anti-coagulant-free blood collecting tubes (Vacuette® with Z 
Serum Clot Activator, Greiner Bio One International AG, Ger-
many). These were then centrifuged at 400g for 12 minutes, 
using a standard laboratory table-top centrifuge (PLC-03®, 
Hi-care International, Taiwan). Immediately after being cen-
trifuged, one L-PRF clot was separated from the underlying 
red blood cell layer and introduced into the 15 osteotomy 
site (Figure 3). The floor of the sinus was in-fractured using a 
3mm osteotome (Southern Implants®, Irene, South Africa), 
and the lining was raised. Once the integrity of the sinus 
membrane was confirmed using the Valsalva manoeuvre, 
four more L-PRF clots were then introduced into the sinus 
with the osteotome to elevate the floor to the desired height. 
A 3.7mm by 13mm implant (Uniti®, Equinox, Holland) was 
then inserted, with the previously introduced L-PRF clots 
acting as a “protective layer” for the sinus lining. 
After primary stability had been reached, titanium cover 
screws were placed on both implants and the remaining L-
PRF was then applied to the lateral aspect of the alveolar 
ridge. The site was closed using 4-0 synthetic absorbable 
braided sutures (Clinisut®, Port Elizabeth, South Africa). An 
immediate post-operative radiograph was then taken that de-
picted the 10mm rise in sinus membrane height (Figure 4).
Post-operative healing was uneventful, and after two weeks 
the sutures were removed. The patient returned after six 
months having encountered no complications associated 
Figure 3: Leukocyte- and platelet-rich fibrin (L-PRF) clot obtained from pa-
tient’s blood.
Figure 4: Immediate post-operative radiograph showing the distal implant in 
the maxillary sinus surrounded by L-PRF. 
Figure 2: Osteotomy site preparation for the placement of two implants in 14, 
15 area.
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with the initial surgery. At this time, the implants were surgi-
cally exposed and the healing abutments were placed. No 
movement or pain was associated with implant 15 and the 
radiographic examination revealed evidence of new bone 
formation extending to the tip of the implant (Figure 5). The 
implants were subsequently successfully restored with two 
cement-retained splinted porcelain-fused-to-metal (PFM) 
crowns (Figure 6).
CASE 2
A 48-year-old healthy male presented with complaints of a 
pain on the left side of his mouth that was associated with an 
unrestored dental implant (Mistral®, MIS implants, Tel Aviv, 
Israel) placed three months previously (Figure 7). Clinically, 
the patient experienced pain on percussion at the implant in 
the 27 area. Further clinical investigation revealed that the 
implant was mobile and had failed to osseo-integrate. It was 
decided to remove the failing implant and to subsequently 
replace it with another, once adequate healing had taken 
place. Taking into account the previous history of implant 
failure together with the risk of potential bone resorption, it 
was decided that an alveolar ridge preservation (ARP) pro-
cedure was to be carried out immediately after removal of 
the failed implant at the same operative procedure.
Surgical procedure for simultaneous implant 
removal and ARP procedure
Under local anaesthesia, the implant in the area of 27 was 
removed and the resulting bony socket thoroughly curetted 
to remove all granulation tissue and fibrous debris. Blood 
was then drawn from the vein of the antecubital fossa and 
L-PRF prepared in a similar manner as described above. 
Three (3) L-PRF clots were then inserted into the 27 socket 
site and secured in place using 4-0 synthetic absorbable 
braided sutures (Clinisut®, Port Elizabeth, South Africa).
Implant placement
Healing was uneventful and three months after initial in-
troduction of the L-PRF clot into the failed implant site, a 
follow-up radiograph revealed substantial new bone forma-
tion that was more radio-opaque compared with the im-
mediate adjacent bone (Figure 8). The patient was then 
scheduled for implant surgery one week later to replace 
the initial failed implant. At surgical exposure of the 27 area, 
substantial new bone formation was evident with only mini-
mal signs of the failed implant site still visible (Figure 9). 
A 4.2mm by 10mm dental implant (Screwvent®, Zimmer, 
California, USA) was then placed into the area without any 
complications being noted.
Figure 5: Although taken at a slightly different angle, this  six month post-
operative  radiograph reveals increased radio-opacity indicating the presence 
of new bone extending to the tip of the implant.
Figure 6: Cement-retained implant-supported PFM crowns (14, 15) in place.
Figure 8: Radiograph indicating increased opacity at the failed implant site 3 
months after the implant removal and placement of L-PRF clot in the area.
Figure 9: Presence of new bone formation as seen clinically at the time of 
implant placement in 27 area.Figure 7: Initial presentation of patient with a painful, failed implant in 27 area.
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DISCUSSION
Leukocyte- and platelet-rich fibrin (L-PRF), a second gen-
eration platelet-rich-plasma (PRP) concentrate, was first de-
scribed by Choukroun in the early part of the 21st century.2 
It is considered a biomaterial that actively promotes wound 
healing in both hard and soft tissues.3 It is prepared from the 
patient’s own blood and requires no additional additives or 
specialised equipment for its preparation.4-8 Blood is drawn 
from the patient directly into glass or silica coated plastic 
blood-collecting tubes and centrifuged at low speed to 
separate the platelets from the red blood cells (RBCs).6 The 
absence of any anticoagulant during the centrifuge process 
allows for the unimpeded activation of platelets, thus trigger-
ing the coagulation cascade.5 This results in the formation 
of a fibrin clot that contains a high concentration of leuko-
cytes and platelets.9 This L-PRF clot can then be moulded 
into a usable “membrane” that acts as a simple method of 
transferring high concentrations of platelets to any wound 
site. A three dimensional analysis of the L-PRF membrane 
indicates that it has a unique structure that traps platelets, 
leukocytes and cytokines in a mesh of fibrin strands. This 
imparts structural integrity to the biomaterial and allows it to 
be manipulated for use in variety of clinical procedures.3
 
The L-PRF membrane traps at least 95% of the platelets 
of the collected blood, allowing for the natural release of 
several growth factors (GFs) to the surgical area.3,10,11 These 
GFs are released from the platelet granules, and include 
vascular endothelium growth factor (VEGF), platelet-derived 
growth factor (PDGF), fibroblast growth factor (FGF), epider-
mal growth factor (EGF), hepatocyte growth factor (HGF), 
insulin-like growth factor (IGF), platelet-derived-growth factor 
(PDGF) and transforming-growth factor-beta (TGF-beta), all 
of which play a role in replacing lost tissue, resurfacing of the 
wound, and restoring vascular integrity.4,12 PDGF stimulates 
the replication of stem cells associated with fibroblasts and 
endothelial cells (thereby promoting angiogenesis) as well 
as the production of fibronectin – a cell-adhesion molecule 
required for proper cellular proliferation and migration during 
healing. PDGF also induces osteoconduction and promotes 
the production of hyaluronic acid, an essential component 
for wound contraction and remodelling. Although similar 
GFs may be released by platelet-rich plasma (PRP), the 
unique structure of L-PRF allows it to release these factors 
over a longer period of time, potentially optimising wound 
healing.12,13 The presence of leukocytes (absent from  PRP) 
also contributes to the release of TGF-beta and VEGF, fur-
ther increasing the concentration of available GFs.3,13
L-PFR has been exploited in various clinical procedures in-
cluding maxillofacial surgery, periodontal surgery, implantol-
ogy and plastic surgery.14,15 In a clinical study of maxillary 
sinus lift procedures in which L-PRF clots and L-PRF mem-
branes were used as the only augmentation material, Mazor 
et al showed that L-PRF was capable of stimulating complete 
bone regeneration in the areas that initially had inadequate 
vertical bone height.8 In a similar six-year follow-up study, Si-
monpeiri et al were able to demonstrate that using L-PRF as 
a sole grafting agent was a viable long-term option in sinus 
augmentation procedures.16 
Case 1 demonstrated the use of L-PRF in osteotome me-
diated sinus augmentation procedures. By applying L-PRF 
to the osteotomy site, before fracturing the sinus floor, the 
biomaterial acts as a “protective cushion” that facilitates the 
safe upward displacement of the sinus membrane.9 Studies 
indicate that using L-PRF in osteotome sinus floor elevation 
techniques, together with immediate implant placement, 
reduces the healing time between surgical placement and 
prosthetic restoration of the implants.9 
L-PRF has been used  to treat periodontal hard and soft tissue 
defects.14,15 In vitro studies have confirmed that L-PRF selec-
tively stimulates the growth of osteoblasts and gingival cells.17 
In a series of clinical trials conducted by Pradeep et al, it was 
shown that L-PRF could be used as a guided-tissue-regen-
eration (GTR) membrane to effect periodontal regeneration in 
three-wall bony defects and degree II furcation lesions.14,15 Del 
Corso et al published several case reports showing the suc-
cessful use of L-PRF membranes in the management of both 
single and multiple gingival recession defects.18 Using multiple 
L-PRF membranes instead of connective tissue grafts, it was 
shown that the lost soft tissue could effectively be restored 
by layering the L-PRF membranes over each other, thereby 
increasing gingival height and thickness. The clinical results 
were maintained for at least one year.18 Ramakrishnan et al 
confirmed this observation and showed that L-PRF could be 
used for root coverage procedures.5 
L-PRF vs PRP (Where is the evidence?)
Since the initial development of PRP in the late 1990’s, the 
platelet concentrate has undergone significant research, es-
pecially in the field of oral and maxillofacial surgery.19 Although 
widely used in a variety of clinical fields, the ability of PRP to en-
hance wound healing has recently been questioned.20 A sys-
tematic review of more than 100 papers concluded that signifi-
cant evidence existed for the use of PRP in periodontal defects. 
However, the same study concluded that the effect of PRP on 
sinus augmentation was less than 10% when compared with 
controls and suggested that no substantial evidence existed 
for its use in other dental procedures.19 The heterogeneity in 
studies that have examined PRP is regarded as a major reason 
for the lack of conclusive evidence supporting its use.
L-PRF is a new form of platelet concentrate which has features 
that are distinctly unique when compared with PRP and there-
fore cannot be regarded as the same biomaterial.4,6,10 However, 
as with PRP, there is a lack of  long-term controlled trials that 
would endorse the use of L-PRF in routine surgical procedures. 
Recently, though, five-year follow-up reports have been pub-
lished which demonstrate the clinical safety and efficacy of us-
ing this new biomaterial. Further reports are awaited.
CONCLUSIONS
In the cases presented above, the clinical application of L-PRF 
in bone regeneration procedures was demonstrated. These po-
tential effects are directly related to the biological properties of 
the material, which allow it to act as a “membrane-laden leuko-
cyte- and platelet-rich concentrate”. Its preparation is inexpen-
sive, requires no specialised equipment or the addition of animal 
derived products, and it could promise a new era in the field of 
wound healing. Further research is required to fully explore the 
broad potential of this biomaterial. 
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In order for a dental implant to be restored optimally, it must be placed in an ideal anatomic position. However, this is not always
possible, since physiological wound healing after tooth removal, often results in hard and soft tissue changes which ultimately
compromises ideal implant placement. With the aim of minimising the need for tissue augmentation, several alveolar ridge
preservation (ARP) techniques have been developed. These often require the use of grafting material and therefore increase the risk
of disease transmission. Leukocyte and platelet-rich fibrin (L-PRF) is a newly developed platelet concentrate that is prepared from
the patient’s own blood. Clinical research has indicated that it improves wound healing and stimulates bone formation. We present
a case where L-PRF was successfully used in an ARP procedure to facilitate implant placement in a compromised extraction socket.
1. Introduction
In order for a dental implant to be restored optimally, it must
be placed in an ideal anatomic position. However, this is
not always possible, since physiological wound healing fol-
lowing either tooth extraction, trauma, or pathology, often
results in a deficiency of both hard and soft tissue. Unless
augmentation procedures are carried out, placing an implant
in these tissue-deficient sites would ultimately compromise
the functional and aesthetic results [1]. Although several
diﬀerent augmentation procedures have been developed,
many of them are associated with a number of disadvantages
such as increased overall cost, the requirement for a second
surgical site, and the use of animal derived products [2].
With the aim of minimizing the need for tissue augmen-
tation, several authors have proposed techniques to preserve
the anatomy of the alveolar ridge after tooth extraction.
These procedures have collectively been termed alveolar
ridge preservation (ARP) or socket preservation [2]. Several
diﬀerent ARP techniques exist, most of which include the
use of a foreign graft materials. Because ARP is a relatively
new procedure, no long-term studies regarding the technique
have been published, and even though several case reports
have been presented, there is no evidence to support the
superiority of one technique over the other.
Recently, Choukroun introduced leukocyte and platelet-
rich fibrin (L-PRF), a second-generation platelet concentrate
that improves healing of the both hard and soft tissues
[3]. We present a case where L-PRF was used in an ARP
procedure to limit ridge resorption after tooth extraction,
in order to maximise the tissue available for ideal implant
placement.
2. Case Presentation
A 43-year-old healthy female presented for the restoration
of her dentition in the upper right jaw. Upon clinical
examination, it was noted that several posterior teeth were
missing from the first quadrant and that the only remaining
multirooted tooth (the upper right first molar) was severely
periodontally compromised (Figure 1). The radiographic
examination revealed the presence of unextracted roots in
the areas immediately mesial and distal to the remaining
molar (Figure 2). Based on the poor prognosis of the
molar as well as the presence of the unextracted roots,
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Figure 1: Initial presentation.
Figure 2: Radiograph shows hopeless upper molar with retained
roots both mesial and distal to the tooth.
a treatment plan that involved the extraction of the remain-
ing tooth and roots, and subsequently replacing them with
an implant-supported prosthesis, was deemed the best long-
term restorative solution. In order to maximise the amount
of available bone for implant placement, an ARP procedure
was indicated at the time of extraction.
3. Initial Visit
After local anaesthesia had been obtained, the upper right
molar together with the residual tooth roots were extracted
atraumatically by using a 5mm dental luxator (Dentsply
Ltd., Surrey, United Kingdom). The remaining tooth sockets
were curetted and all granulation tissue and socket debris
were removed (Figure 3). At the same time, 30mL of blood
was drawn from the antecubital fossa of the patient into three
separate blood collecting tubes (Vacuette with Z Serum Clot
Activator, Greiner Bio One International AG, Germany).
These were then immediately centrifuged at 400 g for 12
minutes, using a standard tabletop laboratory centrifuge
(PLC-03, Hi-care International, Taiwan). Using this method,
the blood in the tubes separated into three visible layers, that
is, a red blood cell layer (RBC) that occupied the lower most
part of the tube, a cell-free layer that occupied the uppermost
part of the tube, and an L-PRF layer that was located
between the two (Figure 4). For each tube, the L-PRF layer
was removed, and compressed between saline soaked sterile
gauze to form an “L-PRF membrane” (Figure 5). A total of
three L-PRF membranes were formed and inserted into the
Figure 3: Extraction site immediately after tooth removal.
Figure 4: Formation of L-PRF.
extraction socket site. These were then stabilised using 4–0
braided resorbable sutures (Clinisut, Port Elizabeth, South
Africa) that were sutured over the wound site. Oral analgesics
and a chlorhexidine 0.2%mouth rinse was prescribed during
the healing period, and the patient was followed up two
weeks later.
4. Follow-Up Visit
On the follow-up visit, the extraction site showed signs
of healing with no evidence of residual inflammation. The
site was free of infection and the L-PRF membrane was
still clearly visible (Figure 6). Even though it remained
exposed to the oral environment, there were no signs of
membrane disintegration or infection. The patient also
reported minimal pain during the postoperative period.
Because of the positive response to treatment, she was
scheduled for implant placement four weeks later.
5. Implant Placement
Implant placement was carried out 6 weeks after tooth
extraction. A radiograph taken prior to implant placement
confirmed new bone formation in the extraction area
(Figure 7). Upon surgical flap reflection, the underlying
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Figure 5: L-PRF membrane.
Figure 6: Extraction site healing 1 week after tooth removal (note
the visibility of the L-PRF membrane).
Figure 7: Radiograph showing new bone formation.
Figure 8: Flap reflection.
Figure 9: Radiograph showing stable peri-implant bone 3 months
after restoration.
alveolar ridge was clearly visible. The ridge had retained
its morphology with no signs of bone resorption or of the
residual socket (Figure 8). At implant insertion, the quality
of the newly formed bone was such that it allowed for the
implant to be inserted at an insertion torque of more than
35Ncm.
6. Prosthetic Management
Eight weeks after implant placement, the implant was re-
stored with a cement retained crown and has since then re-
mained in function without any complications.
At the 3 month follow-up after the restorative treatment
had been completed, radiographic evidence of bone matura-
tion was present at the peri-implant sites (Figure 9).
7. Discussion
The healing of an extraction socket is characterised by both
internal and external changes that ultimately aﬀect the shape
of the alveolar ridge [2]. Studies indicate that during healing,
bone does not regenerate to the level of bone crest or to the
level of the neighbouring teeth, and therefore 100% socket fill
does not occur. Using an animal model, Araujo and Lindhe
showed that in the first 8 weeks following extraction, there is
marked osteoclastic activity, resulting in the resorption of the
facial and lingual bone walls, especially in the crestal region
[4]. They also noted that bone resorption was greater on the
facial wall and that any loss of ridge height was accompanied
by a horizontal losson both facial and lingual walls of the
extraction site.
Alveolar ridge preservation is a relatively new surgical
procedure aimed at retaining maximum bone and soft tissue
after a tooth has been removed [2]. By maintaining the
original ridge morphology, there will be a minimal need
for augmentation procedures thereby allowing the resultant
restoration to be placed in an aesthetically and functionally
ideal position.
During the last decade several diﬀerent ARP techniques
have been developed, most of which include the use of a
graft material that is placed into the extraction socket [2].
This increases the treatment cost as well as increases the risk
of disease transmission. Studies also indicate that in many
cases, the graft material is not totally incorporated into the
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newly formed bone and when compared to sites without
graft material, they show less vital bone formation. In some
cases ARP requires the use of collagen membranes. In these
cases a 25%membrane exposure rate has been reported, and
this directly aﬀects the amount of bone fill that takes place
within the socket [2].
Leukocyte and platelet-rich fibrin (L-PRF) was first
described by Choukroun as cited by Dohan et al. 2006 [5].
It is considered a second-generation platelet concentrate and
has been used in various surgical procedures in an attempt
to enhance wound healing. It is prepared from the patient’s
own blood thereby eliminating the possibility of disease
transmission or foreign body reactions.
The preparation technique of L-PRF is simple and
requires no special equipment. Blood is drawn into standard
glass/silica coated blood collection tubes and centrifuged at
a predetermined speed to ensure cell separation. No anti-
coagulants are used during the procedure and natural coag-
ulation can therefore take place. This unique preparation
technique allows L-PRF to trap at least 95% of the platelets
of the collected blood into a fibrin mesh [6]. The fibrin
mesh can then be easily manipulated into a membrane that
allows it to be transferred to any surgical site. Here, high
concentrations of the collected platelets allow for the slow
release of growth factors (GFs) from the platelet granules
[7]. These GFs include vascular endothelium growth factor
(VEGF), platelet-derived growth factor (PDGF), fibroblast
growth factor (FGF), epidermal growth factor (EGF), hepa-
tocyte growth factor (HGF), insulin-like growth factor (IGF),
platelet-derived growth factor (PDGF), and transforming-
growth factor-beta (TGF-beta). All of these play a role in
replacing lost tissue, resurfacing of the wound, and restoring
vascular integrity. Compared to other platelet concentrates,
L-PRF releases these factors at a sustained rate over a longer
period, thereby optimising wound healing [8]. Recently,
L-PRF has also been shown to stimulate the growth of
osteoblasts and periodontal ligament cells, both of which are
significant for the regeneration of periodontal defects [6, 8–
11].
Because of the in vitro eﬃcacy of L-PRF, several clinical
studies have been carried out to determine its clinical poten-
tial. Currently, L-PRF has been successfully tested in a num-
ber of procedures including maxillofacial surgery, periodon-
tal surgery, and implantology [9]. Mazor et al. successfully
used L-PRF as the only grafting material in a series of sinus
augmentation procedures [10]. With this techniqueMazor et
al. were able to demonstrate that L-PRF could stimulate new
bone formation in areas that were previously deficient of the
amount of bone required for implant placement [10]. In a
similar 6-year follow-up study, Simonpeiri et al. were able to
demonstrate that using L-PRF as a sole grafting agent was a
viable long-term option in sinus augmentation procedures
[11].
L-PRF has also been used successfully to treat periodontal
defects. In vitro studies have confirmed that L-PRF selectively
stimulates the growth of osteoblasts and gingival cells [12].
In a series of clinical trials conducted by Pradeep and
Sharma it was shown that L-PRF could be used as a guided-
tissue-regeneration (GTR) membrane to aﬀect periodontal
regeneration in 3-wall bony defects and degree II furcation
lesions [9, 13]. Del Corso et al. published several case reports
showing the successful use of L-PRF membranes in the
management of both single and multiple gingival recession
defects [14]. The clinical results were maintained successfully
for at least one year. Ramakrishnan et al. confirmed this
observation and showed that L-PRF could be used for root
coverage procedures [15].
8. Conclusion
In the above case report, we demonstrated the successful
use of L-PRF in an ARP procedure. The biomaterial acts by
releasing high-concentration growth factors to the wound
site, thereby stimulating healing and new bone formation
[16]. Unlike other ARP procedures, the use of L-PRF is a
simple method that requires minimal cost and reduces the
need for specialised grafting material. Because it is a com-
pletely autologous product, the risk of disease transmission
and graft rejection is negated. Further long-term research
is required to determine whether ARP procedures would
benefit from the use of L-PRF.
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